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ABSTRACT 
 
Background  
 
Physiological studies have shown that many preterm infants and infants with chronic lung 
disease may suffer chronic hypoxaemia, which possibly leads to poor growth and 
development.  Anecdotal reports indicate that there is a drive to increase the oxygen saturation 
target range to a higher level in these infants due primarily to perceived benefits derived from 
clinical experience and from uncontrolled observational studies of babies discharged on home 
oxygen. 
 
Objective  
 
The BOOST (Benefits Of Oxygen Saturation Targeting) trial is the first randomised trial to 
assess the long-term benefits and harms of two different oxygen saturation target ranges.  
 
Methods  
 
BOOST was a multicentre, double blinded, randomised controlled trial that enrolled 358 
infants born at less than 30 weeks’ gestation who remained oxygen-dependent at 32 weeks 
postmenstrual age. They were randomly assigned to target either a functional oxygen 
saturation range of 91-94% (standard or control group) or 95-98% (higher or treatment group). 
The primary outcomes were growth and neurodevelopmental measures at 12 months corrected 
age. Secondary outcomes included length of hospital stay, retinopathy of prematurity, health 
service utilisation, parental stress, and infant temperament.  
 
Results  
 
Prognostic baseline characteristics did not differ between the two groups. Mean birth weight 
and gestational age of enrolled infants was 917g and 26.5 weeks respectively. The rate of 
antenatal corticosteroid use was 83%.  
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There were no significant differences in any of the short-term growth outcomes (weight, 
length, head circumference at 38 weeks postmenstrual age). Of the 334 infants with complete 
primary outcome data (93% of infants enrolled, 97% of survivors to 12 months corrected age), 
39/168 infants (23.2%) in the treatment group had a major developmental abnormality, 
compared with 40/166 infants (24.1%) assigned to the control group (RR 0.96, 95% CI 0.66 to 
1.42, P=0.8). Similarly, 55/168 infants (32.7%) with complete growth data in the high 
saturation target range group had a weight less than the 10th centile at 12 months corrected 
age, compared with 61/165 infants (37.0%) in the control arm (RR 0.89, 95% CI 0.66 to 1.19, 
P=0.4). No significant differences were found in mean weight, length or head circumference at 
12 months corrected age between the two groups. When the primary outcomes were examined 
in the pre-specified sub-group of infants less than 28 weeks’ gestation at birth, and in the sub-
group of infants who went home on supplemental oxygen, all results remained non-significant.  
 
There were 9 post-randomisation deaths in the higher oxygen group and 5 in the standard 
group (RR 1.78, 95% CI 0.61 to 5.21, P=0.3). Of the secondary outcomes examined, the 
higher saturation target group had a statistically significantly longer duration of oxygen 
(P<0.0001), and increased rates of oxygen dependency at 36 weeks postmenstrual age (RR 
1.40; 95% CI 1.15, 1.70; P=0.0006) and home oxygen (RR 1.78; 95% CI 1.20, 2.64; P=0.004). 
There were no statistically significant differences in any of the other pre-specified secondary 
outcomes including days of ventilation, length of hospital stay, time to full sucking feeds, 
worst stage of retinopathy of prematurity, health service utilisation, or measures of postnatal 
depression, infant or toddler temperament, parenting stress, or family impact.  
 
Conclusions  
 
Targeting a higher oxygen saturation range in chronically oxygen-dependent, extremely 
preterm infants conferred no significant long-term growth or development benefits but did 
increase their duration of oxygen, rate of home oxygen and need for supplemental oxygen at 
36 weeks postmenstrual age.  
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CHAPTER 1: BACKGROUND 
 
1.1 Introduction 
Babies with lower gestational ages are increasingly represented in neonatal intensive care units 
(NICUs) today, due to enhanced survival prospects.1, 2 However, the increased survival of 
these infants has been associated with increased measures of chronic ill health including 
chronic lung disease of infancy. 3 This condition, currently defined as continued oxygen 
dependency at 36 weeks postmenstrual age (pma),4, 5 has become a major clinical challenge as 
chronic lung disease is accompanied by significant morbidity including poor growth,6-17 
neurological impairment14, 16 and adverse pulmonary sequelae.14, 18  These infants are on 
extended stays on supplemental oxygen until they can maintain normal breathing patterns 
which results in considerable health service costs.19-23 
 
1.2 Oxygen therapy 
Supplemental oxygen is probably the most common treatment given to infants in the newborn 
period.24 Increasing the oxygen concentration of inspired air (FiO 2) is the oldest and most 
widely used method of correcting the hypoxia that frequently affects newborns adapting to the 
ex-utero environment.25 Despite its documented use in infants for over 75 years,26 there are 
very few randomised controlled trials which have studied the most appropriate ranges to 
maintain oxygen levels for either term or preterm infants, or a threshold value below which 
oxygen should be administered.25, 27 
 
Each year over 5,000 infants (or approximately 2% of all infants born) in Australasia receive 
oxygen therapy during their initial stay in a neonatal intensive care nursery and more than 300 
of these infants require continued oxygen therapy at home after discharge.28 The incidence of 
oxygen therapy is dependent on gestational age at birth with 96% of infants born at less than 
28 weeks’ gestation receiving supplemental oxygen, whilst only 75% of infants born between 
28 and 31 weeks require oxygen therapy during their initial hospitalisation.28 Similarly the 
incidence of chronic lung disease (defined as supplemental oxygen and/or assisted ventilation  
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at 36 weeks postmenstrual age) decreases from 45% in infants born at less than 28 weeks to 
12% for those born between 28 and 31 weeks’ gestation. 28 
 
1.3 Normal oxygen va lues 
In the past, establishing appropriate parameters for oxygen therapy had been difficult because 
of the lack of information at the time regarding the safe use of oxygen.24 A balance has now 
been achieved between preventing adverse effects to the eye, in particular, retinopathy of 
prematurity (ROP), and decreasing the mortality of preterm infants.27 
 
There have been several attempts to quantify normal or reference values of oxygen saturation 
(SpO2) and/or partial pressure of arterial oxygen (PaO2) levels for both term and preterm 
infants.29-35 These data are summarised in Figure 1 below: 27 
 
Figure 1:  Reference data for SpO2 in infants 
 
Age (days)  Baseline SpO2 (%)___________  
Minimum 
# Subjects  Type  Median  Range  Median Value  5th centile Reference 
55   pt a  1  1-7  99.4  90.7  95.7   29 
160   pt b  20  3-165  99.6  88.7  95.7   30 
110   pt b  62  30-176  100.0  95.3  97.9   30 
90  ft <1 5-23 hrs 98.3 88.7 95.2  31 
60   ft  4  1-7  97.6  92.0  93.2   32 
60   ft  17  8-28  98.0  86.6  91.9   32 
66   ft  39  29-54  99.8  97.0  97.5   33 
16   ft  102  83-146  99.9  98.6  99.2   34 
 
Baseline SpO2 measured during regular breathing, at least 10 seconds away from sighs and apnoeic pauses, using a Nellcor N200 
pulse oximeter which measures functional saturation. Listed are the median and lowest values found in the study and the fifth centile.  
pt, preterm; ft, full-term.  
a Median gestational age at birth: 35 weeks (range 30-36). 
b Mean gestational age at birth (for both groups): 32.5 weeks (SD 2.5). 
 
These studies demonstrated a relatively narrow range of normal baseline SpO2 values during 
regular breathing, that is, in quiet sleep.  For preterm and term infants this is 93-100% (0-28 
days age) and for term infants 97-100% (2-6 months age).27 These data correspond with the 
few existing studies of arterial partial pressures of oxygen which have demonstrated mean 
PaO2 of 70-76mmHg in term infants on day 2-7 of life.35 In contrast, desaturation episodes are 
common in both term and preterm infants in the early neonatal period, but decrease markedly 
with age (see Figure 2).27 
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Figure 2:  Reference data for SpO2  in infants - desaturations  
 
 __Desaturations____________ 
 
___Age (days)   % Recordings  # per 12 h Recording_________________ 
 
# Subjects Ref  Type  Median  Range   with Desats.  # Desats.   95th Centile  
55  29 pt a  1  1-7   18   55   8   
160  30 pt b  20  3-165   71   355   61   
110  30 pt b  62  30-176   31   17   3   
90 31 ft <1 5-23 hrs  26  34  6   
60  32 ft  4  1-7   35   41   16   
60  32 ft  17  8-28   60   165   32   
66  33 ft  39  29-54   16   9   2   
16  34 ft  102  83-146   6   1   0 
 
Desaturat ion was defined as a fall in SpO2 to <80% for at least 4 seconds with the pulse oximeter (Nellcor N200) in a beat -to-beat 
mode and analysed in both regular and non-regular breathing.  
   
 
However, the most appropriate range of oxygen saturation or oxygen tension to target, for both 
term and preterm infants, either in the early newborn period or later, remains largely 
unanswered by the current available research evidence. In 1992, the American Academy of 
Pediatrics recommended an arbitrary PaO2 range of 50-90mmHg.36 
 
1.4 Oxygen monitoring methods  
The most appropriate method of monitoring and assessing adequate oxygenation in the 
neonate remains controversial. There are several different ways of measuring blood oxygen 
levels in neonates and all methods have advantages and disadvantages.  
 
The partial pressure of oxygen in arterial blood (PaO 2) can be measured directly via 
indwelling intra-arterial catheters which are sampled intermittently or by taking arterial 
puncture samples when required. Because PaO2 in the newborn is quite labile,37, 38  intermittent 
measures may not reflect an infant’s steady state oxygen level.25 These measurement methods 
also have a high risk of complications when used in newborns such as haemorrhage due to 
dislodgement and the need for top-up blood transfusions if sampling is frequent due to the 
newborn’s low circulating blood volume.  
 
Hence, the development of continuous, non- invasive methods of measuring blood oxygen 
levels in neonates have been developed in recent years. Transcutaneous measurement of the 
partial pressure of oxygen (TcPO2) was a technology developed in the 1970s. TcPO2 is  
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measured with a sensor which incorporates a miniature Clark electrode and which is applied to 
the skin and heated in order to increase capillary blood flow. The combination of several 
factors (hyperperfusion, heat- induced shift of the oxyhaemoglobin dissociation curve and 
increased tissue oxygen consumption) result in the “arterialising” of the blood in the capillary 
bed below the sensor and the resulting TcPO2 level approximates the actual arterial oxygen 
level well in most circumstances.25 
 
The anticipated benefits of continuous, non- invasive oxygen monitoring methods have not, 
however, necessarily resulted in significant improvements in the outcomes that they were 
designed to affect, such as retinopathy of prematurity (ROP).25, 39  The sensitivity and 
specificity of detecting hypoxia (PaO2 <50mmHg) and hyperoxia (PaO2 >80-100mmHg) using 
transcutaneous monitors have been estimated at 83% and 98%, and 87% and 90% 
respectively. 25 The effect of continuous transcutaneous monitoring on the incidence of ROP 
has had varying results. Some non-randomised studies40, 41 have claimed a near abolition of 
ROP using TcPO2 monitoring whilst others42 have reported no difference in the incidence or 
severity of ROP attributable to TcPO2 monitoring. The only randomised trial43-45 to date which 
has examined the effect of transcutaneous monitoring (continuous TcPO2 monitoring versus 
standard care) on ROP incidence suggested a modest improvement in ROP rates for infants 
with greater than 1000g birthweight, but no effect on smaller infants in whom ROP occurs 
more frequently and is more severe. Conversely there was a trend to higher mortality in the 
group receiving continuous transcutaneous monitoring, and the rates of the combined 
outcome, death or ROP, were nearly identical in the two groups.  Also, this trial did not detect 
any effect of transcutaneous monitoring on the incidence of chronic lung disease. It has been 
hypothesised that it is the variability of oxygen levels rather than a threshold upper level that 
might be the main contributing factor to the development of ROP in at-risk infants.46-48 
 
Oxygen saturation monitoring using pulse oximetry has gained widespread use in neonatal 
nurseries since the early 1980s due to its ease of use and lack of heat-related side effects, 
particularly in extremely preterm infants with sensitive skin, despite very little evidence of its 
effectiveness on clinically important outcomes.25 Pulse oximetry (SpO2) refers to the 
estimation o f the oxygen saturation of arterial blood (SaO2) using a device that measures the  
 21 
Chapter 1: Background  
 
pulsatile changes in light transmission across a tissue bed. Oximeters work on the principle 
that desaturated haemoglobin and oxygenated haemoglobin absorb light of different 
wavelengths (red and infrared). The oximeter emits light of these two wavelengths and 
measures absorption in the pulsatile element of the blood flow, thus producing a measure of 
the oxygen saturation of arterial blood separate from the non-pulsatile venous blood.49 Pulse 
oximeters measure either functional or fractional oxygen saturation. Functional saturation is 
the ratio of oxyhaemoglobin to the sum of oxyhaemoglobin and deoxyhaemoglobin. Fractional 
saturation measures the ratio of oxyhaemoglobin to the sum of all four haemoglobin species in 
the blood, including both functional and dysfunctional haemoglobins (see formulae below).50, 51 
 
Functional saturation =   oxyHb 
oxyHb + deoxyHb 
 
Fractiona l saturation =   oxyHb 
  oxyHb + deoxyHb + COHb + metHb 
 
oxyHb = oxyhaemoglobin 
deoxyHb = deoxyhaemoglobin 
COHb = carbonmonoxyhaemoglobin 
metHb = methaemoglobin 
 
 
Readings from these two types of oximeters are not interchangeable with functional saturation 
readings being approximately 2% higher than those obtained from fractional oximeters.52, 53  
 
The evidence from non-randomised studies suggests that pulse oximetry is a reliable measure 
of oxygenation in infants with chronic lung disease and prolonged oxygen dependency, 
particularly at lower PaO2 levels.54-56 The only randomised trial of pulse oximetry monitoring 
in infants was performed in patients undergoing surgery. 57 This study suggested the value of 
pulse oximetry in detecting major hypoxic events in anaesthetised children. However, the 
ability of pulse oximeters to reliably detect hyperoxia58-60 remains controversial with most 
authors suggesting that oxygen levels should be corroborated with intermittent arterial blood 
gas estimations,61 and/or pulse oximeters should be used in conjunction with, rather than as a 
replacement for, transcutaneous monitoring62, 63  where possible.  
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1.5 Chronic lung disease of infancy 
1.5.1 Description 
Chronic lung disease of infancy (CLD) was originally defined as oxygen dependency and 
abnormal chest X-ray changes at 28 postnatal days64 and was known as bronchopulmonary 
dysplasia (BPD). This definition was devised at a time when very few infants less than 32 
weeks pma survived and hence these infants would be at a minimum of term equivalent age at 
one month, or 28 days, of life. More recently chronic lung disease has been defined as 
continued oxygen dependency at 36 weeks postmenstrual age (pma)4, 5, 65-68 in line with the 
increasing survival of extremely preterm infants. In today’s NICUs infants born as early as 22-
23 weeks pma are surviving and hence it would be unrealistic to expect that such infants 
would be mature enough at 28 days of life to not need supplemental oxygen, when their 
postmenstrual age was only 26-27 weeks. In this population of extremely preterm infants the 
continued need for supplemental oxygen at 36 weeks postmenstrual age is far more predictive 
of the severity of lung disease.69 The pathophysiology of the disease in today’s more 
extremely preterm infants differs from the original histopathological changes described by 
Northway in 1967.64 This so called “new BPD” results in more distal lung injury, 
characterised by derangements in elastic fibre architecture, airway muscle thickening, alveolar 
hypoplasia and saccular wall fibrosis, but with minimal bronchial changes.70 The 
histopathology of the “new” CLD / BPD indicates an interference with the normal anatomical 
development of the lung, which may prevent subsequent lung growth and development.65 
 
1.5.2 Risk factors and prevention strategies for chronic lung disease 
The major risk factor for needing oxygen therapy is extreme prematurity.28, 71-73 Additional 
risk factors for prolonged supplemental oxygen include a long duration of assisted  
ventilation,74 lack of antenatal steroids,75 and other antenatal risk factors such as maternal 
Ureaplasma urealyticum infection.72 As these factors are strong independent predictors of 
chronic lung disease, a randomised controlled trial study design is important when 
investigating the effects of treatments for CLD to ensure baseline comparability of these risk 
factors. 
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The prevention of chronic lung disease remains elusive, ultimately depending on avoiding or 
delaying preterm birth whenever possible.76 However, several other strategies have been 
suggested to prevent extremely preterm infants developing chronic oxygen-dependency. These 
include the prevention of oxygen toxicity and barotrauma by the use of treatments such as 
endogenous surfactant, high frequency ventilation, nitric oxide and extracorporeal membrane 
oxygenation (ECMO),77 and the early use of nasal CPAP, as well as prophylactic treatment of 
patent ductus arteriosus, nutritional supplementation, postnatal steroids and diuretics, blood 
transfusions, bronchodilators, methylxanthines, and respiratory syncytial virus prophylaxis.78 
Although many of these treatments have short-term benefits, none has been shown to 
significantly alter the natural history of the condition.  
 
1.5.3 Summary of existing evidence regarding chronic lung disease 
Physiological studies have found that infants with chronic lung disease have increased rates of 
oxygen consumption79 and lower baseline oxygen saturation levels leading to more frequent 
desaturation episodes80, 81  compared with infants without chronic lung disease. It is 
hypothesised that these infants may be spending a substantial amount of time under-
oxygenated, and that this chronic hypoxaemia may possibly lead to poor growth and 
development.82 Observational studies have suggested improved sleep patterns,82, 83  growth and 
neurodevelopment84, 85 amongst preterm infants permitted more liberal oxygen 
supplementation, either in duration or by aiming for higher blood oxygen levels. However,  
because of the uncontrolled nature of these studies it is not known whether these associations 
are causal. Anecdotal reports from neonatologists indicated that there had been a drive to 
increase the oxygen saturation targets to a higher level than is currently maintained by the 
policies of most neonatal intensive care units.  This was due primarily to perceived benefits, 
derived from clinical experience and from uncontrolled observational studies of babies 
discharged on home oxygen.86 
 
1.6 Effects of differing target oxygen levels on outcomes 
There are wide-ranging consequences of adopting differing policies with regard to which 
infants require supplemental oxygen, what range to target that oxygen therapy and for how 
long infants should receive supplemental oxygen. A policy of more liberal oxygen therapy  
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(that is, aiming for higher infant oxygen levels) compared with one that is more restrictive 
(and thus targets lower oxygen levels) may affect mortality and morbidity including the 
incidence of CLD, home oxygen rates, days in hospital, incidence of ROP, feeding and 
sleeping patterns, respiratory outcomes, use of health care services, and short and long-term 
growth and development measures.    
 
There are very few controlled studies that have investigated the effects of oxygen therapy 
interventions that are relevant to current neonatal populations and management. The following 
review summarises the existing evidence on the effects of differing oxygen therapy policies 
and/or interventions on a variety of outcomes (both physiological and clinical), for term or 
preterm infants, with either acute or chronic respiratory disease.  
 
 
1.6.1 Mortality 
1.6.1.1 Early mortality 
A Cochrane systematic review87 (by the author and supervisor of this thesis) showed that one 
randomised trial88 of targeting either restricted (supplemental oxygen only if PaO2 <40mmHg) 
or liberal oxygen therapy (FiO 2 > 0.40 for 72 hours to keep PaO2 40-120mmHg) showed no 
difference in early mortality (20/74 deaths in the restricted oxygen group vs 23/76 in the 
liberal oxygen group, RR 0.89, 95% CI 0.54, 1.48).  Similarly, the multicentre Cooperative 
trial89 which compared restricted (supplemental oxygen only if clinically indicated, maximum 
FiO2 0.50) and unrestricted (FiO2 > 0.50 for 28 days) oxygen policies in infants born at less 
than 1500g birthweight, who survived more than 48 hours, showed no significant difference in 
death rates (36/144 in the restricted group vs 15/68 in the liberal group, RR 1.13, 95% CI 
0.67-1.92). However, these trials were undertaken in the era before modern neonatal intensive 
care and none tested the intervention in the critical first 48 hours of the infant ’s life when 
mortality effects could be expected to be the most marked. 
 
1.6.1.2 Late mortality  
A randomised trial of restricted (FiO2 < 0.50, only administered for cyanosis) compared with 
unrestricted oxygen exposure (mean FiO 2 0.69, given routinely for 14 days or more or until 
the infant’s weight reached 1500g) in 1000-1850g infants90 showed no significant difference 
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in death rates during the first 3 months life (12/41 for restricted oxygen vs 9/45 for liberal 
oxygen administration, RR 1.46, 95% CI 0.69-3.11). The effects of trials of restricted versus 
liberal oxygen exposure on mortality in preterm or low birthweight infants are summarised in 
a Cochrane review87 and reveal no significant difference in late mortality (45/185 for restricted 
oxygen vs 24/113 for liberal oxygen administration, RR 1.23, 95% CI 0.80, 1.90). Again 
however, these trials were undertaken in an earlier era when actual measurement of infant 
blood oxygen levels was not possible and it is thus difficult to extrapolate these results to 
infants cared for today. A United Kingdom (UK) population-based cohort study91 of infants 
born before 28 weeks during 1990-1994 showed no difference in the proportion who survived 
infancy between infants given enough supplemental oxygen to maintain SpO2 88-98% for at 
least the first 8 weeks of life compared with those only given enough oxygen to maintain an 
oxygen saturation of 70-90%. It should be noted that this study was not a randomised trial and 
therefore factors which could have potentially confounded these results, such as inter-unit 
variation in the type and intensity of oxygen monitoring, cannot be ruled out.  
 
Uncontrolled studies92, 93 and anecdotal evidence94 suggest targeting a SpO2 level of 93% or 
above reduces post-neonatal mortality in infants with chronic lung disease. 
 
1.6.2 Ophthalmic  
Retinopathy of prematurity (ROP) is a common retinal neovascular disorder occurring almost 
exclusively in infants born at less than 30 weeks gestation.28 In most of these infants the 
abnormal retinal vasculature regresses and the ROP resolves. However in a small percentage 
of infants the abnormal vessels continue to grow leading to hemorrhagic and eventually 
fibrotic retinal scarring and detachment.95 Severe ROP may result in unfavourable visual 
outcomes in 40 - 50 percent of cases at 1 year follow up compared to less than 1 percent of 
infants with no or less severe ROP.96 Even with treatment, severe ROP is associated with 
unfavourable visual outcomes in approximately 11 percent of cases at 3 months of age.97 
Retrolental fibroplasia (stage 3 ROP with plus disease98) has been associated with 
supplemental oxygen administration since the 1950's when it was shown that unrestricted 
oxygen exposure for premature infants regardless of clinical requirement resulted in a 
significant increase in this condition.87 
 26 
Chapter 1: Background  
 
Current treatment for severe retinopathy is invasive and involves ablation of the avascular 
retina by cryotherapy99 or laser photocoagulation.97 Non-invasive treatments of ROP have 
been postulated. One of these is supplemental oxygen therapy aimed at targeting higher 
oxygen levels in the blood. The physiology behind the postulation that supplemental oxygen 
can halt and reverse the progression of ROP is as follows. In the first phase of ROP exposure 
of the extremely preterm infant to the relatively hyperoxic extra-uterine environment after 
birth leads to down regulation of vascular endothelial growth factor (VEGF) production and 
the cessation of normal blood vessel growth.100 The density of blood vessels in the retina is 
then insufficient once the metabolic demand from the avascular retina increases.  A rebound 
overproduction of VEGF to compensate for the tissue metabolic imbalance leads to the 
abnormal vascularization typical of ROP.101 Kittens with hyperoxia - induced ROP that 
recovered in 28% oxygen had less severe retinopathy than those recovered in room air.102 
Unfortunately the animal models of ROP do not progress to full detachment and blindness as 
ROP does in some infants and therefore may not completely reflect the pathophysiology in 
humans.102 
 
Although there is broad agreement that restricted versus liberal oxygen policies significantly 
reduce the incidence of severe ROP,87, 95, 103, 104  there is little research into what constitutes a 
safe upper limit of oxygen in the blood in the early neonatal period to prevent ROP.  In 
addition to the available trials, a cohort study also found a significant association between 
duration of exposure to high levels of oxygen tension, as measured by transcutaneous 
monitoring, and the incidence and severity of ROP.105 A UK cohort study91 of infants born 
before 28 weeks during 1990-1994 showed that infants given enough supplemental oxygen to 
maintain SpO 2 at 88-98% for at least the first 8 weeks of life developed severe ROP four times 
as often as infants only given enough oxygen to maintain an oxygen saturation in the 70-90% 
range (27% vs 6%, P<0.01). Of note however, is that the severe ROP rate in the lower oxygen 
range group in this study (6%) is similar to the current Australasian rate for infants less than 
28 weeks’ gestation at birth (7%), despite considerable practice variation within this region 
with respect to oxygen saturation target ranges86 which would encompass both ranges targeted 
in the UK cohort study.  
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The use of supplemental oxygen in the SpO 2 96-99% range has been tested in one large, 
multicentre randomised trial, the STOP-ROP trial,106 and was found to have no significant 
effect on rates of progression of pre-threshold ROP.   However, in this trial treatment allocation 
was not masked to caregivers and it has been criticised for having insufficient sample size to 
detect the expected differences due to the trial being stopped early because of flagging 
recruitment. Conversely, the results of several case-control studies,107-109 animal models,102, 110 
and retrospective audits111 conducted prior to the STOP-ROP trial are consistent and suggest 
supplemental oxygen reduces the progression of pre-threshold ROP.  
 
1.6.3 Growth  
1.6.3.1 Early growth 
The Tin UK cohort study91 showed infants nursed at higher oxygen saturations (88-98%) were 
more likely to have a weight below the third centile at discharge (45% vs 17%, P<0.01). There 
have been no controlled trials that have directly assessed the effects of different target oxygen 
ranges on either short or long-term infant growth. In the STOP-ROP trial,106 there was no 
difference in short-term growth measures between the two groups of preterm infants with pre-
threshold ROP randomly allocated to target either SpO2 89-94% or 96-99%, although this was 
only assessed as a secondary outcome. A case control study in Western Australia reported that 
infants with chronic lung disease achieved full sucking feeds status approximately one week 
later than matched preterm controls.13 
 
1.6.3.2 Long-term growth 
Although there are no controlled trials that have directly assessed the effects of different target 
oxygen ranges on long-term infant growth, there is ample observational data to support the 
hypothesis that inadequate oxygenation contributes to poor long-term growth in preterm/low 
birthweight (LBW) infants with a diagnosis of CLD or BPD.9, 12, 15, 112 Compared with non-
BPD infants, outcomes for these infants include a greater proportion small for their age, and 
poor catch-up growth. Growth following home oxygen therapy has only been examined in 
poorly controlled or uncontrolled circumstances.  Some studies of home oxygen sufficient to 
maintain SpO 2 >92-95% have reported improvements in weight gain,84, 85 whilst others have 
demonstrated continued poor growth compared with non-BPD infants.113 
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Indirect evidence of poor weight gain following impeded oxygenation comes from prospective 
cohort studies of infants with congenital heart disease6 and children with chronic asthma.114 
These studies showed that chronic respiratory insufficiency (defined as PO2 <70mmHg at 
assessment or asthma onset before 3 years of age) appear to be related to poor growth, 
although these effects were confounded by the use of corticosteroids.  
 
1.6.4 Neurodevelopment 
The Tin UK cohort study91 showed no difference in the proportion of infants with cerebral 
palsy at 2 years of age between infants nursed at lower oxygen saturations (SpO2 70-90%) and 
those given enough supplemental oxygen to maintain oxygen saturation between 88-98% 
during the early weeks of life. However, the rates of cerebral palsy seen in both groups were 
high at approximately 16% and, despite excellent follow-up rates, it should be noted that as 
this study was not a randomised trial, causality cannot be inferred from this association.  
 
There have been no controlled trials that have directly assessed the effects of different target 
oxygen ranges on either short or long-term infant development. In the STOP-ROP trial,106 
there was no difference in the short-term development measures (at 3 months corrected age), 
assessed as secondary outcomes, between the two groups of preterm infants with pre-threshold 
ROP randomly allocated to target either SpO2 89-94% or 96-99%. There is ample 
observational data (case control and cohort studies) to support the hypothesis that inadequate 
oxygenation contributes to poor long-term development in preterm/LBW infants with a 
diagnosis of CLD or BPD.1, 8, 10, 11, 14-18, 115-120 Outcomes for these infants include increased 
rates of neurological impairment and significant developmental delay with or without early 
markers of poor neurological outcome (grade 3 or 4 intraventricular haemorrhage (IVH), 
periventricular leukomalacia (PVL)). 
 
1.6.5 Sleep patterns 
Sleep state disturbances have been frequently reported in infants with chronic oxygen 
dependency. 82, 83, 121, 122 However, the long-term significance of such disturbances remains 
controversial as there are no randomised trials that have provided direct evidence that 
increasing the level of oxygen supplementation improves sleep patterns or other related, 
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clinically meaningful outcomes. A 1998 case control study found that targeting a SaO2 of 
>93% was as efficacious as a SaO2 >97% in optimising sleep architecture in preterm CLD 
infants.123 Other work has suggested that continuing oxygen supplementation during sleep to 
maintain SpO 2 >97% improves the proportion of time spent in quiet sleep for infants with 
chronic oxygen dependency.82, 124 
 
1.6.6 Respiratory system 
Physiological studies have consistently demonstrated that preterm infants with lower baseline 
oxygenation have more frequent and prolonged apnoeic episodes125-127 and increased oxygen 
consumption.79, 128-130 
 
Only physiological and observational studies have been undertaken to assess the effect of 
oxygen saturation levels on apnoea and hypoxaemia in chronically oxygen dependent 
preterm/LBW infants. These studies have shown that among infants with increased oxygen 
requirements, oxygen desaturation during sleep and after feeding can result in hypoxaemia and 
apnoea.80, 81, 124, 131, 132  These babies spend a greater than average time at “less than adequate 
oxygen saturation” and have more frequent desaturation episodes,81, 131 although what 
constitutes adequate oxygenation remains unknown. 133 There has also been some concern that 
preterm infants needing respiratory support may be maintained at an inappropriately low 
baseline saturation levels in comparison to non-distressed preterm infants.29, 80, 81, 134, 135 It has 
been hypothesised that desaturation in these infants could be due to an increase in the 
frequency of apnoeic pauses in response to airway hypoxia.30, 127 It appeared that both central 
apnoea and periodic breathing densities decline significantly with improvement in oxygen 
saturation.80 An association between subclinical hypoxaemia and respiratory control in 
preterm infants was demonstrated in a prospective study of 35 infants with CLD throughout 
their first year of life.136 A predischarge mean SpO2 below 90% was identified in eight infants 
who subsequently had an apparent life-threatening event or died of sudden infant death 
syndrome (SIDS).  
 
The effects of mild airway hypoxia (FiO 2 0.15-0.16) on respiratory control have been studied 
in a group of 34 healthy 2-6 month old term infants.137 Although there was an increase in  
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periodic breathing, most infants showed only a modest decrease in their baseline SpO2 during 
breathing of hypoxic gas mixtures (from median 97.5% to 92.8%). Hypoxia may also cause an 
increase in airway resistance in infants with CLD,138 as well as an increased work of 
breathing.139 As a result of their study, the latter authors suggested that SpO2 in infants with 
CLD should be maintained at 94-96%. 
 
A recent physiological study82 has shown that continuing oxygen supplementation during 
sleep in order to maintain SpO2 >98% improves respiratory stability in infants with chronic 
oxygen dependency by reducing desaturations, apnoea and bradycardia. The only randomised 
trial of differing levels of oxygen therapy in preterm infants (for treatment of pre-threshold 
ROP)106 in which pulmonary measures were collected as secondary outcomes found that the 
higher target SpO2 range (96-99%) resulted in a significantly increased risk of adverse 
pulmonary events including pneumonia, exacerbations of chronic lung disease and the need 
for oxygen, diuretics, and hospitalisation at 3 months corrected age.  Several other case control 
and cohort studies have confirmed that infants with prolonged oxygen dependence have 
significantly more days of rehospitalisation.18-22 Long-term follow-up cohort studies have 
shown conflicting results, with some indicating that subclinical pulmonary dysfunction in 
children with BPD persists at school age.140 In contrast, others have found that the exercise 
capacity of children who had had severe BPD is similar to that of term controls,141 whilst 
others have shown that the respiratory health of LBW children at 14 years of age is 
comparable to that of term controls.146 It has been suggested that perhaps a more favourable 
prognosis of pulmonary outcome for extremely low birthweight infants is now warranted.142 
 
1.6.7 Cardiovascular system  
A non-randomised, crossover trial investigated the effects on oxygenation of targeting a higher 
(93-96%) versus lower (89-92%) SpO 2 range in low birthweight infants receiving mechanical 
ventilation in the early neonatal period (median age 42 hours).143 Although there was a  
significant difference in the respective oxygen contents (18.0 vs 16.9 ml/dl, P<0.001), there 
was no change in oxygen consumptio n or any compensatory increase in cardiac output. The 
authors concluded that the “low normal” SpO2 target range allowed for less oxygen exposure 
without deleterious cardiovascular side effects. Similarly, an uncontrolled study of decreasing  
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 arterial blood saturation from 95% to 90% in preterm infants at a mean age of 61.7 hours, 
measured changes in echocardiographic indices.144 This study found that a decrease in SpO2 
did not have any effect on the pulmonary circulatory haemodynamics or the ductus arteriosus. 
 
It is hypothesised that a persistence of inadequate oxygenation beyond term-equivalent age 
may predispose infants with CLD to pulmonary hypertension. 145-149 Several physiological 
studies have also demonstrated that infants with CLD may respond to even small changes in 
oxygenation with significant changes to pulmonary artery pressure (PAP) and/or pulmonary 
vascular resistance (PVR).150-152 However, the effects of these cardiovascular changes on 
clinically important, long-term outcomes have not been demonstrated in randomised trials. 
 
1.6.8 Summary of effects of differing target oxygen levels on outcomes 
Despite oxygen being an exceedingly common therapy used on newborn infants, there is 
surprisingly little direct evidence in the form of randomised controlled trials of the most 
appropriate ranges to maintain oxygen levels for either term or preterm infants, or a threshold 
value below which oxygen should be administered. Generally, targeting higher oxygen levels 
seems to improve short-term outcomes. However, higher oxygen levels have very few 
demonstrable long-term benefits that can be supported by direct evidence, and may potentially 
have significant adverse sequelae. The existing evidence in summarised in Table 1. 
 
It was thus necessary to investigate the benefits and harms of maintaining higher versus 
standard oxygen saturation levels using a randomised controlled trial study design.  As noted 
by Duc and Sinclair (1992, page 194),25 a high priority for future research should be given to a 
"comprehensive assessment of the effects of targeting ambient oxygen concentration to 
achieve a lower vs higher range of PaO2 (or other index of oxygenation)”. Hence it was 
important to address this research question with a sound and appropriate methodological 
design,154 so that this experimental treatment could be evaluated comprehensively, and a real 
improvement in medical care achieved. Moreover, the lack of direct evidence of the effect of 
different oxygen levels on clinically meaningful, long-term outcomes has contributed to the 
wide variation in practice currently seen86, 155-157 and has fuelled the current controversy 
surrounding the issue of what are the most appropriate levels of oxygenation for preterm 
infants.24, 27, 91, 158-165  
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Table 1: Summary of existing evidence regarding effects differing target oxygen levels  
 
System effect 
 
Physiological e vidence 
 
Uncontrolled, human 
observational evidence 
 
Randomised 
controlled trials 
(RCT) 
Early mortality   
87-89 
No major effects 
Late mortality  
91-94 
No major effects 
90 
No major effects 
Ophthalmic 
102, 110 
Suggests adverse effects of 
higher oxygen targeting 
91, 105 
Suggests adverse effects of 
higher oxygen targeting 
 
107-109, 111 
Suggests beneficial effects of 
higher oxygen targeting 
87, 95, 103, 104 
Suggests adverse effects of 
higher oxygen targeting 
 
106 
No major effects 
Early growth 
 
13, 91 
Suggests adverse effects of 
higher oxygen targeting 
106 
No major effects 
Long-term growth 
 
9, 12, 15, 84, 85, 112, 114 
Suggests beneficial effects of 
higher oxygen targeting 
 
113 
No major effects 
No RCT evidence 
Long-term 
neurodevelopment  
1, 8, 10, 11, 14-17, 115-120  
Suggests beneficial effects of 
higher oxygen targeting 
No RCT evidence 
Sleep patterns 
 
82, 83, 121, 122, 124 
Suggests beneficial effects of 
higher oxygen targeting 
123 
No major effects 
No RCT evidence 
Respiratory  
29, 30, 80-82, 125-127, 134, 
135, 137-139 
Suggests beneficial effects of 
higher oxygen targeting 
18-22, 29, 80, 81, 124, 131, 132, 
134-136, 140, 142, 153 
Suggests beneficial effects of 
higher oxygen targeting 
106 
Suggests adverse effects of 
higher oxygen targeting
 
Cardiovascular 150-152 
Suggests beneficial effects of 
higher oxygen targeting
 
143, 144   
No major effects 
145-149 
Suggests beneficial effects of 
higher oxygen targeting 
No RCT evidence 
Numbers indicate reference numbers. 
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1.7 Hypothesis  
The primary hypothesis of this thesis was that maintaining oxygen saturation at a higher level, 
among babies born at less than 30 weeks’ gestation who are oxygen-dependent at 32 weeks 
postmenstrual age, improves physical growth and neurodevelopment at one year corrected age. 
 
1.8 Aims 
The aims of the study were: 
1.8.1 to determine whether there was a clinically important difference between the study 
groups, higher (95-98%) versus standard (91-94%) oxygen saturation targeting ranges, 
in terms of long-term physical growth and neurodevelopment; and 
1.8.2   to determine the benefits and harms of the treatment, as measured by morbidity, 
mortality and burden to the health care system and families. 
  
1.9 Summary of the project’s significance and potential impact 
This is the first randomised controlled trial to examine whether maintaining a higher level of 
oxygen saturation in the blood of chronically oxygen-dependent babies improves growth and 
development. The study aimed to establish whether a specified higher range of oxygen 
saturation, as measured by pulse oximetry, was both safe and efficacious. 
 
The benefits of maintaining a higher oxygen saturation level may occur in the form of: an early 
discharge because of enhanced weight gain and a better respiratory course; a "healthier" infant 
that is more interactive with parents; weight gain and neurodevelopmental outcomes that are 
significantly better at one year corrected age; and less frequent rehospitalisations.  The costs of 
maintaining a higher saturation may occur in the form of: an extended hospitalisation because 
of more time on oxygen; the illness being perceived as more severe by parents and staff; an 
increase in monetary costs to the health care system and to families; and increased stress on 
parents if a baby is discharged home on oxygen and the caring role is shifted to parents. 
 
1.10 BOOST acronym  
The randomised trial described in this thesis operated under the acronym of the “BOOST” 
trial. This stood for the Benefits Of Oxygen Saturation Targeting trial. The BOOST logo 
appears on various forms and documents throughout this thesis. 
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CHAPTER 2: METHODS 
 
The question under investigation, establishing the benefits and harms of higher oxygen 
saturation targeting, was studied using the randomised, controlled trial methodology. The 
detailed methodology of the study design reported as follows conforms to the revised 
CONSORT statement166 for the quality reporting of randomised trials. 
 
2.1 Eligibility criteria  
 
2.1.1 Inclusion criteria 
· Babies born at less than 30 weeks’ gestational age who were oxygen-dependent at 32 
weeks postmenstrual age. 
· Agreement of parents to participate in long-term follow-up. 
· Registration at one of the neonatal intensive care units (NICU) of the eight 
participating perinatal centres (see Appendix 2). 
 
This gestational age limit was chosen as infants born at less than 30 weeks’ gestation are at 
significantly increased risk of both the clinical problem, prolonged oxygen dependency,3 and 
the outcomes to be assessed (see section 2.6).28 Similarly, the choice of studying infants who 
remained oxygen-dependent only after 32 weeks pma, rather than an earlier age, was to 
exclude those infants for whom prolonged oxygen dependency is not a significant clinical 
problem. Using the current definition of chronic lung disease, oxygen dependency at 36 weeks 
pma,4 as the enrolment criterion would have been problematic for two reasons. First, it would 
have substantially increased the recruitment period as the numbers of eligible, oxygen-
dependent infants would have been more than halved from a cohort of 545 eligible infants at 
32 weeks pma to only 262 infants being eligible at 36 weeks pma during the recruitment 
period.167 More importantly however, it is around 32 weeks pma that extremely preterm 
infants are emerging from the acute, critical phase of their illness and clinicians are faced with 
the dilemma of whether to aim the infant’s oxygen saturation level higher to maximise 
potential benefits or target lower levels in order to ensure the infant is discharged home as 
soon as possible.  
 35 
Chapter 2: Methods  
 
The trial was designed to be pragmatic, rather than explanatory,168 in nature (see section 
2.2.2). Hence, there was no requirement for any formal assessment of oxygen dependency, 
such as an air safety test,169, 170 in order to fulfill the inclusion criteria. Infants simply needed 
to be receiving supplementary oxygen, via any mode, in order to be eligible for enrolment. 
Increasing the complexity of the enrolment procedures would have been a barrier to 
recruitment.171 
 
Prior to 32 weeks pma, some otherwise eligible infants would have already been transferred 
back to a special care nursery closer to home. It was not logistically possible to approach all 
these infants, given the trial resources. Hence, only eligible infants who were still in one of the 
eight participating tertiary neonatal intensive care units were approached for consent. In order 
to recruit enough infants in a timely manner (see section 2.7.1) the trial needed to be 
multicentred, which also increased the generalisability of the results by incorporating a 
spectrum of clinical practice. All eight perinatal neonatal intensive care units in New South 
Wales (NSW) and the Australian Capital Territory (ACT) were invited to participate and all 
but one agreed to join. An additional centre from Queensland also joined the collaboration 
approximately one year after recruitment commenced (see Appendix 2 for the full list of 
participating centres).  
  
2.1.2 Exclusion criteria  
Infants with the following characteristics were not eligible for inclusion: 
· lethal and selected congenital defects, including: congenital heart defects; congenital 
lung defects; intestinal atresias or stenoses; anomalies of the abdominal wall 
· major surgery and disease complications influencing growth and development directly, 
including: intestinal resections/ostomies/fistulas; ventriculostomies; ventricular shunts 
· grade 3 or grade 4 intraventricular haemorrhage (IVH), periventricular (cystic) 
leukomalacia (PVL), porencephalic cyst, or any other established neurological injury 
or abnormality by 32 weeks postmenstrual age (diagnosed by head ultrasound at 
enrolment or earlier) 
· babies expected to die imminently at the time of eligibility assessment (as determined 
by the primary clinician) 
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· babies not expected to live with the biological mother (if adoption was planned or if 
baby was to live with family other than the biological mother, as noted in medical 
record or after discussion with clinical staff) 
· infants of multiple confinements if more than two infants were eligible at 32 weeks 
postmenstrual age 
Infants with any of the conditions in the first three exclusion categories are known to be at 
significant risk of poor growth and neurodevelopmental outcomes,1, 17, 28, 172 the primary study 
endpoints, and hence they were not included in the trial population even though this may have 
implications for the generalisibility of the trial’s results. The uncertainty arises in otherwise 
well, extremely preterm infants who remain oxygen-dependent at 32 weeks pma, as to the best 
approach regarding their oxygen saturation levels in order to maximise benefits whilst 
minimising harms.  We thought it unethical to approach parents of infants expected to die 
imminently at the time of eligibility assessment and thus they were also excluded. Infants who 
were not expected to live with their biological mother were also not considered for inclusion 
as several of the secondary outcomes required information that could only be provided by the 
infant’s mother, such as the Edinburgh Postnatal Depression Scale (see section 2.6.3.4).  
 
We thought that parents of infants from multiple births (e.g. twins) might be reluctant to enter 
their children in the trial if there was a possibility that the infants might receive different 
treatments which could potentially result in differing lengths of hospital stay. We anticipated 
that related multiples, that is more than one eligible infant from one birth, would comprise less 
than 10% of the cohort. Hence, we thought it both ethical and feasible to randomise only one 
infant from an eligible pair, and then allocate the second eligible infant to the same treatment 
group as their sibling (see section 2.2.2). Confinements with three or more eligible infants 
were not considered for inclusion as this situation would be extremely rare and would pose 
both ethical and feasibility dilemmas. 
 
2.1.3 Permitted temporary protocol violation 
It was necessary to allow temporary protocol violations in situations where higher oxygen 
targeting was considered established standard practice and where the masking of actual 
saturation values required by the protocol (see section 2.2.3) would not be appropriate. 
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Clinicians were encouraged to discuss the need to temporarily withdraw infants from the 
protocol with the principal investigator (DHS, see Appendix 1) before doing so. Situations or 
conditions that warranted temporary suspension of the trial protocol included a significant 
intercurrent illness, surgery, threshold retinopathy of prematurity,173 or significant 
abnormalities on polygraphic sleep studies. As soon as possible following the resolution of the 
situation or condition, the study protocol was resumed. The days and reasons for temporary 
protocol suspension were documented.  
 
2.1.4 Permanent withdrawal criteria 
All attempts were made to keep permanent protocol withdrawals to a minimum. Legitimate 
reasons for withdrawing an infant from the stud y protocol permanently included parental 
refusal to continue participation, or at the clinician’s request (again following discussion with 
the principal investigator) if it was believed that remaining in the trial would significantly 
compromise the infant’s clinical state. The reasons and dates of permanent protocol 
suspension were documented. All withdrawals were maintained in the groups as originally 
allocated for analysis. 
 
2.2 Study design 
2.2.1 Treatments under study 
The two study arms consisted of maintaining oxygen saturation levels, using pulse oximetry 
(SpO2), at a higher (95-98%) versus standard (91-94%) level. The oximeters used, Nellcor N-
3000 Symphonies, calculate oxygen saturation using an algorithm which assesses functional 
oxygen saturation (see section 1.4).51, 174 Oximeters which assess fractional saturation, such as 
the Ohmeda brand, display values approximately 2% below oximeters using a functional 
saturation algorithm.52, 53 Both types of oximeter were commonly in use in the participating 
NICUs at the time of trial recruitment so staff were familiar with their use and operation.  
 
The two SpO 2 levels were chosen as they represented two ends of the spectrum of current 
accepted clinical practice as assessed by a pre-trial survey of the participating units.86 Opinion 
was evenly divided amongst respondents as to which end of the spectrum was most beneficial  
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with regard to growth and development outcomes, suggesting genuine equipoise regarding the 
treatment options. 
 
2.2.2 Study type and randomisation scheme  
The study design used was a randomised controlled trial as this methodology provides the 
most reliable evidence of the effects of interventions or treatments, particularly when such 
effects are moderate.175 The trial was pragmatic in nature, that is, it was designed to enable a 
comparison of the two treatments under the conditions in which they would be applied in 
practice.168 This approach differs from trials of an explanatory nature that seek to assess the 
effect of a drug or treatment under “laboratory” conditions rather than how the treatment 
would be applied in real clinical practice. It is now well recognised that pragmatic trials give 
clinicians the type of evidence most applicable to their daily practice175 and this is why this 
approach was chosen.  
 
Randomisation was stratified using a dynamic balancing method176 to ensure balance of 
treatment allocation within hospital, confinement status (singleton/unrelated multiple versus 
related multiple births) and gestational age (22-27 versus 28-29 weeks) stratum. Singleton 
births were those with only one infant born per pregnancy. Unrelated multiples were infants 
born of a multiple pregnancy, but in which by 32 weeks pma only one infant from the birth 
was eligible for enrolment (the other infant(s) being either ineligible or dead). For the 
purposes of randomisation, both these types of infants were treated as singletons and were 
allocated within one randomisation scheme. Related multiples were pairs of eligible infants 
from the same birth where one infant of the pair was randomised, and the second infant was 
allocated to the same treatment group as their s ibling. Stratification by hospital was used to 
overcome the potentially confounding effect of differing policies in each of the participating 
centres with regard to oxygen monitoring, titration and weaning, which may affect secondary 
outcome measures such as length of hospital stay. Gestational age is known to be highly 
prognostic of growth and development outcomes1, 3, 28 so balance of treatment allocation for 
this factor was considered essential. Pairs of eligible siblings randomised as a single entity 
were stratified only within hospital strata and not by gestational age strata as the small 
numbers of such pairs rendered further stratification unnecessary. This was managed by  
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having a separate randomisation scheme for related multiples in addition to the main scheme 
for singleton/unrelated multiples. The dynamic balancing method was programmed to allow 
for a maximal imbalance of 4 or 8 infants per hospital strata (depending on NICU size, 
categorised as small or large) within the singleton/unrelated multiple randomisation list. The 
same imbalance limits were allowable for small and large sized NICUs within the related 
multiple randomisation scheme. These imbalance limits were additive, allowing for an overall 
maximum imbalance between the treatment groups of 8 in the smaller hospitals and 16 in the 
larger hospitals.  
 
Concealment of treatment allocation is an important step in ensuring bias is minimised within 
the randomised trial methodology.177-179 Allocation concealment in this trial was ensured using 
the following methods. Randomisation was performed centrally at the National Health and 
Medical Research Council Clinical Trials Centre during a telephone call from the trial 
coordinator (LMA, see Appendix 1).  Randomisation to either treatment group was registered 
at the randomisation centre. Reports were provided to the trial statistician (JMS, see Appendix 
1) by the NH&MRC Clinical Trials Centre every 3 months regarding recruitment progress and 
balance within strata, without identifying the treatment allocation of particular infants by 
ensuring concealment of the actual treatment group. The study oximeter was allocated by the 
trial coordinator and was only identified as allocated to a particular infant. The research 
nurses, staff and parents did not know to which treatment group the infant had been assigned. 
 
2.2.3 Blinding procedure  
Concealing the treatment group to which the patient has been allocated from the patient (or 
parents in this case), clinicians and outcome assessors (“double-blinding”) if feasible, can 
reduce both co- intervention and ascertainment bias within a trial.180, 181 In this trial, double-
blinding was achieved using the following method. Randomised infants were assigned a 
specific study oximeter which, after calculating the infant’s saturation in the usual manner, 
was adjusted to display a value 2% above or 2% below (depending on treatment allocation) 
the infant’s actual saturation. For example, when the displayed value was 94%, the actual 
SpO2 value was either 92% or 96%, depending on the treatment group to which the infant had 
been allocated (Figure 3). 
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Staff and parents were then asked to target the infant’s SpO2 in the 93-96% range, thus 
blinding them to the actual SpO2 ranges being targeted. The adjustment was facilitated by the 
oximeter manufacturer, Nellcor Puritan Bennett, who produced and installed a specific 
research configuration program into each study oximeter which enabled an offset adjustment 
of between -5% and +5%. 
 
Figure 3: Mechanism for blinding of treatment allocation 
 
 
 
 
 
 
 
 
 
 
Quality control checks of each oximeter’s offset were made every 3 months by the study 
coordinator (LMA) using a Nellcor Pulse Oximeter tester (model SRC-2; settings: Light High 
1, Modulation Low, RCAL/MODE 63/Local). How each oximeter was offset, either -2% or 
+2%, was known only to the trial coordinator. Study oximeters were stored centrally at the 
coordinating centre and returned there (by courier or collection by the research nurses) after 
each enrolled infant had completed the intervention, ensuring that no participating centre had a 
store of study oximeters which might allow local staff to deduce the treatment allocation. 
Before the study oximeter was applied to the infant after enrolment, any other form of oxygen 
monitoring (including another oximeter or a trancutaneous oxygen monitor) was removed to 
prevent unblinding of the study oximeter’s offset level. Very few preterm infants beyond 32 
weeks pma routinely underwent any other forms of oxygen monitoring, such as intermittent 
intra-arterial blood gas measurements, that might also potentially unblind treatment allocation. 
Participating institutions agree to keep such interventions to an absolute minimum in trial 
infants. 
Actual target range Actual target range
maintained 91-94% maintained 95-98% 
(2% below displayed value)               (2% above displayed value) 
Study oximeter adjusted to display either 2% 
above or 2% below infant’s actual saturation value
All trial infants target SpO 2 93-96% 
using study oximeter
Standard group   Higher group
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2.3 Recruitment and consent procedures  
The institutional ethics committees of the eight enrolment centres approved the trial protocol 
and the consent forms and information sheets specific to each institution. Annual progress 
reports were submitted to each ethics committee for the duration of trial recruitment and 
follow-up. All ethics committees required immediate adverse event reporting. 
 
Designated medical, nursing and data liaison representatives were identified at each enrolment 
centre to assist with recruitment and consent. These personnel identified eligible infants 
approaching 32 weeks pma and notified the trial coordinator who kept a log of all infants. 
Either the liaison representatives, a research nurse or the infant’s primary clinician (each 
participating hospital had preferred personnel for recruitment procedures) then approached the 
parents or guardians to explain the general outline of the study and invited them to participate 
in the trial. A parent information sheet (again specific to each centre) was given to the parents 
(see Appendix 3). Parents were re-approached a few days later and asked whether they would 
agree to participate in the trial.  If they agreed, a signed and witnessed consent form was 
completed182 (see Appendix 3). This was photocopied and given to the parents.  The original 
consent form was kept at the coordinating centre, and another copy was placed in the infant's 
medical record in the NICU. 
 
If the parents were from a non-English-speaking-background, an individual fluent in the 
parent's language was enlisted for the purposes of interpreting during the consent procedure, 
and to explain and ensure that the details regarding follow-up were understood.  A hospital 
interpreter or other hospital personnel was engaged to assist in interpreting material, and 
relatives of parents were only used if suitable personnel were unavailable. 
 
A pager number for study personnel was noted on the consent form.  In the first instance, the 
research nurse fielded all calls related to involvement in the study.  If necessary, the principal 
investigator (DHS) was also available for consultation. Parents were informed both orally and 
in writing (via the consent and information sheets) that they had the right to withdraw from the 
study at any time without jeopardising the care of their infant. 
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It is well recognised in both adult and paediatric trials that the characteristics of participants 
are often different from those who are eligible, but do not participate in the trial.183-187 This 
phenomenon may have implications for the generalisability of the trial results. In order to 
assess any such effects, a log of eligible but non-enrolled infants was tabulated by the trial 
coordinator following notification from the liaison representative at each individual centre 
when an eligible infant was either missed or the parents refused consent. Data regarding 
several maternal and infant characteristics of all infants born at less than 32 weeks’ gestation 
in NSW and the ACT are routinely collected as part of the NICUS data collection. 188 
Permission was sought to access de-identified, summary data of infants within the NICUS data 
collection who were eligible, but not enrolled in the trial. These summary data were collated at 
the end of the trial recruitment period. 
 
2.4 Enrolment procedures 
 
At enrolment, but prior to randomisation, several measures were made to determine whether 
selected exclusion criteria should be applied and this information was recorded on the trial 
enrolment form (see Appendix 4). The presence or absence of severe intracranial pathology 
was determined via head ultrasound, done at approximately 31 weeks postmenstrual age to 
rule out grade 3 or 4 intraventricular haemorrhage, periventricular leukomalacia or 
porencephalic cyst.  The ultrasound was performed by the technician and radiologist who 
usually performed the procedure and the results were interpreted at each site. 
 
At enrolment, but following randomisation, several measures were made to determine the 
baseline status for some of the potential confounders and/or adverse outcomes. Maternal 
depression could potentially confound the primary developmental outcomes.189, 190 To 
determine whether maternal postnatal depression scores were distributed equally between the 
two groups at baseline, the Edinburgh Postnatal Depression Scale (EPDS) was given to the 
mother for self- completion at enrolment.  If a score on the EPDS was higher than 12, then the 
mother was referred to appropriate psychological and/or psychiatric counselling services as 
scores above this level are predictive of clinical depression.191 An elevated EPDS was not a 
reason to withdraw the family from the study unless the mother and/or the counsellor felt that  
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this was necessary. An infant eye examination was performed by a paediatric ophthalmologist 
at the enrolling NICU.  Examinations were performed at 32 weeks postmenstrual age.  
Grading of the severity of ROP was recorded according to the International Classification of 
Retinopathy of Prematurity.173 Parents were also asked to self-report several psychosocial 
factors that may be prognostic for infant growth and development. These included the highest 
level of parental education, parental height, and maternal age and ethnicity. Information 
regarding parental occupation, both current and usual, was sought and classified according to 
the Daniel occupational status scale score.192 
 
Once eligibility was determined and informed consent obtained, the study coordinator was 
contacted and randomisation occurred (see section 2.2.2). The research nurse was then notified 
of the specific study oximeter to be assigned to each newly enrolled infant.  She then 
facilitated its placement on the enrolled infant as soon as possible either by taking it to the 
infant’s bedside or by having it couriered to centres remote from the coordination centre (such 
as Newcastle, Canberra and Brisbane). Instructions for oximeter use and the desired (blinded) 
target range to be maintained were placed prominently near the study oximeter. Brightly 
coloured “BOOST Trial” stickers were placed on the infant’s crib/cot and on the front of the 
case notes to alert staff that the infant had been enrolled in the trial. These, and other profile 
raising measures (such as “I’m a BOOST Baby” T-shirts given to the parents after enrolment 
and at the completion of data collection, see Appendix 5), are recognised methods for 
promoting a randomised trial.193 
 
2.5 Treatment plan 
2.5.1 Administration of oxygen  
Administration and maintenance of oxygen was managed by the nursing staff and/or parents 
(in the case of home oxygen). Criteria for titrating or ceasing ambient oxygen were determined 
by the attending clinicians and not specified by the trial protocol. The blinded target SpO2 
range for all infants enrolled in the study was 93-96% (see Figure 3). Targeting of the 
allocated saturation range was maintained for the duration of the infant’s oxygen need in either 
a tertiary or non-tertiary nursery, or at home. Prior to any back-transfer of an infant still 
receiving the trial intervention to a non-tertiary hospital, contact was made with the non-  
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tertiary nursery staff in order to provide inservice education, equipment and technical support 
as required. An explanatory letter for the attending clinicians at the back-transfer hospital 
accompanied each study infant on discharge from the recruiting NICU. 
 
2.5.2 Monitoring of oxygen saturation  
The allocated study oximeter was attached to one limb of the infant via a pulse oximeter probe 
in order to obtain a non- invasive reading of the saturation of haemoglobin with oxygen in 
arterial blood (SpO2). The study oximeter was placed next to the infant’s cot or crib and 
displayed the current (blinded) SpO2 and (actual) heart rate on a screen.  The frequency of 
saturation monitoring, either continuous or intermittent, and specific alarm limit settings were 
also determined by the attending clinicians and not specified by the trial protocol.  
 
As the trial was pragmatic in nature,168 assessment of treatment compliance was undertaken 
only to have some measure of whether, in general, two different treatments were being 
administered. Thus the purpose of the compliance monitoring was not to ensure strict 
adherence to the protocol as would be required if treatment efficacy was being assessed (as in 
an explanatory tr ial), but simply to assess compliance with the treatment as it would be 
administered in actual clinical practice (that is, to measure treatment effectiveness).194 Hence, 
continuous oxygen saturation monitoring was not considered necessary or appropriate.  
 
SpO2 measurements for the purposes of monitoring compliance were obtained by collecting 8- 
(for home oxygen infants) or 24-hour (for in-hospital infants) recordings195 on a twice-weekly 
basis whilst the infant remained in hospital and approximately monthly if the infant was 
discharged on home oxygen.  When the research nurse arrived at a neonatal unit for data 
collection, the previous 8 or 24-hour period of SpO2 measurements were “downloaded” into a 
personal computer at the infant’s bedside and analysed using computer software (specifically 
written for the trial’s use) that gave a statistical summary of the SpO 2 values.  Because 
vigorous movements can affect the ability of the oximeter to detect the arterial pulse, such 
artefactual readings were collected but excluded from the compliance analysis.  
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Results from the downloaded recording were summarised on a printable report which 
contained a frequency distribution histogram of the blinded saturation values, the median and 
modal saturation values, the number of valid samples compared with the total number of 
samples, and the proportion of time the infant had spent in the desired target range over the 
download period (Figure 4). This information was fed back immediately to nursing and 
medical staff caring for the infant in order that oxygen therapy could be titrated to comply 
with the target range if required. A copy of the report was also placed in the infant’s case notes 
for future reference. For satisfactory compliance, the median saturation value and at least 
approximately 40% of the SpO2 readings should have been within the blinded 93-96% target 
range. This information was recorded on a data collection form and entered into the trial 
database by the research nurses on return to the coordinating centre (see Appendix 6). 
 
Figure 4: Sample download report form 
 
 
 
 
 
 
 
 
 
 
 
 
 
Once the clinicians deemed an infant to be weaned from supplemental oxygen into room air, 
the designated study oximeter remained at the infant’s bedside for one week (or longer, if 
required). After that time the research nurse collected a final 8 or 24-hour download report 
with the infant in room air. Again, if the median saturation value and at least 40% of the SpO 2 
values fell within the target range, the infant was deemed to have completed the study  
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intervention and the study oximeter was removed. This procedure was undertaken either in the 
hospital or the home depending on where the infant was when weaning to air was achieved. If 
during the first week following weaning to air the infant required further saturation monitoring 
and/or oxygen therapy, his/her study oximeter (still at the bedside) was used. If, after the 
return of the study oximeter to the coordinating centre, the infant required further saturation 
monitoring and/or oxygen therapy in the first year of life, a standard, non-trial oximeter was 
used. Any such periods of additional supplemental oxygen therapy and/or monitoring were not 
considered part of the trial intervention. 
 
Monitoring of the degree to which SpO2 was being kept within the allocated treatment range 
(unblinded compliance) was managed by the study coordinator.  These data and analyses were 
fedback to the research nurses and clinical staff if remedial action was necessary to improve 
compliance, while ensuring continued blinding of treatment allocation.   
 
2.5.3 Equipment  
Specially adjusted Nellcor N-3000 pulse oximeters were used to ensure blinded targeting of 
the allocated oxygen saturation range could be achieved (see section 2.2.3).  
 
Oxygen was administered to infants either by nasal cannulae, positioned under the nares and 
secured to the face with adhesive; headbox with humidification; closed isolette oxygen 
delivery system; or via a mechanical ventilation circuit as each infant’s condition warranted.196 
 
Eligibility for home oxygen was determined by the infants’ attending clinicians. There was no 
specific oxygen-dependency test required by the trial protocol.170 Eligibility criteria for 
readiness for home oxygen usually included respiratory stability, feeding and weight gain 
progress and whether the parents were comfortable taking the baby home on oxygen. Oxygen 
for home use was delivered via cylinders equipped with a flow meter capable of ultra low flow 
delivery (<3 litres/min) or an oxygen concentrator. Infants receiving home oxygen therapy 
were managed in conjunction with the usual services provided by their hospital of discharge. 
This may have included family support nurse visits and follow-up with specialist paediatric 
respiratory physicians and/or paediatricians.  
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2.6 Outcome measures  
 
A variety of clinical, psychosocial and health service utilisation information was collected on 
each infant between enrolment at 32 weeks pma and 12 months corrected age (chronological 
age plus weeks of prematurity). A schema of the data collection timepoints is illustrated in 
Figure 5. 
Figure 5: Outcome measurement timeline schema  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Infants enrolled in the trial had frequent and regular contact with the research nurses in 
hospital and at home whilst receiving their allocated intervention, primarily during visits to 
download oxygen saturation compliance information.  After supplemental oxygen was no 
longer required, contact with parents was maintained by the research nurses on a quarterly 
basis to ascertain health service utilisation data, and determine whether rehospitalisation or 
death had occurred.  This information was confirmed by a combination of parent interview, 
review of the medical record, contact with the primary general practitioner or paediatrician, 
and death certificate.  In addition, confirmation of current contact details was made to decrease 
the opportunity for follow-up losses. To improve communication with other providers  
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regarding study subject participation, a notification sheet identifying the infant as a study 
participant was placed in the front sleeve of the infant’s Personal Health Record booklet (the 
"blue book") along with the discharge summary. 
 
2.6.1 Baseline measures 
The appropriate demographic and clinical variables of each baby were recorded from the 
medical record using standard clinical definitions.  These included: antenatal steroids;197 
gestational age;71, 72 sex;73 birthweight;73 length at birth; head circumference at birth; worst 
grade intraventricular haemorrhage; 1 and 5 minute Apgar scores; exogenous surfactant 
treatment;71 presence or absence of a patent ductus arteriosus;74 days of assisted ventilation;74 
days receiving parenteral nutrition; episodes of necrotising enterocolitis; maternal ethnicity;73, 
198 parental education, occupation levels and health insurance status;199 breast versus bottle 
feeding at discharge;200 parental heights; and other features of the neonatal course (see 
Appendix 7). Collection of these data was necessary to establish baseline comparability 
between the two groups for potential confounders and strong independent predictors of growth 
and development. 
 
2.6.2 Primary outcomes 
2.6.2.1 Growth measures  
Growth was measured at three timepoints during the first year of life: at 38 weeks 
postmenstrual age, and at 4 and 12 months corrected age (see Appendix 8 and Appendix 9). 
These data were collected either during initial hospitalisation, by the infant’s general 
practitioner, or as part of attendance at a high-risk infant follow-up programme, and were 
collated by the research nurses. Growth was measured by mean weight, length, and head 
circumference. An assessment of the proportion of infants small for their age was undertaken 
by calculating the proportion of infants with weight or length less than the 10th centile, or 
head circumference less than the 3rd centile.201 
 
Growth was measured at these timepoints as this was the usual practice in the participating 
units. The significance of early growth failure remains controversial with several investigators 
noting a persistence of poor growth to school age and beyond,112, 140, 202, 203 whilst more recent  
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work has suggested that even though very preterm infants are often smaller than expected in 
early childhood, they show catch-up growth later in life, into adolescence or later.204, 205  
Nevertheless, participating clinicians felt that early growth failure was an important outcome 
as it may be a marker for later problems.  
 
2.6.2.2 Major developmental abnormality 
The proportion of infants in each group with a major developmental abnormality at 12 months 
corrected age was also ascertained. This was defined as blindness, cerebral palsy or a Revised 
Griffiths Developmental Scale score more than 2 standard deviations below the mean (general 
developmental quotient less than 77).206 Deafness was not included within the definition of 
major developmental abnormality as it was not considered that differing oxygen saturation 
target levels would affect this outcome. Blindness was defined as a visual acuity in both eyes 
of less than 6/60.207 Cerebral palsy was diagnosed if the child had non-progressive motor 
impairment characterised by abnormal muscle tone and a decreased range or control of 
movements accompanied by neurological signs.208 Infants were assessed using the Revised 
Griffith’s Scale by accredited Griffith’s assessors. Such assessors were usually developmental 
paediatricians or specialist paediatric clinical psychologists. Each recruitment centre had its 
own high-risk infant follow-up team which included personnel accredited to perform the 
Griffith’s assessments, a follow-up coordinator and usually a paediatric physiotherapist. Seven 
of the eight follow-up teams involved in the trial had undergone joint Griffith’s training but no 
formal inter-rater reliability assessments were undertaken. If the infant was not able to return 
to the follow-up clinic connected to the discharge hospital or a clinic of one of the other 
participating centres, arrangements were made for a regional paediatrician, accredited in 
Griffith’s assessments, to assess the infant if possible. A diagnosis of cerebral palsy was made 
by the paediatrician examining the infant at 12 months corrected age. Ophthalmic assessments 
were made by referral of the infant by their follow-up team to local centres skilled in assessing 
infants born prematurely.  
 
The definition of major developmental abnormality and its assessment methods was standard 
for extremely preterm infants in the NSW, ACT and Queensland region during the time the 
trial was undertaken. The Griffiths Mental Development Scale is a well-validated tool for  
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assessing infant development at one year corrected age.209 The 1996 revision used in this trial 
was re-normed using a cohort of British children from the early 1990s, rather than the 
distribution of developmental quotients based on the original sample of British children from 
1954.206 There are several reasons why the Griffiths Scale is used in this region rather than 
other scales, such as the Bayley Scales of Infant Development.210 The primary reason is that 
the Revised Griffiths Scale looks at development in five different areas including gross motor, 
personal-social, speech and language, eye-hand co-ordination and performance (general play). 
A sixth area, practical reasoning, is also measur ed but this is not part of the assessment until 
the third year of life. This format allows for a more exact assessment of which areas are 
causing difficulty for children. The Bayley Scale uses only a motor index and a cognitive 
index. The Bayley motor assessment combines gross motor and fine motor skills and the 
mental developmental index mixes play and language. This means that areas of development 
that are not necessarily developing at the same rate are mixed together in the assessment. For 
example, if an infant cannot speak or has a specific language delay, an assessment of cognition 
and other scores are still able to be obtained using the Griffith Scale. Alternatively, if a Bayley 
scale were used in this situation, once a ceiling on a language item is reached, the scoring is 
maximised. Moreover, the Griffith Scale can be administered, with good predictive value,211 
into early childhood, making it preferable if longer-term follow-up of the cohort is warranted.  
 
The predictive value of Griffiths assessments at 12 months corrected age in screening for later 
neurodevelopmental problems is variable. In one study the correlation between the 1 year 
Griffiths general quotient and 5 year IQ was 0.47,211 whilst others have found good 
correlations (correlation coefficient 0.71) between developmental assessments at 1 and 7 years 
of age212 suggesting reliable predictive validity for this tool at 12 months corrected age. 
Developmental status as assessed by the Griffiths scale at 1 year has been shown to be 
predictive for developmental status at 2 years,213 the timepoint at which many other studies 
involving preterm infants usually assess children for major developmental abnormality. It was 
for these reasons, and the fact that it was usual clinical practice by the participating centres to 
follow-up these children at 12 rather than 18-24 months, that neurodevelopmental assessment 
was undertaken in this format. 
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Similarly, the predictive value of a diagnosis of cerebral palsy at 12 months corrected age is 
good. 1998 data from the host institution (King George V Hospital) revealed a diagnosis of 
cerebral palsy at 1 year had a 90% sensitivity and 99% specificity in predicting cerebral pals y 
at 5 years of age (n=531 children assessed at 1, 3 and 5 years). Others have demonstrated that 
an early assessment of neuromotor signs has good predictive value for a diagnosis of cerebral 
palsy.214-216  
All outcome data collected at 12 months corrected age were recorded on a data collection form 
(see Appendix 9). 
 
2.6.2.3 Pre-specified sub-group analyses  
Two sub-groups were identified a priori for supplementary analysis in addition to the full 
cohort of trial infants. These included infants born at less than 28 weeks’ gestation and those 
infants receiving continuing supplemental oxygen at home after discharge. Both these sub-
groups are known to have significantly increased risk of poor growth and development 
outcomes.3, 10, 12, 14, 17, 28, 84, 217 It was hypothesised that the experimental treatment, higher 
oxygen saturation targeting, might be more beneficial in these high-risk sub-groups.  
 
2.6.3 Secondary outcomes 
2.6.3.1 Clinical data to discharge  
Several secondary outcomes were measured (see section 2.6.3) as it was hypothesised that 
differing oxygen saturation targeting policies might influence health service utilisation and 
have cost implications if clinicians were to adopt the experimental treatment of higher 
saturation targeting as routine practice. The outcomes assessed included: the length of hospital 
stay (measured in days), in total and after randomisation at 32 weeks pma, and the 
postmenstrual age at discharge home; the duration of oxygen need, in total and following 
randomisation (measured in days); the postmenstrual age (measured in weeks) when 
supplemental oxygen was no longer required; and the duration of assisted ventilation, in total 
and following randomisation (measured in days). Other outcomes that were considered 
clinically important were the proportion of infants who remained oxygen dependent at 36 
weeks pma and the number of infants receiving home oxygen in each group. The proportion of 
infants receiving post-natal corticosteroids and diuretics was also assessed as these outcomes 
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may be indicators of the pulmonary effects of higher oxygen targeting. Prior observational 
evidence13 suggested that infants targeted at a higher oxygen saturation level feed better, hence 
the postmenstrual age at which full sucking feeds was achieved was also assessed and compared 
between the two groups.  
 
2.6.3.2 Deaths  
There was a potential that differing oxygen saturation targeting ranges might either improve or 
adversely affect the number of deaths occurring after randomisation and up to one year 
corrected age.92, 93 Deaths were ascertained by notification from the parents or enrolment 
hospital. The causes of deaths were classified by ICD-9 code218 and confirmed by hospital 
discharge summary, postmortem and/or coroner’s report or death certificate. The 
postmenstrual age at death and whether the death occurred in hospital or at home were also 
recorded (see Appendix 10). 
 
2.6.3.3 Ophthalmic outcomes  
Retinopathy of prematurity (ROP) was assessed by routine, standardised ophthalmic 
examinations by a paediatric ophthalmologist at two-week intervals from enrolment until 
resolution, treatment or stabilisation of the condition.  Grading of the severity of ROP was 
recorded according to the International Classification of Retinopathy of Prematurity173 (see 
Appendix 11). The worst stage of ROP and whether ablative retinal surgery treatment for 
threshold ROP was required were documented as severe ROP, with or without retinal surgery, 
is associated with unfavourable visual outcomes.97, 99, 219 Infants with severe ROP (stage 3 and 
above) underwent an eye examination at 12 months corrected age to assess major 
ophthalmological outcomes and visual acuity.  
 
2.6.3.4 Psychosocial outcomes  
It was hypothesised that higher oxygen saturation targeting might result in a “healthier” and 
thus more interactive infant during the first year of life. Conceivably this might also reduce 
postnatal depression rates, parental stress and the impact an extremely preterm infant has on 
the family unit. However, if higher oxygen targeting resulted in more days in both oxygen and  
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hospital, and/or increased the risk of home oxygen, these events might have adverse effects on 
the infant’s temperament, the parents and the family as a whole. It is well established that 
maternal depression and parenting stress can adversely affect long-term cognitive 
development in children.189, 190, 220-222  To assess these potential effects, several well-validated 
scales were administered during the first year of life. The scales were given to the mother at 
either the enrolment hospital or another centre where the follow-up visit took place.  If this 
were not possible, the forms (with a letter of explanation) were posted to the family. They 
were returned by reply paid mail.  The use of postal questionnaires to assess trial outcomes in 
this population of infants has been shown to be valid .223 
 
The Edinburgh Postnatal Depression Scale (EPDS) (see Appendix 12) was administered 
longitudinally to determine whether any changes occurred over time as a result of the infant 
being allocated to the standard or higher oxygen saturation target ranges. The EPDS was 
administered at four timepoints: upon enrolment at 32 weeks pma, at 38 weeks pma, and at 4 
and 12 months corrected age. The EPDS is a simple, widely used and well-validated screening 
tool for assessing depressive symptoms in the postna tal period.191 It has been validated within 
an Australian population224 and has been used on mothers following preterm birth. 225 
 
The 1978 revision of the Infant Temperament Questionnaire226, 227 was used to assess 
differences in temperament in infants at 4 months corrected age (see Appendix 13). This 
questionnaire has also been validated in an Australian sample228, 229  and in preterm infants.230 
A further development of this scale, the Toddler Temperament Questionnaire,231 was used to 
measure temperament in trial participants at 12 months corrected age (see Appendix 14). 
Again, this tool has been well validated232 and used in populations of Australian children.233 
 
Two further scales were administered at 12 months corrected age in order to assess the impact 
of the two treatments on the infants’ families. The Impact on Family Scale (see Appendix 15) 
was developed to assess the impact of childhood illness on a family234 and has been used in 
cohorts of very low birth weight infants.235, 236 The short form of the Parenting Stress  
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Index237, 238 (see Appendix 16) was chosen to assess parental stress as it has been validated in 
both parents of children with chronic illness239 and those with very low birthweight infants.240  
 
2.6.3.5 Health service utilisation  
It was hypothesised that higher oxygen saturation targeting might result in a “healthier” infant 
who used health care services less often after discharge.241-244 Conversely, it was also plausible 
that higher oxygen saturation targeting might result in increased rates of infants on home 
oxygen, which could in turn result in an increase in health care service usage.  
 
To assess any differences between the two groups, self-report of health service usage during 
the first year of life was ascertained by a combination of quarterly phone interview with the 
parents by the research nurses, review of the medical record and contact with the primary 
general practitioner or paediatrician. Information was also gathered on categories of provider 
(general practitioners, routine hospital follow-up visits, early childhood centre visits, nurse 
home visit, private paediatrician appointments or hospital emergency room / outpatient 
departments visits) and the reason for the visit (routine, specific illness or developmental 
therapy) as each of these ha s quite different associated costs (see Appendix 17).  
 
2.6.3.6 Rehospitalisations  
Similarly, it was hypothesised that higher oxygen saturation targeting might result in less 
frequent rehospitalisations in the first year of life.18-20, 22, 23, 245, 246 Data were collected 
prospectively on the number, postmenstrual age at readmission, duration and reason for 
rehospitalisation episodes during the first year of life. Self- report by the parents was confirmed 
by accessing the infant’s medical record. The reasons for admission were categorised as either 
for respiratory illness, surgery, neurological problems, social problems or for other reasons. 
The diagnosis related group (DRG) categories247 assigned to each readmission were obtained 
along with information about whether the infant had needed admission to an intensive care 
unit (ICU) and/or required mechanical ventilation during each readmission (see Appendix 18). 
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2.7 Statistical issues 
2.7.1 Sample size and power calculations  
2.7.1.1 Baseline risk estimates 
To determine an appropriate sample size, data were used from the follow-up programme at the 
host institution (King George V Hospital) for the year prior to trial commencement, 1995. This 
analysis was restricted to infants with the same inclusion and exclusion criteria as the trial. 
The standard oxygen saturation range during this period for such infants was a SpO 2 target of 
91-94%, hence the outcome rates reflect the trial control population.  Approximately 47% of 
1995 King George V infants who would have been eligible for the trial had a weight less than 
the 10th centile at one year corrected age, and 24% had a major developmental abnormality.  
 
2.7.1.2 Anticipated effects, power and sample size calculations  
Sample size was calculated to detect clinically important effects on the primary outcomes that 
if seen may convince clinicians to change their practice. This included a reduction in the 
proportion of infants with weights less than the 10th centile at 12 months corrected age from  
the baseline estimate of 47% to 30%; and a reduction of the major developmental abnormality 
rate from 24% to 10%. To achieve 80% power, with a 2-sided 0.05 significance level and a 
1:1subject ratio, a sample size of approximately 150 subjects in each arm was required. A total 
sample size of approximately 300 infants would also have the statistical power to detect 
clinically important differences in several other primary and secondary outcomes (see 
Appendix 19 - includes control data from several reference populations). The size of the 
treatment effect was important because it relates to the clinical importance of the effect.248 
Determining the minimal important difference was determined by asking clinical colleagues 
what they thought constituted a clinically meaningful difference in outcome rates.249-251 
Sample size calculations were undertaken using the SAM 2.1 sample size calculator (Glasziou, 
1992) which calculates sample size based on the differences between two proportions or two 
means. For proportions, SAM 2.1 uses an iterative method for Walter’s arcsine transformation 
with a continuity correction.252 
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2.7.1.3 Anticipated participation and follow-up rates 
The eight participating enrolment centres were of varying sizes and hence a different number 
of enrolments from each institution was expected, ranging from 8 to 24 infants per year, with a 
total of approximately 124 eligible infants per year expected to be available for recruitment. A 
90% participation rate and a 90% follow-up rate was anticipated based on other trials 
successfully completed at the participating centres. To allow for a 90% followup rate, the 
target sample size to be enrolled was 333 (= 300/0.9). With a 90% participation rate, 
approximately 111 (= 124 x 0.9) infants per year were expected to be recruited. 
 
2.7.1.4 Anticipated timeline 
Based on the expected numbers and participation rates, the anticipated recruitment period was 
3 years (111 x 3 = 333) with a further one year required for the completion of the primary 
outcome data collection (see dashed line in Figure 6). 
 
Figure 6: Numbers of infants recruited during the enrolment period 
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2.7.2 Database management and data storage 
Data were entered into a Microsoft ACCESS 2000 database for data management purposes.  
This database had levels of security allowing the trial coordinator access to all features of the 
patient record, whilst all other trial personnel were restricted to data fields that did not reveal 
the infant’s treatment allocation. All electronically entered data were stored on a password 
protected network which was routinely backed-up nightly. Hard copies of data forms were 
stored in filing cabinets at the coordinating centre which were locked when not in use by the 
trial staff.  Secure disposal of paper data was available through the use of a shredding 
machine.  Electronic data will be disposed of by erasure from floppy disks and hard disks.  
Data will be kept securely for seven years, as recommended by the NH&MRC. No identifying 
data were revealed to any person not directly involved with the trial. Trial results will be 
published in summary format so participants will never be individually identified.  
 
2.7.3 Analysis methods  
The statistical analysis was performed using Statistical Analysis System (SAS) software, 
version 8.2. All data analyses were performed on the groups as originally allocated (intention-
to-treat analysis). This included temporary and permanent withdrawals and infants lost to 
follow-up where data were available. 
 
For continuous data the treatment effect was calculated as the higher target range group minus 
the standard target range group, with results presented as either means with standard 
deviations (SD) for normally distributed data or medians with interquartile ranges (IQR) for 
non-normally distributed data. Data were assessed for skewness and if this was greater than 1 
or less than -1, non-normal data analysis methods were used. An assessment of significant 
differences between the two groups was undertaken using Student’s t test or the Mann-
Whitney U test and expressed as mean or median differences respectively with 95% 
confidence intervals. Median differences were calculated in SAS using the Moses macro 
provided by the SAS Institute. For categorical data the chi square test was used and the 
treatment effects were expressed as relative risks (RR) of the higher group compared to the 
standard group, with 95% confidence intervals. When appropriate, the number-needed-to-treat  
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(NNT) was calculated as the inverse of the absolute risk difference (the event rate in the 
treatment group minus the event rate in the control group). All P values were two-sided and 
were not adjusted for multiple testing or correlation between outcomes of siblings. A 
sensitivity analysis was undertaken to test the effect of the inclusion of sibling pairs on the 
major outcomes by randomly removing half of the related multiples (see section 2.2.2 and 
Table 4) from the analysis of these outcomes.  
 
Adjustment for known prognostic factors in this cohort of infants (gestation, gender, ethnicity 
and plurality)28 was undertaken, using multiple or logistic regression models, on several 
secondary clinical outcomes (length of hospital stay and days of mechanical ventilation after 
randomisation, pma to full sucking feeds, pma at discharge home, and worst stage of ROP) 
that were expected to show differences between the two oxygen target range groups. Although 
not strictly necessary in the analysis of randomised trial results, particularly if there are no 
imbalances in baseline factors that relate to outcomes,253 such secondary analyses may help 
achieve peace of mind.254 As the trial was pragmatic in nature,168 it was not deemed necessary 
to undertake compliance adjusted analyses as the aim of the trial was to assess which of the 
two oxygen saturation ranges was more effective in actual clinical practice. 
 
Review Manager 4.1 software (Cochrane Collaboration, Update Software) was used to 
produce the boxplots illustrating the main outcome results. The meta-analyses of major 
outcomes by enrolment centre were also undertaken using Review Manager 4.1, using Mantel-
Haenszel methods for combining individual centre results and fixed effects models.  
 
2.8 Safety monitoring committee 
2.8.1 Background 
As the treatment under investigation, higher oxygen saturation targeting, might potentially 
have both beneficial and harmful effects, it was considered important that an independent 
safety monitoring committee (SMC) be included in the trial design.  
 
The composition and numbers suggested for membership of a SMC are somewhat variable.  A 
review of the operational aspects of safety monitoring committees by Hawkins255 found that 
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for multicentre trials sponsored by the National Eye Institute, the average number of members 
was ten.  However, a minimum of three members and an odd number of total members (to 
achieve internal decisions) has been suggested by Pocock.256 The roles and positions may 
depend on the subject under study, and in the Hawkins review, a third of the positions were 
represented by statisticians and another third by ophthalmologists (which would probably 
translate into clinical specialties relevant to the research question).  The recommended number 
of meetings held and the timing of meetings during the progress of a study again depend on 
the objectives and responsibilities of the SMC.  For example, a fixed and pre-specified number 
of examinations of the data or ad hoc examinations based on the number of events accruing  
may be utilised.  Monitoring for efficacy, safety and data quality in combination or alone are 
the most frequent purposes of a SMC.257 
 
2.8.2 Objectives 
The objectives of the trial’s SMC were to monitor for specified adverse outcomes in the 
interest of safety, and to follow trends in the occurrence of other adverse outcomes and 
unanticipated side effects. A secondary objective was to make recommendations to the 
principal investigators (DHS, LI, JMS), as a result of examining the data, to ensure the ethical 
conduct of the study. 
 
2.8.3 Membership 
The SMC comprised three people: a paediatric ophthalmologist, a neonatologist and a 
paediatric respiratory physician who was also an epidemiologist. These appointed members 
had voting status but none had a direct interest in the results of the study.  None of the 
appointed members had investigator status or was employed by any of the centres participating 
in the trial.  
 
2.8.4 Analysis timepoints 
There were five pre-specified analysis timepoints: at 5 months after the first enrolment (to 
check that data could be managed efficiently and submitted in a manner appropriate for the 
SMC), then again after 75, 150, 225 and 300 patients had been enrolled.  
 
 60 
Chapter 2: Methods  
 
2.8.5 Adverse outcomes monitored 
There were two major adverse outcomes that might conceivably be affected by differing 
oxygen saturation target ranges after 32 weeks postmenstrual age: retinopathy of prematurity 
and mortality. Hence, the outcomes assessed by the SMC were stage 3 or 4 ROP (the more 
severe stages with significant long-term sequelae) and mortality to 38 weeks pma. Both 
outcomes were assessed as previously described (see sections 2.6.3.2 and 2.6.3.3).  
 
2.8.6 Stopping rules 
The O’Brien Fleming rules for multiple testing258 were used. If the difference in proportions of 
ROP stages 3/4 or mortality to 38 weeks pma between the standard and higher group at any 
evaluation was statistically significant at a 2-sided P value of 0.01 then the SMC could 
recommend that the trial be stopped. The stopping rules were never breached and the trial was 
permitted to proceed on each occasion. 
 
2.8.7 Presentation and reporting of data 
The trial coordinator (LMA) provided the SMC with the appropriate outcome data in a manner 
that ensured members of the committee assessed the outcomes masked to treatment group 
labels. The summary findings and the decision regarding continuation of the trial were 
reported to the trial coordinator by the SMC chairperson via a written, signed report within 
two weeks of each meeting (see Appendix 20).   
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CHAPTER 3: RESULTS 
3.1 Participants 
3.1.1 Enrolled infants  
Figure 7 shows the flow of infants eligible, assigned and followed-up throughout the trial. 358 
infants were enrolled: 178 infants were allocated to the standard target range group (SpO 2 91-
94%) and 180 to the higher target range group (SpO2 95-98%). Of these, 333 infants were 
individually randomised (167 to the standard group and 166 to the higher group) and a further 
25 eligible infants (11 and 14 in the standard and higher groups respectively) were allocated to 
the same treatment as their enrolled sibling.  
 
Figure 7: Numbers of infants screened, enrolled and for whom follow-up data available 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
703 infants born < 30 wks GA, 
still O2 dependent at 32 wks pma 158 not eligible: 
       lethal congenital abnormalities (n=59) 
       major surgery < 32 wks pma (n=21) 
       grade 3 or 4 IVH / PVL /  cystic lesions 
                                < 32 wks pma (n=78) 
545 infants eligible  
187 eligible infants not enrolled: 
       no consent (n=122) 
       not approached (n=65) 
358 infants enrolled 
178 infants allocated to the               
standard target range group  
SpO2 91-94%  
- 167 individually randomised  
  (133 singletons, 23 unrelated 
multiples, 11 related multiples) 
- 11 related multiples allocated with siblings 
180 infants allocated to the                   
higher target range group 
 SpO2 95-98%  
-  166 individually randomised  
  (129 singletons, 23 unrelated 
multiples, 14 related multiples) 
- 14 related multiples allocated with siblings 
Primary outcome 
data available for 
166 infants (93%) 
12 infants lost to 
follow-up (n=7) or 
dead (n=5) (7%) 
Primary outcome 
data available for 
168 infants (93%) 
12 infants lost to 
follow-up (n=3) or 
dead (n=9) (7%) 
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Randomisation resulted in prognostic baseline infant and maternal characteristics being well 
balanced between the two groups (see Table 2). The mean gestational age of enrolled infants 
was 26.5 weeks (SD 1.7) and the mean birth weight was 917 grams (SD 229). 73% of infants 
were singleton births and 94% of infants were born in a tertiary hospital with NICU facilities. 
83% of the mothers received at least some antenatal corticosteroids prior to delivery. This 
profile of the circumstances surrounding the birth of extremely preterm infants is typical of 
current perinatal practice in Australasia.28 Similarly BOOST trial infants experienced the 
myriad of interventions and conditions that typify modern NICU care.28 This included 77% 
receiving endogenous surfactant, 16% receiving high frequency ventilation, and experiencing 
a median of 12 days (IQR 4-28) of mechanical ventilation via an endotracheal tube. The 
enrolled infants required a median of 13 days of total parenteral nutrition (TPN), 86% required 
active treatment for apnoea and bradycardia and 52% suffered a patent ductus arteriosus 
(PDA). Six infants (3 in each group) had a diagnosis of severe intracranial pathology after 32 
weeks postmenstrual age, despite this being a pre-randomisation exclusion criteria.  
 
Randomisation also helped overcome the potentially biasing effects of imbalances between the 
two groups for factors in addition to the infant’s health status. All the self reported physical, 
socio-economic and psychosocial factors such as parental height, ethnicity, education, 
occupation and depression were well balanced between the two groups at enrolment (see 
Table 2). Significance tests for baseline differences are inappropriate178, 254, 259, 260 and were 
thus not undertaken. 
 
3.1.2 Non-enrolled infants  
During the 4 year recruitment period, there were 703 infants who were born at less than 30 
weeks’ gestation and remained oxygen-dependent at 32 weeks pma. Of these, 158 fulfilled one 
or more of the exclusion criteria and were thus not eligible for enrolment.188 The reasons for 
exclusion are listed in Figure 7. After pre-randomisation exclusions, there were 545 eligible 
infants potentially available for recruitment. Of these, 187 infants were eligible but not 
enrolled, hence 66% (358/545) of eligible infants were actually recruited to the trial. For 122 
of these infants the reason for non-enrolment was refusal of parental consent. This 22% 
(122/545) refusal rate is similar to that reported in other clinical trials where eligible patient 
logs are kept.261-263 
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Table 2: Baseline infant and parental characteristics of enrolled infants 
Variable SpO2 91-94%  
Control group 
N=178 
SpO2 95-98%  
Treatment group 
N=180 
 
Both groups  
N=358 
Gestational age 26.6 weeks (SD 1.7) 26.5 weeks (SD 1.6) 26.5 weeks (SD 1.7) 
Male gender 92 (51.7%) 97 (53.9%) 189 (52.8%) 
Birth weight 917.8 grams (SD 228.5) 916.4 grams (SD 230.6) 917.1 grams (SD 229.3) 
Birth wt <10th centile 14 (7.9%) 21 (11.7%) 35 (9.8%) 
Birth head 
circumference 
24.6 cm (SD 2.0) 24.6 cm (SD 2.2) 24.6 cm (SD 2.1) 
Birth length 35.6 cm (SD 4.1) 35.3 cm (SD 4.0) 35.5 cm (SD 4.1) 
Singletons* 133 (74.7%) 129 (71.7% ) 262 (73.2%) 
5 min Apgar score <7 31 (17.4%) 37 (20.6%) 68 (19.0%) 
Born in tertiary 
hospital with NICU 
163 (91.6%) 172 (95.6%) 335 (93.6%) 
Surfactant 138 (77.5%) 137 (76.1%) 275 (76.8%) 
PDA 94 (52.8%) 91 (50.6%) 185 (51.7%) 
Apnoea/bradycardia 
requiring treatment 
157 (88.2%) 149 (82.8%) 306 (85.5%) 
Days TPN 13.5 days (IQR 9-20) 13.0 days (IQR 9-20) 13.0 days (IQR 9-20) 
No NEC 167 (93.8%) 170 (94.4%) 337 (94.1%) 
Worst IVH Grade 3, 4 
or PVL 
3 (1.7%) 3 (1.7%)  6 (1.7%)  
Days mechanical 
ventilation (via ETT) 
12.0 days (IQR 4-28) 13.0 days (IQR 4-28) 12.0 days (IQR 4-28) 
HFV 28 (15.7%) 28 (15.6%) 56 (15.6%) 
Antenatal steroids 
(any) 
148 (83.2%) 149 (82.8%) 297 (83.0%) 
Maternal tertiary 
education 
60 (33.7%) 64 (35.6%) 124 (34.6%) 
Paternal tertiary 
education 
73 (41.0%) 65 (36.1%) 138 (38.6%) 
Mother’s usual 
occupation score 
4.5 (SD 1.4) 4.6 (SD 1.3) 4.5 (SD 1.4) 
Father’s usual 
occupation score 
4.4 (SD 1.4) 4.7 (SD 1.3) 4.5 (SD 1.3) 
Mother’s height  163.2 cm (SD 7.3) 162.7 cm (SD 7.6) 162.9 (SD 7.5) 
Father’s height 177.0 cm (SD 8.0) 176.1 cm (SD 8.7) 176.5 (SD 8.4) 
Mean EPDS at entry 10.7 (SD 5.7) 10.0 (SD 5.3) 10.4 (SD 5.5) 
Proportion with EPDS  
> 12 at entry 
46 (33.3%, N=138) 42 (31.3%, N=134) 88 (32.4%, N=272) 
Maternal age (years) 29.99 (SD 6.0) 29.47 (SD 6.1) 29.7 (SD 6.1) 
Maternal ethnicity 
Caucasian 
148 (83.2%) 141 (78.3%) 289 (80.7%) 
NICU  - neonatal intensive care unit   * Singletons = births with only one fetus,  
PDA  - patent ductus arteriosus   not including “unrelated multiples” (see Table 4) 
TPN  - total parenteral nutrition                  
NEC  - necrotising enterocolitis  
IVH  - intraventricular haemorrhage  
PVL  - periventricular leukomalacia 
ETT  - endotracheal tube 
HFV - high frequency ventilation 
EPDS  - Edinburgh Postnatal Depression Scale score 
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The main reason (n=38) for refusal of consent was that by 32 weeks pma, when the infant had 
been in hospital for 3-10 weeks since birth, many parents felt that they “did not want to change 
things”, that their baby had reached a stable period and they were reluctant to change to the 
use of a different oximeter which was required to ensure blinding of treatment allocation. 
Relatively few parents (n=9) refused consent because of concerns regarding potentially too 
much or too little supplemental oxygen or because they were unwilling to participate in 
research projects. No parents cited concerns regarding the fact that the study oximeters 
displayed adjusted, rather than actual, values to ensure blinding of treatment allocation (see 
section 2.2.3) as the reason for refusing consent. The main reason (57/65) that eligible infants 
were not approached to participate was that the parents were infrequent visitors and were 
unable to be contacted prior to 32 weeks in order to seek informed consent. Only 4 eligible 
families were not approached due to lack of English fluency and the non-availability of an 
appropriate interpreter. 
 
An analysis of the summary, de- identified NICUS data188 of the 187 eligible but non-enrolled 
infants revealed no clinically important differences in their baseline infant or maternal 
characteristics compared with the 358 eligible and enrolled infants (see Table 3), despite the 
non-enrolled infants being slightly heavier at birth and of 0.7 weeks greater gestation. 
 
Table 3: Baseline infant/maternal characteristics of non-enrolled and enrolled infants 
 
Variable 
 
Non-enrolled infants 
N=187 
 
Enrolled infants 
N=358 
 
P value 
Gestational age 27.2 weeks (SD 1.5) 26.5 weeks (SD 1.7) P<0.00001 
Male gender 105 (56.2%) 189 (52.8%) P=0.5 
Birth weight 1016.3 grams (SD 249.9) 917.1 grams (SD 229.3) P<0.00001 
Birth head circumference 25.4 cm (SD 2.2) 24.6 cm (SD 2.1) P=0.00004 
Singletons 141 (75.4%) 262 (73.2%) P=0.6 
5 minute Apgar score <7 33 (17.7%) 68 (19.0%) P=0.7 
Born in tertiary hospital with NICU 173 (92.5%) 335 (93.6%) P=0.6 
Surfactant 137 (73.3%) 275 (76.8%) P=0.4 
PDA 95 (50.8%) 185 (51.7%) P=0.8 
Days TPN 14.0 days (IQR 9-22) 13.0 days (IQR 9-20) P=0.3 
No NEC 175 (93.6%) 337 (94.1%) P=0.8 
Days mechanical ventilation (via 
ETT) 
7.0 days (IQR 3-18.5) 12.0 days (IQR 4-28) P=0.01 
HFV 20 (10.7%) 56 (15.6%) P=0.12 
Antenatal steroids (any) 169 (90.4%) 297 (83.0%) P=0.01 
Maternal age (years) 29.1 (SD 6.2) 29.7 (SD 6.1) P=0.3 
Maternal ethnicity Caucasian 154 (82.4%) 289 (80.7%) P=0.6 
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3.1.3 Recruitment centres  
The recruitment centres were of varying sizes, with the numbers enrolled at each centre 
ranging from 8 to 77 (Figure 8). The numbers of infants allocated to each gestational age 
stratum, within each institution were well balanced (Table 4) and within the allowable 
imbalance limits nominated within the dynamic balancing stratification programme (see 
section 2.2.2).176 The participating centres recruited at an average rate of 84% of their 
expected number of enrolments. This resulted in the recruitment timeline increasing from the 
expected 3 years to 4 years in total, from 16 September 1996-15 September 2000 (see Figure 6).  
  
Figure 8: Numbers of subjects recruited at each participating centre  
 
 
 
 
 
 
 
 
 
3.2 Intervention 
3.2.1 Commencement 
Trial coordination measures to ensure timely randomisation appeared to be successful, with 
the median postmenstrual age at randomisation being 32.0 weeks (IQR 31.6-32.3) as specified 
in the trial protocol. There was no difference between the two groups in age at randomisation: 
32 weeks pma (IQR 31.7-32.3) for the standard target range group and 32 weeks pma (IQR 
31.6-32.4) for the higher target range group. 
 
3.2.2 Duration 
The intervention, allocation to either oxygen saturation target range, continued for a median of 
17.5 days (IQR 7-41) in the standard group and 40 days (IQR 20.5-73) in the higher target 
range group (P<0.0001), with only 2% (n=7: 1 in the standard group, 6 in the higher group) of 
enrolled infants still requiring supplemental oxygen at 12 months corrected age.  
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Table 4: Numbers enrolled in each gestational age stratum, by hospital 
 
Hospital 
 
Gestational age 
strata 
 
 
SpO2 91-94%  
N=178 
 
SpO2 95-98%  
N=180 
 
Total 
N=358 
Singletons or unrelated 
multiples* 
    
22-27 weeks 9 10 19 Canberra Hospital 
28-29 weeks 6 3 9 
22-27 weeks 18 16 34 John Hunter Hospital 
28-29 weeks 11 11 22 
22-27 weeks 26 26 52 King George V Hospital 
28-29 weeks 10 11 21 
22-27 weeks 11 9 20 Liverpool Hospital 
28-29 weeks 1 2 3 
22-27 weeks 11 14 25 Mater Mothers’ Hospital 
28-29 weeks 8 6 14 
22-27 weeks 18 16 34 Nepean Hospital 
28-29 weeks 5 4 9 
22-27 weeks 2 2 4 Royal Hospital for Women 
28-29 weeks 1 2 3 
22-27 weeks 13 15 28 Royal North Shore Hospital 
28-29 weeks 6 5 11 
Sub total  156 152 308 
Related multiples+     
Canberra Hospital not stratified 0 2 2 
John Hunter Hospital not stratified 8 8 16 
King George V Hospital not stratified 2 6 8 
Liverpool Hospital not stratified 4 2 6 
Mater Mothers’ Hospital not stratified 4 0 4 
Nepean Hospital not stratified 2 4 6 
Royal Hospital for Women not stratified 0 2 2 
Royal North Shore Hospital not stratified 2 4 6 
Sub total  22 28 50 
Total  178 180 358 
* Singleton = one infant per birth; unrelated multiple = from a multiple birth, but by 32 weeks pma only one 
infant of the birth was eligible for enrolment (other infant(s) either ineligible or dead). For the purposes of 
randomisation, both these types of infants were treated as singletons. 
+ Related multiple = pair of infants from the same birth: one infant of the pair was randomised, the second 
infant was allocated to the same treatment group as their sibling. Actual numbers are indicated in this table.  
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3.3 Protocol adherence 
3.3.1 Incorrect treatment allocation 
Upon return of each study oximeter to the coordinating centre after treatment cessation, the 
oximeter adjustment offset (and thus the actual saturation range targeted) was checked by the 
trial coordinator. One infant was assigned the incorrect study oximeter at randomisation and 
was thus not targeted at the allocated range.  
 
3.3.2 Distribution of blinded saturation values targeted 
Recording of the blinded median saturation value of each download by the research nurses 
(see section 2.5.2 and Appendix 6) allowed a comparison of the distribution of these values 
between the two groups. Figure 9 shows the percentage of downloads in oxygen (n=1,913 
download files) with various median saturation values. This confirms that the blinding 
procedures were successful as both groups targeted the same distribution of blinded saturation 
values and both groups had the same blinded median SpO 2 value of 95%.  
 
Figure 9: Distribution of blinded saturation values targeted 
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3.3.3 Distribution of actual saturation values targeted 
There were 1,913 downloads of 8-24 hours duration done on trial infants whilst they were 
receiving supplemental oxygen following randomisation. During these download recordings, 
actual (not blinded) oxygen saturation values were sampled every 10 seconds (see section 
2.5.2 for detailed description). This resulted in 14,432,319 data points being available to assess 
protocol adherence. When these data were analysed the distribution of actual saturation values 
targeted was different between the two groups. Figure 10 shows the percent of downloaded 
(actual, unblinded) oxygen saturation values that were recorded at each oxygen saturation 
level from SpO2 80% to the maximum SpO 2 100%.  The median saturation value for each 
group was within the desired target range: 93% (IQR 90-96) for the standard group who were 
to target the SpO2 91-94% range, and 97% for the higher group who were to target a SpO2 
range of 95-98%.  
 
An early analysis (9 months after recruitment commencement) of these data revealed non-
compliance (time spent in target range <40%) was occurring in more than 40% of downloads 
in 5 participating centres. Several remedial measures were undertaken with the staff of these 
centres to achieve the final desired level of protocol adherence seen in Figure 10, with only 
two of the eight recruitment centres having unsatisfactory compliance in the final analysis. 
 
Figure 10: Distribution of actual saturation values targeted 
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3.3.4 Degree of treatment group crossover 
The degree of crossover between the two treatment groups is summarised in Table 5. Thirty 
seven percent (37%) of median saturation values for infants assigned to the standard group 
were in the higher range or above, and 25% of median saturation values of infants assigned to 
the higher group were in the standard range or lower. The median saturation value was in the 
desired target range for 36% of the time for the standard group and for 52% of the time for the 
higher group. This was close to the expected time in the target range (over 40%) given the 
relatively tight target ranges and the pragmatic nature of the trial design. There was no 
clinically significant differe nce between the two groups in the proportion of very low 
saturation values (SpO2 <85%) with 7% of saturation values recorded at less than this level in 
the standard group and 2% of values lower than SpO 2 85% in the higher target range group.  
 
Table 5: Percentage distribution of infants according to median pulse oximetry for all 
downloads in oxygen - degree of “crossover” between treatment groups 
 
Median pulse oximetry value  for 
all downloads in oxygen 
Standard target range 
SpO2 91-94%* 
n=134 
Higher target range 
SpO2 95-98%* 
n=162 
<89 16.4 3.7 
89 4.8 1.1 
90 6.0 1.5 
91 7.6 2.3 
92 8.6 3.5 
93 9.9 5.5 
94 9.8 7.6 
95 9.6 10.8 
96 8.3 13.3 
97 6.6 14.6 
98 4.9 13.5 
99 3.6 10.9 
100 3.9 11.7 
 
The     symbols indicate the targeted ranges of saturation values for each arm of the study. 
* Each study arm column gives the percentage of all subjects in that column whose median pulse 
oximetry whilst in supplemental oxygen was at the level shown in the left hand column. 
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3.3.5 Proportion of motion artefact  
Artefactual saturation readings caused by vigorous movement of the limb to which the 
saturation probe is attached can be one of the disadvantages of using this technology in non-
anaesthetised infants. The type of oximeter used in the trial, the Nellcor N-3000, purports to 
minimise motion artefact174 and the levels seen seem to confirm this. Overall, only 3.2% of the 
readings were affected by motion artefact: 2.1% of readings in the standard group and 3.9% of 
readings in the higher group. The level of motion artefact is considerably lower than that 
reported in other studies of neonates264 which can be as high as 20-30% of the total saturation values. 
 
3.3.6 Permitted protocol violations  
Permitted protocol violations for open oxygen saturation targeting (as described in section 
2.1.3) occurred relatively infrequently and were equally distributed between the two groups 
(Table 6). The most common reason for protocol violation was to treat threshold ROP with 
either high oxygen targeting and/or ablative retinal surgery. A smaller number of infants 
violated the protocol when high oxygen targeting was ordered following abnormal sleep 
studies. Parental request or problems with the study oximeter or the downloading programme 
were relatively uncommon reasons for protocol violation. Of the 26 infants who violated the 
protocol in the standard range group, 13 did so only temporarily, for a median of 3 days (IQR 
1-17), compared with 14/28 infants in the higher range group who had a median of 5 days 
(IQR 1-8) of temporary protocol violation (Table 7). 
Table 6: Reasons for permitted protocol violations - temporary and permanent 
 
Reason 
SpO2 91-94%           SpO2 95-98% 
        N=178                    N=180 
Number (%) 
ROP treatment (high O2, cryotherapy) 9 9 
After sleep study (ordered high O2) 3 6 
Hernia surgery 4 1 
Clinically unwell e.g. sepsis  6 5 
Parental request 3 5 
Oximeter or downloading problems 1 2 
Total 26 (15%) 28 (16%) 
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Table 7: Numbers of permitted protocol violations - temporary and permanent 
 
 
Type of protocol violation 
 
SpO2 91-94%           SpO2 95-98% 
        N=178                    N=180 
Number 
Temporary* 13 14 
Permanent 13 14 
Total 26  28  
 
The 13 infants in the standard range group who violated the protocol temporarily 
did so for a median of 3 days (IQR 1-17), compared with 14 infants in the higher  
range group who had a median of 5 days (IQR 1-8) of temporary protocol violation. 
 
3.4 Primary outcomes 
3.4.1 Follow-up rates and missing data  
Primary outcome ascertainment rates were 93% in both the standard and higher target range 
groups (see Figure 7). Of the 334 infants assessed at approximately 12 months corrected age, 
96% (n=321) underwent a Revised Griffiths assessment (95% in the standard group and 98% 
in the higher group). 72% (n=232) of these infants were assessed by one of the nine trained 
Griffiths assessors located at the eight recruitment centres. A small number of infants (n=13) 
were unable to be assessed using the Revised Griffiths Scale. Whenever possible the original 
version of the Griffiths Developmental Scale was used as an alternative (n=9). One infant was 
assessed using the Bayley Scale210, 265  and 3 infants had other types of validated 
developmental assessments. 10 infants still alive at 12 months corrected age (7 in the standard 
group and 3 in the higher group) did not undergo a formal developmental assessment. The 
baseline characteristics of infants with missing primary outcome data (due to death, n=14, or 
lost to follow-up, n=10) did not differ significantly from those with outcome data available at 
12 months corrected age (Table 8; see also Table 2).  
 
The median age at primary outcome assessment did not differ between the two groups: 12.1 
(IQR 11.8-12.7) and 12.2 (IQR 11.9-12.9) months corrected age in the standard and higher 
groups, respectively. 
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Table 8: Baseline infant and parental characteristic for infants with missing primary               
outcome data  
 
 
 
Variable 
 
SpO2 91-94%  
Control group 
N=12 
 
SpO2 95-98%  
Treatment group 
N=12 
 
 
Both groups  
N=24 
Gestational age 26.0 weeks (SD 1.7) 26.4 weeks (SD 1.8) 26.2 weeks (SD 1.7) 
Male gender 6 (50.0%) 7 (58.3%) 13 (54.2%) 
Birth weight 869.0 grams (SD 217.3) 908.4 grams (SD 258.1) 888.3 grams (SD 236.4) 
Birth head 
circumference 
24.3 cm (SD 2.0) 24.7 cm (SD 2.3) 24.5 cm (SD 2.2) 
Birth length 35.1 cm (SD 3.6) 35.4 cm (SD 4.7) 35.2 cm (SD 4.1) 
Singletons 10 (83.3%) 8 (66.6%) 18 (75.0%) 
5 minute Apgar <7 3 (25.0%) 4 (33.3%) 7 (29.2%) 
Born in tertiary 
hospital with NICU 
10 (83.3%) 11 (91.7%) 21 (87.5%) 
Surfactant 10 (83.3%) 10 (83.3%) 20 (83.3%) 
PDA 6 (50.0%) 6 (50.0%) 12 (50.0%) 
Apnoea/bradycardia 
requiring treatment 
10 (83.3%) 9 (75.0%) 19 (79.2%) 
Days TPN 15.5 d ays (IQR 9.5-24.5) 14.0 days (IQR 6-22) 14.0 days (IQR 8-24) 
No NEC 10 (83.3%) 11 (91.2%) 21 (87.5%) 
Worst IVH Grade 3, 4 
or PVL 
0 (0%) 1 (8.3%)    1 (4.2%)  
Days mechanical 
ventilation (via ETT) 
24.0 days (IQR 5.5-39) 8.0 days (IQR 3-31) 17.0 days (IQR 3-36) 
HFV 3 (25.0%) 2 (16.7%) 5 (20.8%) 
Antenatal steroids 
(any) 
10 (83.3%) 10 (83.3%) 20 (83.3%) 
Maternal tertiary 
education 
4 (33.3%) 2 (16.7%) 6 (25.0%) 
Paternal tertiary 
education 
4 (33.3%) 3 (25.0%) 7 (29.2%) 
Mother’s usual 
occupation score 
4.8 (SD 1.1) 4.1 (SD 2.0) 4.4 (SD 1.6) 
Father’s usual 
occupation score 
4.8 (SD 1.2) 4.8 (SD 1.9) 4.8 (SD 1.5) 
Mother’s height  161.1 cm (SD 8.3) 165.6 cm (SD 7.9) 163.4 (SD 8.3) 
Father’s height 173.6 cm (SD 9.1) 173.3 cm (SD 8.3) 173.4 (SD 8.5) 
Mean EPDS at entry 11.4 (SD 5.1) 9.7 (SD 4.7) 10.7 (SD 4.9) 
Proportion with EPDS 
> 12 at entry 
3 (25.0%) 2 (16.7%) 5 (20.8%) 
Maternal age (years) 28.8 (SD 5.80) 24.9 (SD 5.1) 27.0 (SD 5.8) 
Maternal ethnicity 
Caucasian 
8 (66.7%) 8 (66.7%) 16 (66.7%) 
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3.4.2 Growth outcomes  
There were no significant differences between the two groups for any growth measures at any 
of the follow-up time-points: 38 weeks pma, 4 or 12 months corrected age (Table 9).  These 
included measures of mean weight, length or head circumference. The mean weight of infants 
at 12 months corrected age was 9.10 kg (SD 1.5) and 9.25 kg (SD 1.6) in the standard and 
higher groups respectively.   
Table 9: Growth outcomes, by treatment group 
 
 
 
Variable 
 
SpO2 91-94%  
Control group 
N=178 
 
SpO2 95-98%  
Treatment group 
N=180 
 
Mean Difference or        
Relative Risk [95% CI] 
 
Mean wt at 38 wks pma 
 
 
2345g (SD 429, N=175) 
 
2369g (SD 428, N=178) 
 
MD 24g [-66.1, 113.3] 
P=0.6 
Mean leng at 38 wks pma 44.2cm (SD 3.2, N=172) 44.2cm (SD 3.2, N=167) MD 0.0cm [-0.63, 0.73] 
P=1.0 
Mean hc at 38 wks pma 33.1cm (SD 2.2, N=176) 32.9cm (SD 1.9, N=178) MD -0.2cm [-0.67, 0.18] 
P=0.3 
Mean wt at 4 mths corr 5845g (SD 1161, N=167) 5811g (SD 1141, N=168) MD -34.1g [-281.5, 213.3] 
P=0.8 
Mean leng at 4 mths corr 60.1cm (SD 4.4, N=157) 59.3cm (SD 4.7, N=162) MD -0.8cm [-1.88, 0.13] 
P=0.1 
Mean hc at 4 mths corr 41.3cm (SD 1.8, N=161) 41.2cm (SD 1.8, N=161) MD -0.1cm [-0.53, 0.27] 
P=0.5 
Mean wt at 12 mths corr 9.10kg (SD 1.5, N=165) 9.25kg (SD 1.6, N=168) MD 0.15kg [-0.18, 0.49] 
P=0.4 
Mean leng at 12 mths corr 74.0cm (SD 3.9, N=162) 74.1cm (SD 4.1, N=164) MD 0.1cm [-0.75, 0.98] 
P=0.8 
Mean hc at 12 mths corr 46.3cm (SD 2.0, N=165) 46.3cm (SD 1.9, N=165) MD 0.0cm [-0.40, 0.44] 
P=1 
Mean wt at 12 mths corr 
for only infants with wt 
<3rd centile 
7.30 kg (SD 0.6, N=34) 7.18 kg (SD 0.7, N=31) MD –0.12kg [-0.44, 0.20] 
P=0.5  
wt <10th centile at 12 mth 61 (37.0%, N=165) 55 (32.7%, N=168) RR 0.89 [0.66, 1.19]  
P=0.4 
leng <10th centile at 12 
mth 
42 (25.9%, N=162) 41 (25.0%, N=164) RR 0.96 [0.67, 1.40]  
P=0.8 
Hc <3rd centile at 12 mth 5 (3.0%, N=165) 8 (4.9%, N=165) RR 1.60 [0.53, 4.79]  
P=0.4 
wt < 3rd centile at 12 mth 34 (20.0%, N=165) 31 (18.5%, N=168) RR 0.92 [0.59, 1.43]  
P=0.7 
 
pma = postmenstrual age, wt = weight, leng = length, hc = head circumference, mths corr = months of corrected 
age, N = number in denominator, SD = standard deviation  
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Similarly, the proportion of infants small for their age at 12 months corrected age (for either 
weight, length or head circumference) was not significantly different between the two groups 
(Table 9). This included the primary outcome of the proportion of infants with weight less 
than the 10th centile at 12 months corrected age which showed a relative risk of 0.89 (95% CI 
0.66 1.19; P=0.4) (see Figure 11). When a more stringent criterion of poor growth, weight less 
than the 3rd centile at 12 months corrected age, was examined the results remain non-
significant (Table 9, and Figure 12). The proportion of infants with weight less than the 3rd 
centile at 12 months corrected age was 20% in the standard group and 19% in the higher target 
range group (RR 0.92; 95% CI 0.59,1.43; P=0.7). 
Figure 11: Boxplot of main primary outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Box and whisker graph of growth in infants with mean weight <3rd centile 
compared with all infants at 12 months corrected age 
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3.4.3 Developmental outcomes  
There were no significant differences in any of the developmental measures, assessed at 12 
months corrected age (Table 10). This included the primary developmental outcome of the 
proportion of infants with a major developmental abnormality (RR 0.96; 95% CI 0.66, 1.42; 
P=0.8) (see also Figure 11). It should be noted that the mean Revised Griffiths Developmental 
Quotient (DQ) score for both groups (88.3 and 86.8 for the standard and higher groups 
respectively) was more than one standard deviation below the mean for normal, full term 
children (-1 SD = 88.7).206 This low mean developmental score is similar to that found in other 
populations of preterm infants at one year corrected age.212, 213, 266 The proportion of infants 
with a Revised Griffiths Developmental Quotient (DQ) score more than one, but less than two, 
standard deviations below the mean was also similar in the two groups: 19% and 20% for the 
standard and higher groups respectively (RR 1.08; 95% CI 0.69, 1.69; P=0.7). 
 
Table 10: Developmental outcomes for all infants, by treatment group 
 
 
Variable 
 
 
SpO2 91-94%  
Control group 
 
 
SpO2 95-98%  
Treatment group 
 
Relative Risk or 
Mean Difference 
[95% CI] 
 
 
Major dev abnormal at 
12 mths corr (CP or blind 
or DQ <2SD below 
mean) 
 
40 (24.1%, N=166) 
 
39 (23.2%, N=168) 
 
RR 0.96 [0.66, 1.42] 
P=0.8 
 
 
CP rate at 12 mths corr 11 (6.6%, N=166) 16 (9.5%, N=168) RR 1.44 [0.69, 3.00] 
P=0.3 
 
Mean Rev Griffiths score 
at12 mths corr 
 
88.3 (SD 18.3, N=158) 86.8 (SD 21.8, N=164) MD -1.5 [-5.9, 2.9] 
P=0.5 
 
DQ < 2 SD at 12 mths 
corr 
30 (19.2%, N=156) 34 (20.7%, N=164) RR 1.08 [0.69, 1.67] 
P=0.7 
 
DQ < 1 SD at 12 mths 
corr 
63 (40.4%%, N=156) 71 (43.3%, N=164) RR 1.07 [0.83, 1.39] 
P=0.6 
 
DQ between 1 and 2 SD 
below mean at 12 mths 
corr 
 
29 (18.6%, N=156) 33 (20.1%, N=164) RR 1.08 [0.69, 1.69] 
P=0.7 
 
dev abn = developmental abnormality, CP = cerebral palsy, DQ = developmental quotient, Rev Griffiths = 
Revised Griffiths Developmental Scale, mths corr = months of corrected age, SD = standard deviation 
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3.4.4 Growth and development outcomes for a priori sub-groups 
When the primary growth outcomes were examined in the sub -group of 256 high risk infants 
born at less than 28 weeks’ gestation, there were no statistically significant differences in any 
of the growth and developmental outcomes between the two groups (Table 11). Similarly, in 
the sub-group of 84 infants who were discharged home whilst still receiving supplemental 
oxygen, all the differences in primary growth and development outcomes remained non-
significant (Table 12). 
 
Table 11:  Primary outcomes for 256 infants born at less than 28 weeks’ gestation 
 
 
 
Variable 
 
 
SpO2 91-94%  
Control group 
N=124 
 
SpO2 95-98%  
Treatment group 
N=132 
 
Mean Difference or  
Relative Risk  [95% CI] 
 
Mean wt at 38 wks 
pma 
 
 
2321g (SD 437, N=121) 
 
2369g (SD 409, N=131) 
 
MD 48g [-57.6, 152.4] 
P=0.4 
 
Mean leng at 38 wks 
pma 
43.9cm (SD 3.2, N=120) 43.9cm (SD 3.0, N=121) MD 0.0cm [-0.71, 0.86] 
P=0.8 
 
Mean hc at 38 wks 
pma 
32.9cm (SD 2.2, N=122) 32.7cm (SD 2.0, N=131) MD -0.2cm [-0.73, 0.30] 
P=0.4 
 
Mean wt at 12 mths 
corr 
8.91kg (SD 1.4, N=115) 9.13kg (SD 1.5, N=122) MD 0.23kg [-0.60, 0.15] 
P=0.2 
 
Mean leng at 12 mths 
corr 
73.8cm (SD 3.9, N=112) 74.0cm (SD 4.1, N=118) MD 0.2cm [-0.85, 1.23] 
P=0.7 
 
Mean hc at 12 mths 
corr 
46.0cm (SD 1.7, N=115) 46.0cm (SD 1.9, N=121) MD 0.0cm [-0.41, 0.52] 
P=0.8 
 
Wt <10 th centile  
At 12 mth 
44 (38.3%, N=115) 39 (32.0%, N=122) RR 0.84 [0.59, 1.18] 
P=0.3 
 
Length <10th centile  
At 12 mth 
30 (26.8%, N=112) 29 (24.6%, N=118) RR 0.92 [0.59, 1.42] 
P=0.7 
 
HC <3rd centile  
At 12 mth 
5 (4.3%, N=115) 7 (5.8%, N=121) RR 1.33 [0.43, 4.07] 
P=0.6 
 
Major dev abn  
at 12 mth corr 
(CP or blind or DQ 
<2SD below mean) 
32 (27.8%, N=115) 27 (22.1%, N=122) RR 0.80 [0.50, 1.20] 
P=0.3 
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Table 12:  Primary outcomes for 84 home oxygen infants  
 
 
 
Variable 
 
 
SpO2 91-94%  
Control group 
N=30 
 
SpO2 95-98%  
Treatment group 
N=54 
 
Mean Difference or      
Relative Risk  [95% CI] 
 
Mean wt at 38 wks pma 
 
2331g (SD 509) 
 
2353g (SD 468) 
 
MD 22g [-196.7, 240.9] 
P=0.8 
 
Mean length at 38 wks pma  43.5cm (SD 3.7) 43.7cm (SD 3.2) MD 0.2cm [-1.46, 1.70] 
P=0.9 
 
Mean hc at 38 wks pma 32.7cm (SD 2.4) 32.4cm (SD 2.0) MD -0.3cm [-1.27, 0.70] 
P=0.5 
 
Mean wt at 12 mths corr 9.21kg (SD 2.1) 9.27kg (SD 1.5) MD 0.06kg [-0.76, 0.89] 
P=0.9 
 
Mean length at 12 mths corr 74.0cm (SD 4.8) 74.0cm (SD 4.1) MD 0cm [-2.1, 2.0] 
P=1.0 
 
Mean hc at 12 mths corr 46.5cm (SD 3.3) 46.3cm (SD 1.9) MD -0.2cm [-1.4, 0.94] 
P=0.7 
 
Wt <10th centile at 12 mth 12 (40%) 14 (26%) RR 0.65 [0.35, 1.22] 
P=0.2 
 
Length <10th centile at 12 mth 9 (30%) 14 (26%) RR 0.86 [0.43, 1.76] 
P=0.7 
 
HC <3rd centile at 12 mth 1 (3.3%) 3 (5.6%) RR 1.67 [0.18, 15.33] 
P=0.7 
 
Major dev abn at 12 mth corr 
(CP or blind or DQ <2SD 
below mean) 
13 (45%, N=29) 17 (33%, N=51) RR 0.74 [0.42, 1.30] 
P=0.3 
 
3.5 Secondary outcomes 
3.5.1 Oxygen therapy outcomes  
The proportion of infants still oxygen dependent at 36 weeks pma was significantly higher for 
those targeting the higher saturation range (64%) compared with infants in the standard range 
group (46%) (RR 1.40, 95% CI 1.15, 1.70; P=0.0006) (Table 13, Figure 13). An event rate 
difference of this magnitude results in a number needed to harm267 of 6 (1/(0.644 - 0.461) = 
5.46, 95% CI 3,14). That is, for every 6 infants targeted at the higher saturation range, one 
additional case of oxygen dependency at 36 weeks pma could be expected.  
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Table 13: Oxygen therapy outcomes for all infants, by treatment group 
 
 
 
Variable 
 
SpO2 91-94%  
Control group 
N=178 
 
 
SpO2 95-98%  
Treatment group 
N=180 
 
Relative Risk  or 
Median Difference 
[95% CI]  
 
Supplemental oxygen 
at 36 wks pma  
 
 
82 (46.1%) 
 
116 (64.4%) 
 
RR 1.40 [1.15, 1.70] 
P=0.0006 
Total days of oxygen 56 days (IQR 38-89) 72 days (IQR 53-123) MedD 19 [10, 27] 
P<0.0001 
 
Days oxygen after 
randomisation 
 
18 days (IQR 7-41)  40 days (IQR 21-73) MedD 17 [12, 23] 
P<0.0001 
pma when oxygen 
ceased 
 
35.4 wks (IQR 33-40) 37.9 wks (IQR 35-45) MedD 2.3 [1.3, 3.3] 
P<0.0001 
Home oxygen 30 (16.9%) 54 (30%) RR 1.78 [1.20, 2.64] 
P=0.004 
 
Days of home oxygen  92 (IQR 34-208, N=30) 99 (IQR 53-199, N=54) MedD 11 [-28, 57] 
P=0.5 
 
 
 
 
Figure 13: Boxplot of significant secondary outcomes 
  
SpO2 95 - 98% 
n/N 
SpO2 91 - 94% 
n/N  
RR 
95% CI 
RR 
95% CI  
116/180 82/178 
p value 
1.40 [1.15 1.70]  p=0.0006 
Outcome 
O 2 36 wks pma 
Home oxygen 54/180 30/178 1.78 [1.20, 2.64] p=0.004 
0.1 0.2 5 10 1 
Favours SpO2 91-94% Favours SpO2 95-98% 
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Measures of oxygen supplementation duration were significantly longer in the higher target 
range group (Table 13). The total days of oxygen supplementation was a median of 56 days 
(IQR 38-89) in the standard group compared with a median of 72 days (IQR 53-123) in the 
higher group (MedD 19 days; 95% CI 10, 27; P<0.0001). Similarly, the days of oxygen 
supplementation after randomisation was significantly different between the two groups: 18 
days (IQR 7-41) in the standard group versus 40 days (IQR 21-73) in the higher target group 
(MedD 17 days; 95% CI 12, 23; P<0.0001). The postmenstrual age when oxygen was ceased 
was also significantly different at 35.4 weeks (IQR 33-40) in the standard group compared 
with 37.9 weeks (IQR 35-45) in the higher group (MedD 2.3 weeks; 95% CI 1.3, 3.3; 
P<0.0001).  
 
This increased duration of oxygen therapy in the higher target range group resulted in 
significantly more infants being discharged home on supplemental oxygen (Table 13 and 
Figure 13). The proportion of infants receiving home oxygen was significantly higher in the 
higher range group (30%) compared with the standard target range group (17%) (RR 1.78, 
95% CI 1.20, 2.64; P=0.004). If translated into a number needed to harm (NNH), this would 
mean that for every 8 infants treated with higher oxygen targeting one additional case of home 
oxygen could be expected (1/(0.300 - 0.169) = 7.6, 95% CI 4, 29). Although significantly 
more infants received supplemental oxygen after discharge, the duration of home oxygen was 
not different between the two groups. Infants in the standard range group who went home on 
oxygen received this therapy for a median of 92 days (IQR 34-208) after discharge, whilst 
those in the higher target range group had a median duration of home oxygen of 99 days (IQR 
53-99) (MedD 11 days; 95% CI -28, 57; P=0.5).  
 
3.5.2 Clinical outcomes  
None of the other clinical outcomes collected during the infants’ initial hospitalisation were 
significantly different between the two groups (Table 14). This included the use of postnatal 
corticosteroids or diuretics for chronic lung disease, the length of hospital stay (either in total 
or after randomisation), pma at discharge, pma to reach full sucking feeds, total days of 
assisted ventilation, or days of assisted ventilation after randomisation (for those infants who 
ceased assisted ventilation after randomisation).  
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Table 14: Clinical outcomes for all infants, by treatment group 
 
 
 
Variable 
 
SpO2 91-94%  
Control group 
N=178 
 
 
SpO2 95-98%  
Treatment group 
N=180 
 
Relative Risk  or      
Median Difference      
[95% CI]  
 
Postnatal steroids   
 
89 (50%) 
 
104 (57.8%) 
 
RR 1.16 [0.95, 1.40] 
P=0.14 
 
Diuretics for CLD  78 (43.8%) 93 (51.7%) RR 1.18 [0.95, 1.47] 
P=0.14 
 
Length of hospital stay (days) 85.0 (IQR 74-107) 92.0 (IQR 77-106.5) MedD 4 [-1, 9]  
P=0.9 
 
Length of stay, after randomisation 
(days) 
50.0 (IQR 39-60) 50.0 (IQR 42-61.5) MedD 2 [-1, 5]  
P=0.2  
 
pma at discharge (weeks) 39.1 (IQR 37-40) 39.1 (IQR 38-41) Med D 0.3 [-0.1, 0.9] 
P=0.2  
 
pma at full sucking feeds (weeks) 37.7 (IQR 37-39) 37.7 (IQR 36-39) MedD -0.4 [-0.9, 0] 
P=0.9 
 
Days assisted ventilation (all types) 31.0 (IQR 17-54) 37.0 (IQR 19-52) MedD -5 [-10, 0]  
P=0.3 
 
Days assisted ventilation (all types), 
after randomisation - only if ended 
ventilation after randomisation 
 
14.0 (IQR 7-28) 14.0 (IQR 6-35) MedD 0 [-4, 4]  
P=0.9  
Death (all causes) by 12 mths corr 5 (2.8%) 9 (5.0%) RR 1.78 [0.61, 5.21] 
P=0.3 
 
Death (pulmonary causes) by 12 
mths corr 
1 (0.6%) 6 (3.3%) RR 5.93 [0.72, 48.79] 
P=0.1 
 
 
3.5.3 Deaths  
There was no significant difference in the numbers of deaths, from randomisation to 12 
months corrected age, between the standard (n=5, 2.8%) and higher (n=9, 5.0%) target range 
groups (RR 1.78, 95% CI 0.61, 5.21; P=0.3). Of these deaths, one was due to pulmonary 
causes in the standard oxygen target group, compared with 6 in the higher range group (RR 
5.93 95% CI 0.72, 48.79; P=0.1) (Table 14). One death in the standard range group occurred 
after discharge from the infant’s initial hospitalisation compared with 5 post-discharge deaths 
in the higher target group (Table 15). 
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Table 15: Causes and timing of post-randomisation deaths, by treatment group 
 
 
Treatment 
Allocated 
 
Cause of death 
 
 
pma at 
discharge 
(weeks) 
 
pma at 
death 
(weeks) 
 
 
SpO2 91-94%  
Control group 
 
   
 Hypertrophic obstructive cardiomyopathy 
 
38 38 
 
 
Intestine, acute vascular insufficiency 34 34 
 
 
NEC 33 33 
 
 
Pneumonia 39 39 
 
 
SIDS 42 61 
 
SpO2 95-98%  
Treatment group 
 
   
 
 
Abdominal abscess, treatment withdrawn 36 36 
 
 
NEC 32 32 
 
 
Respiratory failure 48 48 
 
 
Respiratory failure 39 39 
 
 
Respiratory failure 37 92 
 
 
Chronic lung disease 49 60 
 
 
Chronic lung disease 41 73 
 
 
Pneumonia 41 43 
 
 
SIDS 39 46 
 
3.5.4 Ophthalmic outcomes  
There were no statistically significant differences in the rates of any stage of retinopathy of 
prematurity,  nor in the need for ablative retinal surgery (20/178, 11%, in the standard group 
versus 11/180, 6%, in the higher group, P=0.09) (Table 16).  
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Table 16: Ophthalmic outcomes, by treatment group 
 
 
Variable 
 
SpO2 91-94%  
Control group 
 
 
SpO2 95-98%  
Treatment group 
 
 
Relative Risk   
[95% CI]  
 
All infants: 
 
   
Worst ROP  = none 97 (54.5%, N=178) 94 (52.2%, N=180) RR 0.96 [0.79, 1.16] 
P=0.7 
 
Worst ROP  = stage 1 12 (6.7% N=178) 14 (7.8%, N=180) RR 1.15 [0.55, 2.42] 
P=0.7 
 
Worst ROP  = stage 2 41 (23.0%, N= 178) 50 (27.8%, N=180) RR 1.21 [0.84, 1.72] 
P=0.3 
 
Worst ROP  = stage 3 27 (15.2%, N=178) 22 (12.2%, N=180) RR 0.8 [0.48, 1.36] 
P=0.4 
 
Worst ROP  = stage 4 1 (0.6%, N=178) 0 (0%, N=180) RR 0.33 [0.01, 8.04] 
P=0.5 
 
Worst ROP  = stage 3 or 4  28 (15.7%, N=178) 22 (12.2%, N=180) RR 0.78 [0.46, 1.30] 
P=0.3 
 
Retinal ablative surgery  20 (11.2%, N=178) 11 (6.1%, N=180) RR 0.54 [0.27, 1.10] 
P=0.09 
 
Blind at 12 mths corr (unilateral 
or bilateral) 
4 (2.4%, N=166) 1 (0.6%, N=168) RR 0.25 [0.03, 2.19] 
P=0.2 
 
Poor eye outcome by 12 months 
corr (ROP stage 3/4 or ablative 
retinal surgery or blind) 
 
31 (17.7%, N=175) 22 (12.4%, N=178) RR 0.70 [0.42, 1.16] 
P=0.2 
    
 
Infants <28 weeks’ gestation 
only: 
 
   
Worst ROP = stage 3 or 4  28 (22.6%, N=124) 21 (15.9%, N=132) RR 0.70 [0.42, 1.17] 
P=0.18 
 
Retinal ablative surgery 20 (16.1%, N=124) 11 (8.3%, N=132) RR 0.52 [0.26, 1.03] 
P=0.06 
 
Blind at 12 mths corr (unilateral 
or bilateral) 
4 (3.4%, N=118) 1 (0.8%, N=122) RR 0.24 [0.03, 2.13] 
P=0.2 
 
Poor eye outcome by 12 mo nths 
corr (ROP stage 3/4 or ablative 
retinal surgery or blind) 
31 (17.7%, N=122) 21 (12.4%, N=131) RR 0.63 [0.38, 1.04] 
P=0.07 
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All but one infant with severe ophthalmic outcomes (worst stage ROP = 3 or 4, ablative retinal 
surgery or blindness, N=52) was less than 28 weeks’ gestation at birth, and all but one of these 
infants retained vision in at least one eye (1 case bilateral blindness in standard target range 
group). All infants who required ablative retinal surgery (N=31) were les s than 28 weeks’ 
gestation at birth. The rates of ablative retinal surgery in this sub-group of infants were 16% 
(20/124) in the standard target range group, compared with 8% (11/132) in the higher target 
range group (RR 0.52, 95% CI 0.26, 1.03; P=0.06) (Table 16). 
3.5.5 Psychosocial outcomes  
The follow-up rates for the self-administered questionnaires assessing the psychosocial 
outcomes ranged from 71-77%. There were no significant differences between the groups in 
the measures of postnatal depression, infant or toddler temperament, parenting stress, or 
family impact (Table 17). Edinburgh Postnatal Depression Scale (EPDS) scores decreased 
over time from a mean of 10.4 (SD 5.5) at enrolment to 6.2 (SD 4.9) when assessed at 12 
months corrected age. The proportion of mothers with an elevated EPDS score (>12)191 was 
32% (88/272), 18% (45/252), 8% (20/248) and 11% (30/265) at 32 weeks pma, 38 weeks pma, 
4 and 12 months corrected age respectively. The high rates of elevated EPDS during the 
infant’s initial hospitalisation are similar to those reported in other extremely preterm 
populations.225 
Table 17: Psychosocial outcomes, by treatment group 
 
Variable 
 
 
SpO2 91-94%  
Control group 
 
 
SpO2 95-98%  
Treatment group 
 
Mean Difference  
[95% CI] 
 
Mean EPDS at 32 weeks pma 
 
10.7 (SD 5.7, N=138) 
 
10.0 (SD 5.3, N=134) 
 
MD -0.7 [-2.03, 0.60] 
P=0.4 
Mean EPDS at 38 weeks pma 7.5 (SD 5.0, N=124) 8.1 (SD 5.5, N=128) MD 0.6 [-0.78, 1.9] 
P=0.4 
Mean EPDS at 4 mths corr 5.6 (SD 4.5, N=123) 6.5 (SD 5.3, N=125) MD 0.9 [-0.38, 2.1] 
P=0.2 
Mean EPDS at 12 mths corr 5.9 (SD 5.1, N=135) 6.5 (SD 4.8, N=130) MD 0.6 [-0.6, 1.8] 
P=0.3 
Mean ITS at 4 mths corr 2.3 (SD 0.7, N=126) 2.4 (SD 0.7, N=129) MD 0.1 [0.0, 0.3] 
P=0.06 
Mean TTS at 12 mths corr 3.2 (SD 0.6, N=132) 3.1 (SD 0.6, N=133) MD -0.1 [-0.2, 0.1] 
P=0.6 
Mean PSI at 12 mths corr 71.7 (SD 20.6, N=132) 72.9 (SD 21.1, N=129) MD 1.2 [-3.9, 6.3] 
P=0.7 
Mean IFS at 12 mths corr 40.0 (SD 11.0, N=131) 39.8 (SD 11.7, N=127) MD -0.20 [-2.98, 2.59] 
P=0.9 
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3.5.5.1 Psychosocial outcomes for home oxygen sub -group 
Psychosocial outcomes were examined for the sub-group of infants who received home 
oxygen therapy (N=84) as families of these infants are known to have increased psychological 
stress.268 Data from this trial showed that infants receiving home oxygen were rated as having 
a more difficult temperament at 4 months corrected age than those infants not receiving home 
oxygen (mean difference in infant temperament scores 0.2; 95% CI 0.06, 0.46; P=0.01), and 
their parents had higher parenting stress index scores (70.8 for the no home oxygen group 
versus 67.5 for the home oxygen group; MD 5.7; 95% CI -0.02, 11.42; P=0.05). However, it 
should be noted that these sub-group analyses were not done on the groups as originally 
randomised and thus these results should be treated with caution. 
 
3.5.6 Health service utilisation and rehospitalisation outcomes  
Measures of health service utilisation and rehospitalisation rates in the first year of life did not 
differ by treatment group (Table 18). The proportion of infants visited by a family support 
team269, 270 was 44% (158/358). The median number of health service usages in the first year 
of life was 27.5 visits per infant (IQR 25-30) for the standard range group and 31.3 visits per 
infant (IQR 27-35) for the higher range group (MedD 3.8; 95% CI -0.84, 8.51; P=0.1). 
Rehospitalisation was quite common for trial infants in the first year with 51% (174/341) 
being readmitted at least once. However only a small proportion of these readmissions (5.5%, 
25 of 452 readmissions) were for an illness severe enough to require the infant to be re-
ventilated or receive intensive care.  
Table 18: Health service utilisation and rehospitalisation outcomes, by treatment group 
 
Variable 
 
 
SpO2 91-94%  
Control group 
 
 
SpO2 95-98%  
Treatment group 
 
Relative Risk or             
Median Difference  
[95% CI] 
 
Family support team 
visited 
 
78 (43.8%, N=178) 
 
80 (44.4%, N=180) 
 
RR 1.01 [0.08, 1.28] 
P=0.9 
Median health service 
usages to 12 mths corr 
27.5 visits/infant  
(IQR 25-30, N=171) 
31.3 visits/infant  
(IQR 27-35, N=170) 
MedD 3.8 [-0.84, 8.51] 
P=0.1 
# infants rehospitalised to 
12 mths corr 
82 (48%, N=171,  
       212 readmissions) 
92 (54%, N=170,  
       240 readmissions) 
RR 1.13 [0.92, 1.39] 
P=0.3 
# readmissions requiring 
mechanical ventilation 
7 (3.3%, N=212 
             readmissions) 
11 (4.6%, N=240   
              readmissions) 
RR 1.39 [0.55, 3.52] 
P=0.5 
# readmissions to ICU 
 
10 (4.7%, N=212 
              readmissions) 
15 (6.2%, N=240 
              readmissions) 
RR 1.32 [0.61, 2.89] 
P=0.5 
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3.5.6.1 Health service utilisation and rehospitalisation outcomes for home oxygen sub-group 
Health service utilisation and rehospitalisa tion outcomes were examined more 
comprehensively for the sub-group of infants who received home oxygen therapy as these 
infants are known to have increased health service needs.22, 113, 271-273 These outcomes in the 
home oxygen infants (N=84) compared with trial infants who did not receive home oxygen 
(N=274) are summarised in Table 19. This analysis revealed infants receiving home oxygen 
are significantly more likely to be visited by a family support team (RR 1.55; 95% CI 1.24, 
1.95, P=0.0001) and have an increased number of health service usages, with 31 visits per 
infant for the home oxygen group compared with 24.5 visits per infant for those not receiving 
home oxygen (MedD -8; 95% CI -12, -3; P=0.001). A greater proportion of home oxygen 
infants also required rehospitalisation with 65% of home oxygen infants compared with 47% 
of non-home oxygen infants being readmitted in the first year of life (RR 1.40; 95% CI 1.14, 
1.72; P=0.001). They also had a significantly increased median number of readmissions 
(P=0.0001). 
 
3.6 Adjustment of outcomes for known prognostic factors  
It was hypothesised that although baseline prognostic characteristics were well balanced 
between the two groups (see Table 2), adjustment for factors known to strongly predict some 
of the outcomes in this cohort of infants (gestation, gender, ethnicity, plurality)28 and the 
baseline EPDS (which showed a different rate of change over time between the groups, see 
Table 17) might influence the results. Several clinical outcomes (length of hospital stay or 
days of mechanical ventilation after randomisation, pma to full sucking feeds, pma at 
discharge home and worst stage of ROP) as well as longer term growth and development 
outcomes that were expected to show differences between the two oxygen target range groups 
did not do so in the unadjusted analysis. Hence adjusted analyses for the aforementioned 
factors were undertaken using multiple or logistic regression models.  None of these outcomes 
changed from a non-significant to a statistically significant result in the adjusted analyses for 
either the whole cohort of trial infants or for the sub-group of high risk infants born at less 
than 28 weeks’ gestation (see Tables 20 and 21, Appendix 21).  
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Table 19: Health service utilisation and rehospitalisation outcomes, by home oxygen 
status 
 
 
Variable 
 
 
No home oxygen 
N=274 
 
 
Home oxygen 
N=84 
 
Relative Risk or 
Median Difference 
[95% CI] 
 
 
Family support team 
visited 
 
 
107 (39.1%, N=274) 
 
51 (60.7%, N=84) 
 
RR 1.55 [1.24, 1.95] 
P=0.0001 
 
median # health services 
usages 
24.5 visits/infant         
(IQR 16-36) 
31 visits/infant            
(IQR 19-48.5) 
MedD -8 [-12, -3] 
P=0.001 
 
median # emergency 
room visits/infant 
2 (IQR 1 -3, n=104 visits) 1.5 (1-3, n=44 visits) MedD 0 (0, 0) P=0.6 
median # GP visits/infant 5 (IQR 2 -8, n=231 visits) 4 (IQR 3 -8, n=75 visits) MedD 0 (0, 0) P=0.5 
 
median # ECC 
visits/infant 
5 (IQR 2 -10, n=195 visits) 4 (IQR 2 -7, n=49visits) MedD 1 (-1, 2) P=0.3 
 
median # specialist 
visits/infant 
3 (IQR 2 -6, n=194 visits) 6 (IQR 3 -8, n=67 visits) MedD -2 (-3, 1) 
P<0.0001 
 
# infants rehospitalised  120 (283 readmits, N=258, 
47%) 
54 (169 readmits, N=83, 
65%) 
RR 1.40 [1.14, 1.72] 
P=0.001 
 
median # 
readmissions/infant 
0 (IQR 0-1, Range 0-17) 1 (IQR 0-2.5, Range 0-12) MedD 0 (0, 0) 
P=0.0001 
 
# readmissions requiring 
mechanical ventilation 
10 (3.5%, n=283 readmits) 8 (4.7%, n=169 readmits) RR 1.34 [0.54, 3.33] 
P=0.5 
 
# readmissions to ICU 13 (4.6%, n=283 readmits) 12 (7.1%, n=169 readmits) RR 1.55 [0.72, 3.31] 
P=0.3 
 
# infants needing ICU or  
mechnical ventilation 
during readmission 
 
13 (5.0%, N=258 pts) 9 (10.8%, N=83 pts) RR 2.15 [0.95, 4.85] 
P=0.06 
 
# readmissions for 
respiratory illness 
175 (62%, n=283      
                      readmits) 
109 (65%, n=168  
                       readmits) 
RR 1.05 [0.91, 1.21] 
P=0.5 
 
# readmissions for 
neurological problems  
6 (2.1%, n=283 readmits) 1 (0.6%, n=168 readmits) RR 0.28 [0.03, 2.31] 
P=0.2 
 
median LOS per 
readmission (days) 
 
3 (IQR 1 -6, Range 1-366) 2 (IQR 1 -5, Range 1-311) MedD 0 (0, 0) P=0.3 
total days 
rehospitalisation 
 
1690 (N=120 infants,   
          n=283 readmits) 
1840 (N=54 infants,  
           n=169 re admits)                   
P<0.0001 
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3.7 Major outcomes, stratified by centre 
In multicentre trials, centre-adjusted analysis may be useful secondary analyses but should not 
replace the overall results.254 Hence, the major outcomes (proportion of infants with weight 
less than 10th centile at 12 months corrected age, presence of a major developmental 
abnormality, continuing oxygen requirement at 36 weeks pma, and home oxygen therapy) 
were examined for each enrolment centre, combined using meta-analysis with a fixed effects 
model and tested for statistical heterogeneity. The results (see Appendix 22) showed there was 
homogeneity across centre strata for all four major outcomes, and the combined Mantel-
Haenszel test statistics were unchanged from the unadjusted analyses (see Tables 9,10, 13).  
 
3.8 Sensitivity analysis of major outcomes for effect of sibling pairs 
There were 25 sibling pairs, termed “related multiples”, totaling 50 infants enrolled (see 
section 2.2.2 and Table 4). They made up 14% (50/358) of the total enrolment cohort. A 
sensitivity ana lysis was performed by randomly removing 50% of the related multiples from 
the dataset and re-analysing the four major outcomes (see Appendix 23). This analysis 
confirmed that the inclusion of sibling pairs made no difference to the overall results for these 
major outcomes, confirming that it was unnecessary to adjust the results for correlations 
between sibling outcomes.  
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CHAPTER 4: DISCUSSION 
 
4.1 Summary of main results 
Targeting a higher oxygen saturation range in chronically oxygen dependent, extremely 
preterm infants conferred no significant long-term growth or development benefits but did 
result in some increased health service burdens for these infants. Higher oxygen targeting 
resulted in 40% more infants being in oxygen at 36 weeks postmenstrual age and 78% more 
being discharged home on supplemental oxygen. Hence, one could expect an additional case 
of home oxygen therapy for every 8 infants if higher oxygen saturation ranges were targeted 
routinely. Thus the routine use of higher oxygen targeting for chronically oxygen-dependent, 
preterm infants cannot be recommended. The results of this trial should not be extrapolated to 
practice recommendations for oxygen-dependent, preterm infants prior to 32 weeks 
postmenstrual age. 
 
4.2 Primary growth and development outcomes 
The results of this trial contradict much of the previous physiological, observational and 
anecdotal evidence regarding the beneficial growth and development effects of higher oxygen 
targeting in chronically oxygen-dependent, preterm infants (see sections 1.6.3 and 1.6.4). 
There may be several reasons for this. First, it is well recognised that studies which do not use 
randomisation in an attempt to overcome potential confounding factors can substantially 
overestimate the effects of interventions.274-276 To date, there have been no randomised trials 
that have assessed the effect of higher oxygen targeting on long-term infant growth and 
development.24, 87  Hence, the apparent beneficial effects of higher oxygen saturation targeting 
seen in previous non-randomised studies may have been due to other factors that could not be 
accounted for in non-randomised trial study designs, such as socioeconomic differences, and 
differences in clinical practices in different time periods and between different clinicians. 
 
Previous work had addressed only short-term growth and development outcomes, such as 
growth during initial hospitalisation and intracranial pathology prior to discharge. These  
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measures are only surrogates for more important, longer term outcomes relating to growth and 
development. Surrogate outcomes are not always good predictors of the true outcomes of 
interest even when the correlation between the surrogate and the longer term outcome appears 
strong.277-279 Hence, prior work which relied on only short-term surrogate outcomes may have 
found results that differ from those in this study.  
 
A potential limitation of the study design is that more subtle, longer-term outcomes, such as 
minor disability, are unable to be detected as early as the 12 months corrected age endpoint 
used in this trial. However, a Griffiths Developmental Scale score of more than 1 but less than 
2 standard deviations below the mean has been shown to be predictive of later minor 
developmental disability.211, 280 In our cohort of infants there was no significant difference 
between the two groups for this outcome (19% and 20% for the standard and higher groups, 
respectively; RR 1.08, 95% CI 0.69, 1.69; P=0.7), suggesting that the experimental treatment 
does not affect development in this way and that further longer term follow-up of these 
children is not justified.  
 
Much of the previous work also selected a particularly high-risk group of infants (preterm 
infants still oxygen-dependent at 36 weeks pma) on whom the experimental treatment may 
have been more effective. Our trial enrolled infants with less severe lung disease by choosing 
an earlier entry point for reasons previously outlined in section 2.1.1. This more pragmatic 
approach should ensure that the trial’s results are more generalisable, but may have 
contributed to an attenuation of the effect of the treatment.  
 
The trial was not designed to answer the question of how best to monitor preterm infants’ 
oxygen levels during acute respiratory failure in the first weeks of life.  This would best be 
answered in the context of another, well-designed randomised trial and a planning group 
(including the author) has been formed to achieve this goal.281 However, a potential limitation 
of the current study design is that infants were enrolled 3-10 weeks after birth during which 
time the effect of higher oxygen targeting may have been diluted by targeting practices prior 
to randomisation. The current study design attempted to overcome the potential, well-
recognised effects of differing oxygen targeting policies for titrating and weaning oxygen on  
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the outcomes by stratifying treatment allocation by enrolment hospital in order to assure a 
balance of the two treatments within each institution (see section 2.2.2 and Table 4).  
 
The trial had approximately 80% power to detect the differences in effect sizes on which the 
sample size calculations were made. Although effect size differences of this magnitude (see 
section 2.7.1.2) may have been optimistic, it was thought that without this size of difference in 
the primary endpoints clinicians would have remained reluctant to change their practice in 
response to the trial’s results. The 24% rate of major developmental abnormality in the control 
group of this trial was exactly as estimated for the sample size calculations. The proportion of 
infants small for their age at 12 months corrected age, the other primary outcome on which the 
sample size estimations were based, was only 37% in the trial’s control group, rather than the 
estimated 47%. However, the 95% confidence interval seen for this outcome (RR 0.96; 95% 
CI 0.66, 1.42) suggests sufficient power to detect real differences despite the reduced control 
event rate. Post hoc power calculations showed that the trial’s sample size had 79% power to 
detect a real difference in this outcome. 
 
The study design allowed for the allocation of eligible infants of multiple births to the same 
treatment group as their siblings (see section 2.2.2). There were 25 such infants in addition to 
the 333 infants individually randomised (see Figure 7). We believed that very few outcomes 
(potentially only length of hospital stay) would be substantially influenced by the lack of 
independence in these sibling pairs. This, coupled with the fact that they only comprised a 
relatively small proportion of the total sample size (50/358 = 14%), suggested there was no 
need to adjust the analyses for any correlation of outcomes between siblings. Hence, data from 
all 358 infants (including the additional 25 related multiple siblings) were included as data 
from independent individuals in the analyses. The sensitivity analysis undertaken by randomly 
removing half of the related siblings from the analysis confirmed that their presence made no 
difference to the overall results for the major outcomes (see Appendix 23).  
 
A final potential limitation of the study was the degree of “crossover” between the two groups 
with regard to the interventions received. Unlike the only other randomised trial to allocate 
preterm infants to target a standard or higher oxygen saturation range (but in order to assess  
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different outcomes), the STOP-ROP trial,106 whose trial management procedures expended 
considerable effort to maximise the time infants were in their targeted saturation ranges, 
BOOST was a pragmatic trial. It was designed to test the effect of employing the two different 
target saturation range policies in the “real world” in order to assess whether the experimental 
treatment would benefit infants across a range of neonatal care settings. Hence, whilst the 
research nurses regularly downloaded information regarding protocol adherence and discussed 
these results with the infants’ carers (see sections 2.5.2 and 3.3.4), it was expected that there 
would be some degree of overlap between the two groups. In the STOP-ROP trial only 8% of 
saturations for infants targeting the standard group were in the higher range or above, and 2% 
of saturations for infants assigned to the higher group were in the standard range or lower. In 
our trial, the corresponding results were 37% and 25%, respectively, with the actual median 
values of 93% (for the SpO2 91-94% target group) and 97% (for the SpO 2 95-98%) group (see 
section 3.3.3). These results suggest that the two groups did in fact receive two different 
treatments and that the lack of difference between the two groups in terms of primary 
outcomes was not due to overwhelming crossover of the two treatments. Although there are 
methods available to attenuate the results of a trial to account for the degree of crossover 
(whilst still maintaining an intention-to-treat analysis),282 they were not employed in the 
analysis as the degree of crossover was thought to be acceptable in the context of the 
pragmatic trial design. Compliance adjusted analyses were also not considered appropriate for 
a pragmatic trial design. Such analyses would have been difficult to undertaken as infants 
were back-transferred to one of 52 non-tertiary hospitals and compliance data obtained from 
these hospitals could thus not be attributed to the original enrolling hospital. It would be 
outside the scope of the project’s original aim to assess the effect of non-compliance in this 
way, and such analysis would not assist clinicians trying to choose between the two oxygen 
saturation range policies under study in real clinical practice settings. 
 
4.3 Oxygen outcomes 
All measures of oxygen duration were significantly increased in the higher target range group, 
including the duration of oxygen (in total and after randomisation), postmenstrual age when 
oxygen therapy was ceased, and the proportion of infants still requiring supplemental oxygen 
at 36 weeks pma (see section 3.5.1). These results may seem self evident, given that infants in  
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the higher target range group were required to achieve a higher target oxygen level and would 
thus be expected to take longer to achieve this milestone. However, this suggests that our 
original hypothesis (see sections 1.7 and 1.9) that higher oxygen targeting might enhance 
respiratory health and thus infants in this group may have had decreased duration of oxygen, 
cannot be supported by data from this trial. 
 
Increases in the duration of oxygen of the magnitude found in this trial would have significant 
health service implications. There was a median difference in the numbers of days in oxygen 
after 32 weeks pma of 17 days and a median difference in the postmenstrual age at 
supplemental oxygen cessation of 2.3 weeks (see Table 13). Higher oxygen targeting resulted 
in 40% more infants being in oxygen at 36 weeks postmenstrual age (RR 1.4, 95% CI 1.2, 1.7; 
P=0.0006). These findings have both statistical and clinical significance. Infants requiring 
supplemental oxygen therapy have a higher level of nursing dependency than those who do 
not require such therapy.283 A change in the number of infants with increased nursing 
dependency of this magnitude could have serious health service implications. Interestingly, 
although there were significantly more infants requiring supplemental oxygen at 36 weeks 
pma their respiratory health did not appear worsened by higher oxygen targeting. Infants in the 
higher target range group did not have an increase in postnatal steroid or diuretic use, or have 
an increased duration of assisted ventilation as would be expected if their respiratory status 
was worse than those in the standard group. The length of hospital stay, either in total or after 
randomisation, was also not different between the two groups (see section 3.5.2), again 
suggesting that infants targeting the higher oxygen saturation range were not necessarily 
“sicker” than those targeting the standard range.  
 
These results contrast with the only other randomised trial that has allocated infants to higher 
versus standard oxygen saturation ranges. The STOP-ROP trial106 randomised preterm infants 
with pre-threshold ROP (mean age at randomisation 35.6 weeks) to target higher versus 
standard oxygen saturation ranges for a minimum of two weeks to assess the effect on 
progression to threshold ROP. That trial assessed pulmonary measures as secondary outcomes 
at 3 months corrected age. Whilst the STOP-ROP infants who targeted a higher oxygen 
saturation range were significantly more likely to be in oxygen at 3 months corrected age  
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(47% vs 37%, P=0.02), they were also significantly more likely to have at least one marker of 
poor pulmonary health defined as remaining in hospital, or on oxygen, steroids, 
methylxanthines or diuretics at 3 months corrected age (57% in the higher group versus 46%  
in the standard group, P=0.005). Similarly, a recent UK cohort study91 found that infants 
targeting a higher saturation range required assisted ventilation and supplemental oxygen for 
significantly longer than those targeted at lower ranges (31 days of ventilation and 96 days of 
supplemental oxygen for the higher oxygen target infants versus 14 days of ventilation and 40 
days of supplemental oxygen for the standard target range infants, P<0.01). So whilst infants 
in the BOOST trial did not appear to have signs of increased respiratory ill health and did not 
require increased length of hospitalisation, the increased duration of oxygen translated into 
78% more infants receiving home oxygen therapy (RR 1.78; 95% CI 1.20, 2.64; P=0.004) (see 
section 3.5.1).  Hence one could expect an additional case of home oxygen therapy for every 8 
infants if higher oxygen saturation ranges were targeted routinely. Taking an infant home who 
requires continuous supplemental oxygen is known to cause considerable psychological and 
physical disruption as well as financial stress for the affected families.268, 284 Thus, a policy of 
routine higher oxygen targeting could have major health service implications with little 
evidence of the growth and development benefits it is hypothesised to achieve.  
 
The economic implications of implementing a policy of routine higher oxygen targeting with 
regard to home oxygen costs can be summarised as follows. Based on detailed costings done 
in 1993,285 the daily cost in 2002 of home oxygen is approximately AUD$144 (converting to 
2002 AUD$ rates, source: Reserve Bank of Australia <www.rba.gov.au>). Using the trial 
results of a 30% home oxygen rate in the higher group compared with a rate of 17% in the 
standard group (see Table 13), one could expect an additional 131 infants per year to require 
home oxygen therapy for every 1,000 infants routinely targeted at higher oxygen saturation 
levels. Assuming the mean days of home oxygen for these additional infants would be 165 
(mean days of home oxygen in higher target range group was 165), this would mean an 
additional AUD$3,112,560 (131 infants x 165 days x $144/day) of unnecessary health care 
expenditure for every 1,000 infants treated with higher oxygen targeting. 
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The psychological impact of increased home oxygen rates is more difficult to assess. A post 
hoc sub-group analysis of data from this trial showed that infants who received home oxygen 
were rated as having a more difficult temperament at 4 months corrected age than those who 
had not received home oxygen and their parents had higher parenting stress index scores (see 
section 3.5.5.1). However, it should be noted that as these sub-group analyses were not done 
on the groups as originally randomised, these results should be treated with caution. There are 
no randomised controlled trials that have directly addressed the question of whether infants 
requiring home oxygen (by whatever discharge criteria) grow and develop better if their 
oxygen saturation levels are targeted at a higher level after discharge, and whether such an 
intervention has any effects on other important secondary outcomes such as duration of home 
oxygen, infant temperament, parenting stress or family impact (see section 5.2).  
  
4.4 Pulmonary deaths  
The unexpected finding of an excess of pulmonary deaths in infants in the higher target range 
group (see section 3.5.3) was not statistically significant, but the trial had low power to detect 
real differences in this outcome as the number of late deaths was very small. Our results are 
consistent with the findings of the only other trial to randomise preterm infants to differing 
oxygen saturation target ranges, the STOP-ROP trial.106 That trial found increased adverse 
pulmonary sequelae (although not increased pulmonary deaths) in preterm infants with pre-
threshold ROP when a higher oxygen saturation range was targeted (see section 4.3). In the 
BOOST trial there were four deaths after discharge due to respiratory causes in the higher 
oxygen group compared with no post-discharge respiratory deaths in the standard group (see 
Table 15, section 3.5.3).   
 
The unexpected finding of increased pulmonary deaths is biologically plausible. There is 
evidence that the by-products of oxygen metabolism can be toxic, particularly when humans 
are exposed to high oxygen concentrations in inspired air.25 It is well demonstrated in animal 
models that exposure to pure oxygen for only a few hours results in pulmonary capillary 
endothelial thinning and after 2-5 days of high oxygen exposure alveolar oedema and 
haemorrhage, hyaline membrane formation and complete destruction of the lung capillary 
endothelium can be observed.286 Moreover, it is hypothesised that preterm infants are  
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particularly susceptible to oxygen-radical injury because of their low levels of anti-
oxidants.287, 288 Oxidative stress increases lung antioxidants in some experimental models of 
chronic lung disease and hyperoxia is known to affect fetal lung growth. Surfactant production 
and function are also altered by both hyperoxia and reactive oxygen species, thereby making 
the lungs more vulnerable to injury.289 
 
Another factor which may explain both the adverse pulmonary sequelae but improved 
ophthalmic outcomes seen in infants targeted at a higher oxygen saturation level (see section 
4.5) is the influence of vascular endothelial growth factor (VEGF). Hyperoxia-induced injury 
to the developing lung results in disordered vascular development. In animal models, during 
acute lung injury VEGF levels are markedly decreased but during post-injury recovery, up-
regulation of VEGF accompanies the re-establishment of normal vasculature.290 Similarly, in 
the first phase of ROP, exposure of the extremely preterm infant to the relatively hyperoxic 
extra-uterine environment after birth leads to down regulation of VEGF production and the 
cessation of normal blood vessel development in the retina.100 A rebound overproduction of 
VEGF to compensate for the resulting tissue metabolic imbalance leads to the abnormal 
vascularisation typical of human ROP.101 Hence it is plausible that the decrease in VEGF 
production seen in these infants during their initial lung and eye injury, followed by the up-
regulation of VEGF in the recovery phase of both conditions, could explain the somewhat 
contradictory findings of adverse pulmonary sequelae but improved ophthalmic outcomes.   
 
The only other two existing trials88, 291 that have randomised preterm infants to target higher or 
lower blood oxygen levels (in these trials the measure of oxygenation was PaO2) reported only 
one clinically important outcome, death. A Cochrane Systematic Review87 showed that when 
the death outcomes from the two trials were meta-analysed, there was no statistically 
significant difference between the high and low PaO2 groups (RR 0.91, 95% CI 0.57, 1.44; 
P=0.85). Synthesis of the results from the BOOST trial with this Cochrane review data would 
not be feasible as both of the included trials use the intervention in the first days of life when 
death rates would be expected to be high, rather than in the chronic phase of the infant’s 
illness as applied in the BOOST trial when death rates would be expected to be quite low.  
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4.5 Ophthalmic outcomes 
The BOOST trial was not designed to answer the question of the effect of higher oxygen 
targeting on ophthalmic outcomes, and as such did not have sufficient statistical power (only 
approximately 60%) to detect clinically meaningful differences in these secondary outcomes. 
The trial would have needed a sample size of approximately 570 infants (almost double its 
actual size) to assess ophthalmic outcomes reliably. However, the effect of differing oxygen 
saturation target ranges on ROP is of interest, as infants were randomised to the differing 
treatments at 32 weeks postmenstrual age before threshold ROP usually develops and as these 
were important clinical outcomes they were pre-specified as measures for analysis.  
 
Current treatment for severe ROP (stage 3 or greater, known as threshold disease) is invasive 
and involves ablation of the avascular retina by cryotherapy or laser photocoagulation101 as 
this form of therapy has been shown to reduce unfavourable ophthalmic outcomes by up to 
50%.292 However, even after this invasive treatment, retinal detachment and blindness still 
occur in some infants.293 Retinal ablation is also not without complication, with iris atrophy, 
cataracts and hypotony being reported following this procedure.294 A reduction in the need for 
this form of therapy would suggest that infants had less severe eye disease as they did not 
require this invasive treatment. When interpreting rates of ablative retinal surgery in the 
future, the results of the ongoing ET-ROP trial,295 which is comparing ablative surgery prior to 
reaching threshold ROP with current practice, should be considered, as future rates may not be 
comparable with those of the current study. 
 
Both STOP-ROP106 and this trial suggest less ophthalmic intervention use when a higher 
oxygen saturation range is targeted in a sub-group of early gestation infants with more severe 
eye disease. Whilst not statistically significant, a difference in the rate of ablative retinal 
surgery in the BOOST trial of 16% in the standard range group compared with a rate of 8% in 
the higher oxygen group for infants less than 28 weeks’ gestation at birth (see section 3.5.4) 
may be important information for clinicians weighing up the harms and benefits of the 
treatment. The rates of ablative surgery were not reported directly in the STOP-ROP trial. 
However, it can be assumed that virtually all infants reaching threshold ROP in that trial 
received ablative surgery treatment as this was the standard practice of the participating units  
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(personal communication: Dale Phelps, 2002). If this is the case, the STOP-ROP trial results 
also demonstrated a reduced need for ablative retinal surgery in infants targeted at a higher 
saturation range (48% in the standard group versus 41% in the higher group), although again 
this was not statistically significant.  
 
Three early trials 87 and a recent UK cohort study91 found that infants nursed at lower levels of 
oxygen or who were targeted at lower SpO 2 levels during the early weeks of life had 
significantly less severe eye disease. Both the STOP-ROP and BOOST trials randomised 
infants during the chronic phase of their oxygen dependency, after many of the factors that 
potentially contribute to the development of ROP have already occurred. The potentially 
beneficial effects of higher oxygen targeting in reducing the amount of ablative retinal surgery 
required for infants with severe ROP seen in both these trials, needs to be considered in the 
context of when during the course of the infant’s illness the intervention was given. Hence the 
results of both the BOOST and STOP-ROP trials, which show some improved eye outcomes 
with higher oxygen targeting should not automatically be extrapolated to preterm infants of an 
earlier postnatal age.  
 
The fact that there were no significant differences in the rates of severe ROP (stage 3 or 
greater) in this trial may have been a function of insufficient sample size for this secondary 
outcome analysis. As ophthalmic outcomes are clinically important, any new trial assessing 
the effects of differing oxygen saturation levels in the early weeks of life on the prevention of 
ROP should be designed with sufficient sample size to detect this outcome.281 
 
4.6 Psychosocial outcomes  
The trial was not resourced sufficiently to achieve follow-up rates for the secondary 
psychosocial outcomes of greater than the 71-77% achieved. This has implications for the 
interpretation of the results as it has been demonstrated that subjects who fail to participate in, 
or comply with treatment allocation or the follow-up regime within a trial have, on average, 
worse outcomes than trial participants in either the active or control arm of the study.186 
 
However, the mean and median values for each scale (see section 3.5.5) were similar in the 
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trial infants to those reported with each instrument’s normative data and/or when used in other 
populations of preterm infants.191, 225, 230, 233, 235, 240 The mean Edinburgh Postnatal Depression 
Score (EPDS) and the proportion of women with elevated EDPS scores decreased over time as 
would be expected, although the high rate of elevated EDPS scores during the infant’s initial  
hospitalisation (32% of mothers at 32 weeks pma) warrants consideration by clinicians caring 
for such families. The prior hypothesis that higher oxygen saturation targeting may result in 
infants with improved temperament who are thus less stressful for their families cannot be 
supported by the data from this trial.  
 
4.7 Health service utilisation and rehospitalisation outcomes  
As with the psychosocial outcomes, there were no significant differences between the two 
groups with regard to the use of health care services and rates of rehospitalisation in the first 
year of life (see section 3.5.6). The hypothesis that higher oxygen targeting results in a 
“healthier” infant cannot be supported by the data from this trial.  
 
Both groups had very high use of health services during their first months at home: 28 and 31 
visits per infant in the standard and higher groups respectively. This translates to, on average, 
more than one visit to a health care provider every fortnight. Similarly, rehospitalisation was 
quite common for these infants with more than half (51%) requiring at least one readmission 
to hospital during their first year of life. Despite the increased need for services and support, 
less than half of these high-risk infants were visited by a trained family support nurse, the use 
of which has been documented to decrease general practitioner visits, improve infant 
temperament and reduce maternal anxiety. 269 
 
The sub-group of infants receiving home oxygen therapy used health care services 
significantly more in the first year of life and were much more likely to require 
rehospitalisation (see section 3.5.6, Table 19). Our findings are consistent with other studies 
that have found increased health service needs for these particularly high risk infants.19, 23, 284 
These results should be noted by clinicians, considering that in this trial infants in the higher 
oxygen targeting group were 1.78 times more likely to receive home oxygen compared with 
infants in the standard group (see section 3.5.1). 
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CHAPTER 5: CONCLUSIONS 
 
5.1 Implications for clinical practice  
 
The results of this double-blind randomised trial show no evidence of growth or development 
benefits of targeting a functional oxygen saturation range of 95-98% compared with a range of 
91-94% in chronically oxygen-dependent preterm infants. 
 
The results of this randomised trial contradict much of the previously published observational 
evidence suggesting the benefits of routine higher oxygen targeting in chronically oxygen 
dependent, preterm infants. Based on the BOOST Trial results, for every 1,000 infants 
targeted at higher oxygen saturation levels, 183 additional infants would remain in oxygen at 
36 weeks postmenstrual age and 131 more would be discharged on home oxygen. These 
potential health service costs come with no convincing evidence of growth or 
neurodevelopment benefits and thus, the routine use of higher oxygen targeting for chronically 
oxygen-dependent, preterm infants cannot be recommended.  
 
The BOOST Trial addressed only the question of the effects of two different oxygen saturation 
target ranges in chronically oxygen-dependent, preterm infants. Hence, the results of this trial 
should not be extrapolated to practice recommendations for oxygen-dependent, preterm 
infants prior to 32 weeks postmenstrual age. 
 
One of the major findings of the trial was the significantly increased rate of home oxygen 
therapy in the higher oxygen group. From information gained by extensive interaction with 
this group of high-risk infants by the research team, considerable variation was observed in the 
types of services and support provided by different centres, and the way in which those 
services were administered. There were no established models of post-discharge care that were  
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used by all centres. It is thus recommended that a coordinated, state-wide home oxygen 
service should be established to enhance equity of service provision in this area. 
 
5.2 Implications for future research  
 
Whilst this trial has helped answer the question of whether targeting a higher oxygen 
saturation range for chronically oxygen-dependent preterm infants is beneficial in the long-
term, it has not resolved the question of the most appropriate oxygen saturation range for 
preterm infants in the early weeks of life. This important clinical question can only be 
answered in the context of further large, well-designed randomised trials with good long-term 
follow-up.24 A collaborative group (including the author) has been formed to bring this idea to 
fruition.281 
 
It is important that the results of the BOOST trial are applied in clinical practice. In addition to 
the initial survey of current practice prior to the commencement of the trial,86 another survey 
of trial-participating centres was conducted following completion of the trial but prior to the 
public release of the results. This showed that clinicians remained in equipoise regarding the 
most appropriate oxygen saturation target range for oxygen-dependent preterm infants. A 
further survey of clinical practice is planned for 6-12 months following publication of the 
primary manuscr ipt in a major peer-reviewed journal. The information gained from this survey 
will also assist the planning committee of the next oxygen saturation trial in assessing 
clinicians’ uptake of research findings.  
 
The other research translation project that is currently underway is the formulation of 
guidelines for oxygen weaning and titration based on the data and experience gained in this 
trial. There are very few published data regarding the best method of maintaining a specific 
oxygen saturation target range and/or how best to titrate oxygen in order to wean infants into 
air appropriately. 103, 104 
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Finally, in the sub-group of home oxygen infants more research work is needed. Elucidating 
the impact of this therapy on families is currently being investigated by the author in 
collaboration with others using qualitative study methodologies. There are no randomised 
controlled trials that have addressed the question of whether infants requiring home oxygen 
(by whatever discharge criteria) grow and develop better if their oxygen saturation levels are 
targeted at a higher level after discharge, and whether such an intervention has any effects on 
other important secondary outcomes such as duration of home oxygen, infant temperament, 
parenting stress or family impact. This should be a priority for future research and would 
benefit from the collaboration of paediatric respiratory physicians, neonatologists and neonatal 
nurses.   
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Title of Research Project: A Randomised Trial of Oxygen Therapy on Growth and 
Development of Infants 
 
Chief Investigator:  Professor David Henderson-Smart, MB BS, PhD, FRACP 
  Director, Centre for Perinatal Health Se rvices Research 
  University of Sydney, NSW 
 
 
 PARENTAL CONSENT  
 
 
I,........................................................................……………………................................... of 
 
................................................................................................………………….................. 
 
............................................................................................................…………………...... 
 
Have read and understood the Information for Participants on the above named research study  
and have discussed the study with 
 
.........................................................................................................…………………......... 
 
  
I freely choose to participate in this study and understand that I can withdraw at any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
 
 
NAME: .....................................................................................…..................... 
 
SIGNATURE: ..........................................................................................……............. 
 
DATE:  ................................................................................................……....... 
 
NAME OF WITNESS: …………………………………………………………….… 
  
SIGNATURE OF WITNESS:  ...............................................................…………..… 
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A Randomised Trial of Oxygen Therapy on Growth and Development of Infants 
 
 
INFORMATION SHEET FOR PARENTS  
 
You are invited to enrol your baby in a study of whether keeping oxygen at a higher level in the blood 
improves growth and development.  The study is being coordinated by the specialist obstetric hospitals 
in New South Wales. Your baby has been selected as a possible participant in this study because she/he 
was been born before 30 weeks gestation (premature) and needed extra oxygen for at least 3 weeks 
after birth. 
 
Very premature babies commonly need extra oxygen for a long time because of their lung problems ,  
and they o ften do not grow or develop well during the first year of life.  There is a standard or 
usual amount of oxygen in the blood that is kept by monitoring the oxygen saturation (this tells us 
how much oxygen is in the blood).  A certain level is maintained by turning the oxygen higher or 
lower.  You may have heard that in the past very high oxygen given to premature babies caused 
eye damage, but this level of oxygen is no longer used in modern neonatal intensive care.  The 
amount of oxygen used now is safe, and your baby is considered too old to have any side effects 
on the eyes from oxygen.  We think it is important to find out whether we can improve the health 
of babies like yours.  Doctors are uncertain whether babies will be healthier on lower or higher 
levels of oxygen, and this is why we are doing this study. 
 
If you agree to participate in this study, your baby will be randomly assigned (like the toss of a coin) to 
be kept at either the usual or the higher oxygen.  Your baby will be kept at either type of oxygen level 
only for the amount of time that they need extra oxygen.  On the one hand, it may take more time for 
the baby to be weaned off oxygen if they are getting the higher amount, and she/he may be in hospital 
for a slightly longer time.  On the other hand, your baby may go home earlier and not get as many 
illnesses in the first year, because they are healthier as a result of getting more oxygen.  Our study aims 
to see if overall there is a benefit to babies and their families. 
 
The research nurse will keep track of how much oxygen the baby gets by recording it twice a week.  
We need to find out how your baby grows and develops, so a research nurse will measure the length, 
weight, and the size of the head before the baby goes home, and again at one year of age.  At the time 
the baby goes home, again after several months, and at one year, we will also ask you to complete 
surveys that tell us about how your baby's premature birth affected you.  At one year of age, a research 
psychologist will carry out tests to find out how developed your child is.  Because the one year visit 
involves coming to hospital, we will make an appointment that is convenient for you and give you a 
refund for the amount it costs to get to hospital. 
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Title: A Randomised Trial of Oxygen Therapy on Growth and Development of Infants 
 
 
 
Any information about you and your baby that we get in this study will remain private and will only be 
seen by research staff unless any very serious or life threatening problems were uncovered, in which 
case your baby's doctor would be notified.  The results of the study will be published only in a way that 
will not name you or your baby. 
 
Whether you take part in this study or not, it will not make any difference to the medical care your 
baby will receive from nurses and doctors in the hospital.  If you decide to take part in the study, you 
can still withdraw at any time and this will not make any difference to your baby's medical care either. 
 
When you have read this information, the research nurse or your doctor will talk to you about the study 
more and answer any questions you may have.  If you have any questions at any time, Professor David 
Henderson-Smart, or his assistant, Lisa Askie on (02) 9351 7739, or pager: (02) 9963 3540, will be 
happy to answer them.  You will be given a copy of this sheet to keep. 
 
This study has been approved by the Ethics Review Committee of the Central Sydney Area Health 
Service, which is responsible for King George V Hospital for Mothers and Babies. If you have any 
worries or complaints about the research study, you can contact the Secretary of the Ethics Review 
Committee of the Central Sydney Area Health Service on (02) 9515 6766. 
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ENROLMENT FORM  
IDENTIFYING DETAILS: 
 
Baby name: _________________________________________ 
Baby record number:^^^^^^^^^^ 
 
Date of birth:  _______ / _______ / _______ 
   day     month      year 
 
Time of birth:  ________ : ________ 
 
ELIGIBILITY CRITERIA: Tick  box þ if applicable 
   Gestational age < 30 weeks 
  Oxygen dependent at 32 weeks postmenstrual age 
   Parent(s) reside where follow up is possible  
 
Only if all above  boxes ticked, then continue: At which perinatal centre is the infant registered:  
  John Hunter Hospital      Royal Hospital for Women 
   King George V Hospital    Royal North Shore Hospital 
 Liverpool Hospital     Mater Mothers Hospital 
   Nepean  Hospital     Canberra Hospital 
 
EXCLUSION CRITERIA: Tick box þ if applicable  
  Lethal  and selected congenital malformations, including: congenital heart defects; congenital lung defects; 
intestinal atresias or stenoses; anomalies of the abdominal wall.  (Please specify): 
__________________________________________________________________________________ 
   Major surgery and disease complications influencing growth and development directly, including: intestinal 
resections/ostomies/fistulas; ventriculostomies; ventricular shunts.  (Please specify):  
__________________________________________________________________________________ 
   Infant expected to die imminently 
   Infant not expected to live with the biological mother 
   Three or more eligible infants from a multiple confinment 
F  EXCLUDE INFANT IF ANY OF EXCLUSION CRITERIA ARE TICKED 
Has head ultrasound at approximately 4 weeks of life  been performed?         yes      no 
If no, then need to wait for ultrasound to be done 
If yes, were results:    Grade 3 or 4 intraventricular haemorrhage (IVH) 
   Periventricular leukomalacia (PVL)  
   Porencephalic cyst 
F  EXCLUDE INFANT IF ANY OF BOXES  IMMEDIATELY ABOVE ARE TICKED 
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F  ONLY IF INFANT IS ELIGIBLE,  PROCEED TO CONSENT 
 
CONSENT: Tick  box þ when completed 
   First approach to parents by neonatologist or nurse liaison representative 
   Study explained to parents by neonatologist, nurse liaison representative or research nurse 
   Consent form signed and witnessed 
  Parents given a copy of the consent form and information sheet 
 
F  IF CONSENT REFUSED OR NOT SOUGHT ON ELIGIBLE INFANTS,  
 COMPLETE  “REFUSAL / MISSED ELIGIBLES  SECTION”  NEXT PAGE 
 
FWHEN ALL CONSENT BOXES ARE TICKED,COLLECT RANDOMISATION DETAILS 
 
RANDOMISATION DETAILS: 
Perinatal Centre No.:          ^^^^  
 
Confinement Status:      Singleton        Unrelated Multiple       Related Multiple 
 
Gestational Age Grouping:    23-27 weeks   28-29 weeks 
 
Primary doctor:    ____________________________________________________________ 
 
Dr's phone number: (            ) __________________________________ 
 
 
F WHEN ALL ABOVE DETAILS ARE COMPLETE, PROCEED TO RANDOMISATION 
 
Contact:   Study Coordinator on (02) 9351 7739  or   call: 016-020  &  ask for pager no. 225 656 
 
Eligibility will be counter-checked and Study Coordinator will organise randomisation. 
 
F   ONCE COMPLETE,  PLACE THIS FORM IN  BOOST  PROCEDURE MANUAL  IN 
           "COMPLETED ENROLMENT FORMS" SECTION  -  Study Coordinator will collect  
 
To be completed by Study Coordinator: 
Study Identifier No.:  ^^^^^  -  ^^^^ 
 
Date of randomisation:    _________/_________/_________ 
                           day          month           year 
 
Date study intervention commenced:  _________ / _______ / ________ 
                             day         month    year 
 
NICUS number:        ^^^^^^^           (if applicable) 
 
Research nurse initials:  _________________ Study coordinator initials:  _________________ 
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REFUSALS / MISSED ELIGIBLES  SECTION:  Complete this section only if applicable 
 
 
IDENTIFYING DETAILS: 
 
Baby name: _________________________________________ 
Baby record number:   ^^^^^^^^^^ 
 
Date of birth:  _______ / _______ / _______ 
   day     month      year 
 
Registration hospital:  ______________________________ 
 
NICUS number:        ^^^^^^^           
 
 
 
Reason for refusal:      parent(s) refused (baby believed to be too ill) 
(by parents)      parent(s) refused (protection of baby) 
       parent(s) refused (other) 
          please specify  ______________________________________ 
 
Reason for missed eligible:    doctor refused (baby believed to be too ill) 
(eligible but not asked)      doctor refused (protection of parents) 
       doctor refused (other)  
          please specify  ______________________________________ 
       assessed too late for inclusion 
       unknown 
       other 
          please specify _______________________________________ 
 
   ONCE COMPLETE,  PLACE THIS FORM IN  BOOST  PROCEDURE MANUAL  IN 
 
    "COMPLETED ENROLMENT FORMS" SECTION  -  Study Coordinator will collect 
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OXYGEN / NURSING DEPENDENCY / WEIGHT FORM (Clinical Data Form 2) 
Study Identifier No.:    ^ ^^^ - ^^^  Baby's name: ______________________________________________ 
 
  from  notes:        from  download:       from  notes: 
 
Date  FiO2(%/lpm)      / SpO2 (median)    SpO2 (median) SpO2 (mode)  % time spent  Dependency Weight 
  Range        (middle value)       in target range  level 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
 
_________ ______________ / _____________      ___________ __________  _________ %  __________ ______ g 
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CLINICAL DATA FORM (Data form 1) 
 
IDENTIFYING DETAILS: 
 
Study Identifier No.:       ^^^^^ - ^^^^ 
 
Download files name: _______________________________ 
 
Baby surname: _________________________  Baby first name: ______________________ 
 
Also known as:  surname ______________________  first name ______________________ 
Baby medical record number:   ^^^^^^^^^^^ 
 
Baby date of birth:    _______/_______/_______     Time of birth:  _____ : ______ 
             day        month       year 
 
Hospital/place of delivery:  __________________________________________________ 
 
Perinatal Centre for trial enrolment: 
¨  Canberra Hospital     ¨  Nepean Hospital 
¨  John Hunter Hospital    ¨  Royal Hospital for Women 
¨  King George V Hospital    ¨  Royal North Shore Hospital 
¨  Liverpool Hospital     ¨  Mater Mothers Hospital 
NICUS number:   ^^^^^^^ Transferred via NETS: ¨  yes       ¨  no 
 
 
CLINICAL DATA FOR BABY:   
Gestational age:  ^^^  weeks 
 
Sex:    ¨ Unknown     ¨ Male         ¨  Female        ¨ Ambiguous 
 
Plurality:       ¨ Singleton        ¨ Twins     ¨  Triplets     ¨  Quads   ¨  More 
 
Birth order:   ¨ Singleton        ¨ First           ¨  Second     ¨  Third   ¨  Fourth 
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Birthweight:       ^ ^^^^    grams 
Head circumference at birth:        ^ ^^ . ^^  centimetres 
Length at birth (or first attended): ^^^ . ^^  cm _______/_______/_______ 
and date attended                day        month       year 
1 minute Apgar score:     ^^^      5 minute Apgar score:     ^^^   
 
Primary respiratory diagnosis: 
 ¨  Unknown    ¨  Transient tachypnoea of newborn 
 ¨  Hyaline membrane disease  ¨  Meconium aspiration 
 ¨  Pneumonia     ¨  Pulmonary hypertension 
 ¨  Immature lung   ¨  Apnoea 
 ¨  Congenital anomaly  ¨  Other (specify)____________________ 
 
Surfactant:           yes       no 
Patent ductus arteriosus:         yes       no 
If  yes, treatment with:       Indomethacin        Surgery 
      Other (specify)__________________________ 
 
Apnoea/bradycardia requiring treatment:   yes       no 
 If  yes,  type of treatment:    Methylxanthines   CPAP 
       Other (specify)___________________________ 
 
Total days TPN:     ^^^^   days 
 
Postnatal steroids for lung disease:       yes      no 
Abnormal CLD CXR  &  O2 dependent at 36 weeks pma:    yes     no 
Diuretic therapy for chronic lung disease:      yes      no 
 
Worst episode of necrotising enterocolitis: 
 None     Clinical diagnosis  Proven radiologically/at surgery 
 
Worst grade of IVH: 
  None  Grade I  Grade II  Grade III  Grade IV
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Worst grade of ROP:  Right eye 
  Normal  Grade I  Grade II  Grade III  Grade IV 
 
Worst grade of ROP:  Left eye 
  Normal  Grade I  Grade II  Grade III  Grade IV 
 
Treatment for ROP:     yes   no  
 
If Yes, was treatment:  one eye  both eyes 
 
 
OXYGEN CONSUMPTION: 
 
A.  General: Date supplemental oxygen started:       _________/_________/_________  
                        day          month           year 
 
  Date supplemental oxygen last needed:   _________/_________/_________ 
             day          month           year 
Total days in oxygen (all types of administration):       ^^^^    days  
 
B.   Was infant ever ventilated?:    yes   no  If yes : 
 
Date assisted ventilation (mechanical vent or CPAP) started:        ______/_______/_______ 
                    day        month        year 
 
Date assisted ventilation (mechanical vent +all CPAP) completed: ______/_______/_______ 
                       day        month         year 
Total days of mechanical ventilation (IMV, IPPV, HFV, SIMV, SIPPV):   ^^^^ days 
Total days of CPAP (continuous via ETT, NP, nasal prongs):                 ^^^^ days  
Total days of CPAP (intermittent via NP, nasal prongs):                 ^^^^  days   
Total days of assisted ventilation (mechanical ventilation + all CPAP):     ^^^^  days 
 
Treated with high frequency ventilation:        yes      no 
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Was home oxygen required?:      yes     no  If yes:  
 
Date commenced home oxygen:  ________ / ________ / ________ 
         day         month       year 
 
Date completed home oxygen:  ________ / ________ / ________ 
         day         month       year 
Total days of home oxygen:                   ^^^^    days 
 
ENROLMENT IN OTHER STUDIES: 
 
Enrolled in Oracle trial:      yes     no 
Enrolled in ActoMgSO4 trial:     yes     no 
Enrolled in TIPP trial:      yes     no 
Enrolled in any other trial:     yes     no 
 
     If  yes, specify: _____________________________ 
 
___________________________________________________________________________ 
 
 
 
PHYSICAL MEASUREMENTS AT 38 WEEKS POSTMENSTRUAL AGE (pma): 
 
Weight at 38 weeks pma:  ^^^^^ grams    Date:_______ / _______ / ______ 
           day         month        year 
 
Length at 38 weeks pma: ^^^ . ^^ cm    Date:_______ / _______ / ______ 
           day         month        year 
 
Head circ at 38 weeks pma: ^ ^^ . ^^ cm    Date:______ / _____ / ______ 
         day       month        year 
 
 
Grade 3 or 4 ROP (any eye) at 38 weeks pma:    yes     no 
 
 
Death by 38 weeks pma:      yes     no 
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FEEDING AND NUTRITION DATA: 
 
Date established all sucking feeds:     ________ / _________ / _________ 
         day           month     year 
 
Date birthweight regained and maintained: ________ / _________ / _________ 
         day           month     year 
 
Feeding at discharge to home: 
 
  fully breast fed  combination breast/formula fed  formula fed 
 
 
TRANSFER/DISCHARGE DATA: 
 
During hospitalisation, was the baby transferred temporarily :    yes     no 
 If  yes, was the baby transferred to:    another Level 3 NICU 
         a Level 4 NICU 
         other (specify) ____________________ 
 
 
Discharged from registration hospital on:      _________/_________/_________ 
        day          month           year 
 
From the  registration hospital, 
was the baby discharged to:      home 
    another Level 3 NICU  
specify hospital ______________________________ 
specify reason _______________________________ 
___________________________________________ 
     level 4 NICU  
specify hospital ______________________________ 
specify reason _______________________________ 
___________________________________________ 
    level 2 nursery 
specify hospital______________________________ 
specify reason _______________________________ 
___________________________________________ 
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     other hospital/setting (e.g. interstate, overseas, fostered) 
specify setting _______________________________ 
specify reason _______________________________ 
___________________________________________ 
 
 
Date of final discharge from all hospitals:  _________/_________/_________ 
         day          month           year 
 
Total days of initial hospitalisation:   ^^^^ days 
 
 
 
 
STUDY INTERVENTION DETAILS: 
 
Commencement of study intervention: 
 
Randomisation Status:   Singleton  Unrelated Multiple   Related Multiple  
 
Gestational Age Grouping:   24-27 weeks  28-29 weeks 
 
 
Date reached 32 weeks pma:   _________ / _______ / ________ 
                             day         month    year 
 
Date of randomisation:    _________/_________/_________ 
                           day          month     year 
 
Date study intervention commenced:  _________ / _______ / ________ 
                             day         month    year 
 
Age at randomisation (in pma weeks + days  eg 32+3 wks):  _________________  weeks  
 
Completion of study intervention: 
 
Date study intervention (supplemental O2) ceased: __________ / _________ / _________ 
       day   month   year 
 
Download in air after one week off study intervention:    Normal    Abnormal 
 
Date study oximeter removed (final):     ________ / _________ / ___________ 
           day          month                year  
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Temporary removal from study intervention: (complete only if applicable)  
 
Date removed     Date returned Reason for removal                Authorised by 
 
___ / ___ / ___     ___ / ___ / ___     _________________________________    __________ 
 
___ / ___ / ___     ___ / ___ / ___     _________________________________    __________ 
 
 
NURSING DEPENDENCY DATA:  During initial hospitalisation:  
Total days  at  Level 4       dependency:  ^^^^ days 
Total days  at  Level 3       dependency:  ^^^^ days 
 
Total days  at  Level 2a     dependency:  ^^^^ days 
 
Total days  at  Level 2b     dependency:  ^^^^ days 
 
 
 
CLINICAL DATA FOR MOTHER: 
Mother's age:  ^^^     years  Mother's height: ^^^^     cm 
Total no. previous pregnancies: ^^^  Total no. deliveries >20wks &/or BW > 400g ^ ^^  
 
Previous preterm birth (> 20wks &/or BW > 400g)      Yes     No 
Total no. previous perinatal deaths (>20wks &/or BW >400g & died < 28 days)    ^^^ 
 
Antenatal steroids:  Unknown       None       < 24 hours      Complete      >7 days 
 
Delivery: 
 Normal vaginal    Forceps         Forceps rotation    Vacuum extraction 
 
 Vaginal breech     CS not in labour (elective)     CS in labour (emergency) 
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SOCIAL/OTHER DATA FOR MOTHER: 
 
Marital status:      Married/de facto       Single       Divorced/widowed 
Insurance status:     Medicare        Private 
 
Mother's country of birth:  ____________________________________ 
 
Mother's ethnic/racial origin:   
   Unknown      Caucasian 
   Aboriginal/Torres Strait Islander   Asian 
   Other (describe) _____________________________________________ 
 
Primary language spoken at home by mother: _____________________________________ 
 
Highest level of mother's education completed: 
 
  Some primary school     Completed HSC 
  Primary school      Some trade, TAFE or university 
  Some secondary school     Completed trade or TAFE 
  Completed school certificate     Completed university 
 
Prior to the baby's birth was the mother working in paid employment:       yes         no 
If  yes:     Part-time    Full-time 
 
Mother's current occupation: ___________________________________________________ 
 
Mother's usual occupation: _____________________________________________________ 
 
 
Financial support received (tick all that apply) : 
   Single parent pension    Invalid pension 
  Unemployment benefit    Child disability allowance 
  Other benefit (specify) ________________________________________ 
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SOCIAL/OTHER DATA FOR FATHER: 
 
Father's age:  ^^^     years  Father's height:  ^ ^^^   cm 
 
Father’s country of birth:  ____________________________________ 
 
Father's ethnic/racial origin: 
   Unknown      Caucasian 
   Aboriginal/Torres Strait Islander   Asian 
   Other  (describe) _____________________________________________ 
 
Primary  language spoken at home by father: ______________________________________ 
 
 
 
Highest level of father's education completed: 
 
  Some primary school     Completed HSC 
  Primary school      Some trade, TAFE or university 
  Some secondary school     Completed trade or TAFE 
  Completed school certificate     Completed university 
 
 
Is father currently employed:        yes      no 
 If  yes:       Part-time    Full-time 
 
Father's current occupation: _________________________________________________ __  
 
Father's usual  occupation: ____________________________________________________ 
 
 
Financial support received (tick all that apply) 
 
  Unemployment benefit  
  Invalid pension  
  Other benefit (specify) _________________________________________ 
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CONTACT DETAILS: 
 
Mother: 
 
Mother's surname: __________________________ Mother's first name: ________________ 
 
Mother's address:______________________________________________________ (Street) 
 
    ____________________________________________ (Suburb/City/Town) 
 
Mother's phone: (________)___________________________________ 
 
Father:  
 
Father's surname: _________________________ Father's first name: ___________________ 
 
Father's address: _______________________________________________________(Street) 
(if different from mother's) 
     ___________________________________________ (Suburb/City/Town) 
 
Father's phone: (_________)___________________________________ 
(if different from mother's) 
 
 
Grandmother (mother's mother): 
 
Surname: ________________________________ First name: ________________________ 
 
Address: _______________________________________________________ (Street) 
 
  _____________________________________________ (Suburb/City/Town) 
 
Phone:  (_________)___________________________________ 
 
 
Other:  
 
If the maternal grandmother is unavailable, have parent(s)  nominate one other  person who is likely to 
know their whereabouts beyond the coming year. 
 
Other relation to parent(s): _____________________________________________________ 
 
Other surname: __________________________  Other first name: _____________________ 
 
Other address: _______________________________________________________ (Street) 
 
  _____________________________________________ (Suburb/City/Town) 
 
Other phone: (________)____________________________________ 
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4 MONTHS CORRECTED FOLLOW-UP FORM (Data form 6) 
 
 
IDENTIFYING DETAILS: 
 
Study Identifier No.:       .:   ^ ^^^^ - ^^^^  
 
Baby surname: _________________________  Baby first name: ______________________ 
 
Also known as:  surname ______________________  first name ______________________ 
 
Date of birth:    _______/_______/_______  
    day        month       year 
Baby medical record number:   ^^^^^^^^^^^ 
 
Perinatal Centre for trial registration: 
  John Hunter Hospital      Royal Hospital for Women  
  King George V Hospital     Royal North Shore Hospital 
 Liverpool Hospital       Mater Mothers’ Hospital 
  Nepean Hospital       The Canberra Hospital 
 
 
CLINICAL DATA AT 4 MONTHS CORRECTED AGE: 
 
Date reached 4 months corrected:  _______/_______/_______  
        day        month       year 
 
Weight:   ^^^^^    grams  Date:_______ / _______ / ______ 
         day         month        year 
Head circ: ^^^ . ^^  centimetres Date:_______ / _______ / ______ 
         day         month        year 
 
Length:  ^^^ . ^^     centimetres Date:_______ / _______ / ______ 
         day         month        year
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12 MONTHS CORRECTED FOLLOW-UP FORM (Data form 7) 
 
 
IDENTIFYING DETAILS: 
 
Study Identifier No.:   ^^^^^ - ^^^^ 
 
Baby surname: _________________________  Baby first name: ______________________ 
 
 
Also known as:  surname ______________________  first name ______________________  
 
Date of birth:    ________/________/_________  NICUS No. ^^^^^^^ 
                         day             month             year 
 
Baby medical record number:  ^^^^^^^^^^^ 
 
 
Date reached 12 months corrected age:   __________/__________/__________  
              day            month            year 
 
 
¨ Griffiths   ¨ Eyes   ¨ Hearing 
 
 
1. PHYSICAL / NEUROLOGICAL EXAMINATION: 
 
Date of physical/neuro assessment:   __________/__________/__________  
             day            month            year 
 
Physical/neuro assessment was completed at: 
 
¨  Canberra Hospital    ¨  Nepean Hospital 
¨  John Hunter Hospital    ¨  Royal Hospital for Women 
¨  King George V Hospital   ¨  Royal North Shore Hospital 
¨ Liverpool Hospital    ¨ Mater Mothers Hospital 
¨ Other - please specify: _____________________________________________________________ 
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PHYSICAL EXAMINATION 
 
Growth Parameters  
 
 
Weight   ........................... .. kgs 
 
Height   ............................. cms 
 
Head Circumference  ............................. cms 
 
 
Physical Examination    Normal / Abnormal   If “Abnormal”, please specify:-  
 
............................................................................................................................................................... 
 
.............................................................................................................................................................. 
 
............................................................................................................................................................... 
 
............................................................................................................................................................... 
 
NEUROLOGICAL PROBLEMS  Newly diagnosed since discharge:  Y / N 
 
Meningitis / Encephalitis    Y / N / Unknown 
 
 If yes, are there any sequelae? Y / N 
 
 If yes, please specify:- 
 
 
Hydrocephalus     Y / N / Unknown 
 
 If yes:   Age diagnosed .........................  months 
 
  Type  Congenital / Acquired 
 
  Treatment Shunt / Reservoir / Arrested 
 
 
Seizures     Y / N / Unknown 
 
  If yes:   Age of onset .........................  months 
 
   Type(s) Febrile / Partial / Generalised / Syndrome (specify) 
 
   No. in the last year:    0  /  1 or more 
 
 
Other Neurological Problems   Y / N / Unknown 
 
  Porencephalic cyst  Y / N 
 
  Cortical atrophy   Y / N 
 
  Periventricular leucomalacia  Y / N 
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Summary of Neurological Checklist : 
 
 
 1  =  NORMAL 
 
 2  =  PROVISIONAL DIAGNOSIS OF CEREBRAL PALSY / MOTOR DELAY WITH  
         NEUROLOGICAL SIGNS 
 
 3  =  MOTOR DELAY,  WITH OR WITHOUT SUSPECT NEUROLOGICAL SIGNS 
 
 
 If  “2” circled, i.e. provisional diagnosis of cerebral palsy, then: -  
 
  Severe functional disability due to cerebral palsy Yes / No  
 
  (where “Severe functional disability” = not sitting independently) 
 
 
 
Oro-motor function  
 
Problems :-     Treatment:- 
 
 Chewing Y / N    Tube Feeding  Y / N 
 Drooling Y / N   Gastrostomy   Y / N 
 Swallowing  Y / N   Speech Therapy  Y / N 
 Voice   Y / N   Other   Y / N 
       If yes, please specify:-  
 
 
 
 
 
THERAPEUTIC SERVICES USED 
 
Have any of the following services or treatment been used for this child since discharge? 
 
      Past, but  not current / No / Referred / Current 
 
 Hearing Impairment Centre  P / N / R / C 
 Visual Impairment Centre   P / N / R / C 
 Motor Impairment Centre    P / N / R / C 
 Developmental Disability Centre   P / N / R / C 
 Emotional / Behavioural problem advice P / N / R / C 
 Physiotherapy    P / N / R / C 
 Occupational therapy   P / N / R / C 
 Speech pathology   P / N / R / C 
 Other early intervention   P / N / R / C 
 Dept of Community Services (DOCS)  P / N / R / C 
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2. HEARING TEST     
 
 
Date of Most Recent Test ................................. Who Tested .............................................................. 
 
TYPE OF TEST 
RESULTS BAER NOISEMAKERS VROA AUDIO
GRAM 
TYMPANO
GRAM 
OTO ACOUSTIC 
EMISSION 
Normal (L)   Y / N      Y / N       Y / N       Pass / Fail 
Normal (R)   Y / N      Y / N       Y / N       Pass / Fail 
Passed 30dB 
screen 
    Y / N    
Severe loss 
excluded 
            Y / N     
 
 
 
RESULT  Normal / Abnormal / Ongoing surveillance / Unknown  
 
   If Abnormal:- Right / Left / Both 
 
   Conductive deafness R / L / B 
   Sensory  Neural deafness R / L / B 
   High Frequency Loss Y / N 
 
If deafness present, 
   Level of loss in better ear:- mild (30-40 dB)  Y / N 
       moderate (41-60 dB) Y / N 
       severe (61-90 dB)  Y / N 
       profound (>91 dB) Y / N 
 
HEARING AID in place R / L / B VENTILATION TUBES in place R / L / B / Nil 
 
 
 
 
3. VISION TEST    
 
 
Date of Most Recent Test ................................ Who tested ................................................................ 
 
 
RESULT  Normal / Abnormal / Ongoing Surveillance / Unknown  
 
   If abnormal:- None / Right / Left / Both 
 
Myopia   N / R / L / B  Strabismus   N / R / L / B  
Retinopathy  N / R / L / B  Tortuosity of retinal vessels N / R / L / B 
Surgery   N / R / L / B  Patching   N / R / L / B 
Corrective Lenses N / R / L / B  Drops    N / R / L / B 
Blind   N / R / L / B 
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4. DEVELOPMENT 
 
Type of developmental assessment test: Revised Griffiths / “Old” Griffiths / Unknown / Other (specify) 
 
                  .......................................................................................... 
 
Date of Assessment   .......................................................................................... 
 
Name of Person Administering Test ....................................................................................................... 
 
Address    ......................................................................................................... 
 
    ......................................................................................................... 
 
 
   RESULTS OF REVISED GRIFFITHS SCORE 
Scale Raw Score Age Equivalent 
score(mths) 
Sub and General 
Quotients 
Percentile Score 
A   Locomotor     
 
B  Personal-Social     
 
C  Hearing-
Language 
    
 
D Hand-Eye     
 
E Performance     
 
TOTAL     
 
 
 
Any Other Problems? 
 
 If yes, please specify:- 
 
 
 
 
 
 
 
 
CHECKLISTS 
 
Have the following been received, completed and returned ? 
 
 1) Toddler Temperament completed    Y / N 
 
 2) Parenting Stress Index completed   Y / N 
 
 3) Impact o n Family Scale completed   Y / N 
 
 4) Edinburgh Postnatal Depression Scale completed Y / N 
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DEATH REGISTRATION FORM (Data Form 5) 
 
IDENTIFYING DETAILS: 
 
Study Identifier No.: ^^^^ - ^^^ 
 
 
Baby surname: _________________________  Baby first name: ______________________ 
Baby medical record number:  ^^^^^^^^^^                        
 
Baby date of birth:    _________/_________/_________ 
          day          month           year 
 
DETAILS OF DEATH: 
 
Baby date of death:    _________/_________/_________  
          day          month           year 
 
Place of death:   Hospital: (specify): __________________________________________ 
   Home 
   Other:      (specify): __________________________________________ 
 
Primary cause of death:  _______________________________________________________ 
ICD-9 code:     ^^^^ . ^^^ 
 
Source of data:    Hospital discharge summary 
    Autopsy/postmortem 
    Death certificate 
    Coroner's report 
    Other (specify)______________________________________________ 
 
Primary doctor:       ___________________________________________________________ 
 
Dr's phone number (          ) __________________________________ 
 
Research nurse initials  ____________ 
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Retinopathy of prematurity (ROP) screening report form 
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EDINBURGH POSTNATAL DEPRESSION SCALE 
 
 
Stage:   ¨ Entry  ¨ 38 weeks pma ¨  4 months   ¨ 12 months  
 
As you have recently had a baby, we would like to know how you are feeling.  Please UNDERLINE 
the answer which comes closest to how you have felt PAST SEVEN DAYS,  
not just how you feel today. 
 
Here is an example, already completed. 
 
I have felt happy: 
Yes, all the time. 
Yes most of the time.  
No, not very often.  
No, not at all. 
 
This would mean :"I have felt happy most of the time" during the past week.   
Please complete the othe r questions in the same way. 
 
 
 
IN THE PAST SEVEN DAYS: 
 
1.  I have been able to laugh and see the funny side of things  
  1 As much as I always could  
  2 Not quite so much now  
  3 Definitely not so much now  
  4 Not at all 
 
2.  I have looked forward with enjoyment to things  
  1 As much as I ever did  
  2 Rather less than I used to  
  3 Definitely less than I used to  
  4 Hardly at all 
 
3.  I have blamed myself unnecessarily when things went wrong  
  1 Yes, most of the time  
  2 Yes, some of the time  
  3 Not very often  
  4 No, never 
 
4.  I have been anxious and worried for no good reason  
 1 No, not at all  
 2 Hardly ever  
 3 Yes, sometimes  
 4 Yes, very often 
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5.  I have felt scared or panicky for no good reason  
 1 Yes, quite a lot  
 2 Yes, sometimes  
 3 No, not much  
 4 No, not at all 
 
6.  Things have been getting on top of me  
  1 Yes, most of the time I haven't been able to cope 
  2 Yes, sometimes I haven't been able to cope as well as usual 
  3 No, most of the time I have coped well 
  4 No, I have been coping as well as ever 
 
7.  I have been so unhappy that I have had difficulty sleeping 
  1 Yes, most of the time  
  2 Yes, sometimes 
  3 Not very often 
  4 No, not at all 
 
8.  I have felt sad or miserable  
  1 Yes, most of the time  
  2 Yes, quite often  
  3 Not very often  
  4 No, not at all 
 
9.  I have been so unhappy that I have been crying  
  1 Yes, most of the time  
  2 Yes, quite often  
  3 Only occasionally  
  4 No, never 
 
10.  The thought of harming myself has occurred to me  
  1 Yes, quite often  
  2 Sometimes  
  3 Hardly ever  
  4 Never 
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SHORT TEMPERAMENT SCALE FOR INFANTS (4-8 MONTHS OF AGE) * 
 
 
 
 
 
 
 
 
 
 
 
 
FOR EACH QUESTION, PLEASE CIRCLE THE NUMBER WHICH BEST DESCRIBES YOUR 
CHILD’S RECENT AND CURRENT BEHAVIOUR. 
 
 
IF ANY QUESTION DOES NOT APPLY TO YOUR CHILD OR CANNOT BE ANSWERED, JUST 
DRAW A LINE THROUGH IT. 
 
 
 
 
 
 
 
 
 
 
 
* Copyright ATP 1987 
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           Almost     Not    Variable, Variable, Frequently Almost  
            never    often      usually    usually    always 
           does not      does 
 
1. The baby is fretful on waking up and/or  1 2 3 4 5 6 
    going to sleep (frowns, cries).  
 
2. The baby accepts straight away any change 1 2 3 4 5 6 
    in place or position of feeding, or person 
    giving the feed. 
 
3. The baby is shy (turns away or clings to  1 2 3 4 5 6 
     mother) on meeting another child for the 
     first time. 
 
4. The baby continues to fret during nappy  1 2 3 4 5 6 
     change in spite of efforts to distract  
     him/her with game, toy or singing etc. 
 
5. The baby amuses self for 1/2 hour or more  1 2 3 4 5 6 
    in cot or playpen (looking at mobile, 
    playing with toy, etc.) 
 
6. The baby moves about a lot (kicks, grabs  1 2 3 4 5 6 
    squirms) during nappy-changing and dressing. 
 
7. The baby makes happy sounds (coos, smiles,  1 2 3 4 5 6 
    laughs) when being changed ore dressed. 
 
8. The baby is pleasant (smiles, laughs)  1 2 3 4 5 6 
    when first arriving in unfamiliar places 
    (friend’s house, shop). 
 
9. The baby gets sleepy at about the same  1 2 3 4 5 6 
    time each evening (within 1/2 hour). 
 
10. The baby accepts regular procedures (hair 1 2 3 4 5 6 
     brushing, face washing, etc) at any time 
     without protest. 
 
11. The baby moves a lot (squirms, bounces, 1 2 3 4 5 6 
     kicks) while lying awake in cot. 
 
12. For the first few minutes in a new place or 1 2 3 4 5 6 
     situation (new shop or home) the baby is  
     fretful. 
 
13. The baby continues to cry in spite of   1 2 3 4 5 6 
     several minutes of soothing. 
 
14. The baby keeps trying to get  a desired  1 2 3 4 5 6 
     toy, which is out of reach, for 2 minutes 
     or more. 
 
15. The baby greets a new toy with a loud voice 1 2 3 4 5 6 
     and much expression of feeling (whether 
     positive or negative). 
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Study ID No.    ëûëûëûëû  - ëûëûëû 
 
           Almost     Not    Variabl e, Variable, Frequently Almost  
            never    often      usually    usually    always 
           does not      does 
 
16. The baby’s first reaction (at home) to   1 2 3 4 5 6 
      approach by strangers is acceptance. 
 
17. The baby wants daytime naps at differing  1 2 3 4 5 6 
      times (over 1 hour difference) from day  
      to day. 
 
18. The baby cries when left to play alone.  1 2 3 4 5 6 
 
19. The baby's daytime naps are about the same  1 2 3 4 5 6 
 length from day to day (less than 1/2 hour 
 difference). 
 
20. The baby displays much feeling (strong   1 2 3 4 5 6 
      laugh or cry) during changing or dressing. 
 
21. The baby wants and takes feedings at about 1 2 3 4 5 6 
      the same time (with 1 hour) from day to day. 
 
22. The baby is content (smiles, coos) during  1 2 3 4 5 6 
      interruptions of milk or solid feeds. 
 
23. The baby accepts within a few minutes a  1 2 3 4 5 6 
 change in place of bath or person giving 
 the bath. 
 
24 The baby's time of waking in the morning  1 2 3 4 5 6 
 varies greatly (by 1 hour or more) from 
 day to day. 
 
25. The baby reacts strongly to strangers;  1 2 3 4 5 6 
 laughing or crying. 
 
26. The baby’s period of greatest activity comes 1 2 3 4 5 6 
 at the same time of day. 
 
27. The baby is irritable or moody throughout a 1 2 3 4 5 6 
 cold or a stomach virus. 
 
28. The baby can be distracted from fretting  1 2 3 4 5 6 
 or squirming during a procedure (nail cutting, 
 hair brushing, etc) by a game, singing, TV, etc. 
 
29. The baby's first reaction to seeing doctor 1 2 3 4 5 6 
       or infant welfare sister is acceptance (smiles, coos).  
 
30. The baby lies still during procedures like  1 2 3 4 5 6 
      hair brushing or nail cutting 
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1 
 
 
 
 
 
 
 
SHORT TEMPERAMENT SCALE FOR TODDLERS* 
 
 
 
12 months corrected 
 
 
 
 
 
 
FOR EACH QUESTION, PLEASE CIRCLE THE NUMBER WHICH BEST DESCRIBES YOUR 
CHILD’S RECENT AND CURRENT BEHAVIOUR. 
 
 
IF ANY QUESTION DOES NOT APPLY TO YOUR CHILD OR CANNOT BE ANSWERED, JUST 
DRAW A LINE THROUGH IT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* The STST is an uncopyrighted abbreviation of The Toddler Temperament Scale (Fullard, McDevitt 
& 
Carey 1978) The original TTS is copyrighted in the U S
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           Almost     Not    Variable, Variable, Frequently Almost  
            never       often    usually    usually    always 
              does not      does 
 
1. The child gets sleepy at about the same 1 2 3 4   5       6 
    time each evening (within 1/2 hour). 
 
2. The child is pleasant (smiles, laughs),  1 2 3 4   5       6   
    when  first arriving in unfamiliar places. 
 
3. The child plays continuously for more than 1 2 3 4   5       6 
    10 minutes at a time with a favourite toy. 
 
4. The child sits still while waiting for food. 1 2 3 4   5       6 
 
5. The child cries after a fall or bump.  1 2 3 4   5       6 
 
6. The child fusses or whines when bottom   1 2 3 4   5       6   
    is cleaned after bowel movements. 
 
7. The child smiles when unfamiliar adults 1 2 3 4   5       6     
    play with him/her. 
 
8. The child responds to frustration intensely  1 2 3 4   5       6 
    (screams, yells). 
 
9. The child eats about the same amount of  1 2 3 4   5       6 
    solid food at meals from day to day. 
 
10. The child remains pleasant when hungry  1 2 3 4   5       6 
      and waiting for food to be prepared. 
 
11. The child allows face washing without   1 2 3 4   5       6 
       protest (squirming, turning away). 
 
12. The child plays actively (bangs. throws  1 2 3 4   5       6 
      runs) with toys indoors. 
 
13. The child ignores voices when playing 1 2 3 4   5       6 
      with a favourite toy. 
 
14. The child wants a snack at a different time  1 2 3 4   5       6 
       each day (over one hour difference). 
 
15. The child runs to get where he/she wants 1 2 3 4   5       6   
        to go. 
 
16. The child takes daytime naps at differing 1 2 3 4   5       6 
      times (over 1/2 hour difference) each day. 
 
17. The child is outgoing with adult strangers  1 2 3 4   5       6 
      outside the home 
 
18. The child stops play and watches when  1 2 3 4   5       6       
      someone walks by. 
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          Almost     Not    Variable, Variable, Frequently Almost  
                        never    often      usually    usually  always 
                         does not      does 
 
 
19. The child goes back to the same           1 2 3 4 5 6       
      activity after brief interruption (snack,  
      trip to toilet). 
 
20. The child continues to play with a            1 2 3 4 5 6 
      toy in spite of sudden noises from   
      outdoors (car horn, siren etc). 
 
21. The child has moody “off” days when 1 2 3 4 5 6 
      he/she is irritable all day. 
 
22. The child stays with a routine task  1 2 3 4 5 6 
      (dressing, picking up toys) for 5  
      minutes or more. 
 
23. The child stops eating and looks when 1 2 3 4 5 6 
      he/she hears a sudden noise (telephone,  
      doorbell). 
 
24. The child sits still (moves little) during  1 2 3 4 5 6 
      procedures like hair brushing or nail  
      cutting. 
 
25. The child shows much bodily movement 1 2 3 4 5 6 
      (stomps,writhes, swings arms) when upset 
      or crying. 
 
26. The child's initial reaction at home to 1 2 3 4 5 6 
       approach by strangers is acceptance  
       (looks at, reaches out). 
 
27. The child stops to examine new objects  1 2 3 4 5 6 
      thoroughly (5 minutes or more). 
 
28. The child is moody for more than a few  1 2 3 4 5 6 
      minutes when corrected or disciplined. 
 
29. The child is still shy of strangers   1 2 3 4 5 6 
      after 15 minutes. 
 
30. The child frowns or complains when left 1 2 3 4 5 6 
       to play by self. 
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IMPACT ON FAMILY SCALE 
 
 
The following statements have been made by people living with a child who is, or has been, ill. 
Please circle  the number which best reflects whether you strongly agree, agree, disagree or 
strongly disagree with each statement at the present time.  
 
Statements that include “my child’s illness” or “my child’s state” are referring to your child’s 
prematurity, neonatal intensive care stay, and need for ongoing follow-up. Please try to answer 
honestly. Your answers are anonymous and will help us get a better idea of how having a 
premature baby affects families as a whole. 
 
 
     Strongly    Strongly 
     Agree  Agree      Disagree Disagree 
 
1. The illness is causing financial 
    problems for the family  1      2  3       4 
__________________________________________________________________________ 
2. I worry about what will happen to 
    my child in the future (when he/she 
    grows up, when I am not around)  1      2  3       4 
__________________________________________________________________________ 
3. Relatives interfere and think they 
    know what’s best for my child 1      2  3       4 
__________________________________________________________________________ 
4. Additional income is needed in 
    order to cover medical expenses 1      2  3       4 
__________________________________________________________________________ 
5. Because of the illness, we are  
    not able to travel out of the city 1      2  3       4 
__________________________________________________________________________ 
6. People in the neighbourhood  
    treat us specially because of my  
    child’s illness   1      2  3       4 
__________________________________________________________________________ 
7. We have little desire to go out 
    because of my child’s illness  1      2  3       4 
__________________________________________________________________________ 
8. It is hard to find a reliable person 
    to take care of my child  1      2  3       4 
__________________________________________________________________________ 
9. Sometimes we have to change 
plans about going out at the last 
minute because of my child’s state 1      2  3       4 
__________________________________________________________________________ 
10. We see family and friends less  
    because of the illness   1      2  3       4 
__________________________________________________________________________ 
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     Strongly    Strongly 
     Agree  Agree      Disagree Disagree 
 
l1. Because of what we have shared we  
    are a closer family    1      2  3       4 
__________________________________________________________________________ 
12. Sometimes I wonder whether my  
    child should be treated “specially” 
    or the same as a normal child  1      2  3       4 
__________________________________________________________________________ 
13. My relatives have been under- 
    standing and helpful with my child 1      2  3       4 
__________________________________________________________________________ 
14. I think about not having more  
    children because of the illness 1      2  3       4 
__________________________________________________________________________ 
15. My partner and I discuss my child’s 
    problems together   1      2  3       4 
__________________________________________________________________________ 
16. We try to treat my child as if he/she 
    were a normal child   1      2  3       4 
__________________________________________________________________________ 
17. I don’t have much time left over for 
   other family members after caring  
    for my child    1      2  3       4 
__________________________________________________________________________ 
18. Our family gives up things  
    because of my child’s illness  1      2  3       4 
__________________________________________________________________________ 
19. Fatigue is a problem for me 
    because of my child’s illness  1      2  3       4 
__________________________________________________________________________ 
20. I live from day to day and don’t 
    plan for the future   1      2  3       4 
__________________________________________________________________________ 
21. Nobody understands the burden 
    I carry    1      2  3       4 
__________________________________________________________________________ 
22. Travelling to the hospital is a  
    strain on me    1      2  3       4 
__________________________________________________________________________ 
23. Learning to manage my child’s 
    illness has made me feel better  
    about myself     1      2  3       4 
__________________________________________________________________________ 
24. Sometimes I feel like we live on  
     a roller coaster: in crisis when my  
     child is acutely ill, OK when things 
     are stable     1      2  3       4 
__________________________________________________________________________ 
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If you have other children in your household, please respond to the following statements. 
 
     Strongly    Strongly 
     Agree  Agree      Disagree Disagree 
 
25. It is hard to give much attention 
      to the other children because of 
      the needs of my child    1      2  3       4 
__________________________________________________________________________ 
26. Having a child with an illness  
      makes me worry about my other 
      children’s health   1      2  3       4 
__________________________________________________________________________ 
 
 
 
 
If the other children in your household are 4 years or older, please respond to the following 
statements: 
     Strongly    Strongly 
     Agree  Agree      Disagree Disagree 
 
27. There is fighting between the  
      children because of my child’s 
      special needs    1      2  3       4 
__________________________________________________________________________ 
28. My other children are frightened 
      by my child’s illness  1      2  3       4 
__________________________________________________________________________ 
29. My other children seem to have 
     more illnesses, aches and pains 
     than most children their age  1      2  3       4 
__________________________________________________________________________ 
30. The school grades of my other  
      children suffer because of my 
      child’s illness   1      2  3       4 
__________________________________________________________________________ 
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PSI  Short Form 
 
Instructions  
 
 This questionnaire contains 36 statements. Read each statement carefully. For each statement, please 
focus on the child you are most concerned about, and circle the response that best represents your opinion. 
 
 
  Circle the SA if you strongly agree with the statement. 
 
  Circle the A if you agree with the statement. 
 
  Circle the NS if you are not sure. 
 
  Circle the D if you disagree with the statement. 
 
  Circle the SD if you strongly disagree with the statement. 
 
 
 For example, if you sometimes enjoy going to the movies, you would circle A in response to the 
following statement: 
 
   I enjoy going to the movies. SA A NS D SD 
 
 
 While you may not find a response that exactly states your feelings, please circle the response that 
comes closest to describing how you feel. YOUR FIRST REACTION TO EACH QUESTION SHOULD BE 
YOUR ANSWER. 
 
 
 Circle only one response for each statement, and respond to all statements. DO NOT ERASE!  If you 
need to change an answer, make an “X” through the incorrect answer and circle the correct response. For 
example: 
 
   I enjoy going to the movies. SA A NS D SD 
 
 
 Before responding to the statements, write your name, gender, date of birth, ethnic group, marital status. 
child’s name, child’s gender, child’s date of birth, and today’s date in the space at the top of the questionnaire. 
 
 
 
 
 
 
 
 
PAR   Psychological Assessment Resources, Inc./P.0. Box 998/0dessa, FL 33556/Toll-Free 1-800-331-TEST 
 
Copyright81990, 1995 by Psychological Assessment Resources. All rights reserved. May not be reproduced in whole or part  in any form or 
by any means without written permission of Psychological Assessment Resources, Inc. This form is printed in blue ink on carbonless paper. 
Any other version is unauthorised. 
9  8  7  6  5  4  3  2  1   Reorder #RO-3095     Printed in the U.S.A 
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       SA=Strongly Agree  A=Agree NS=Not Sure D=Disagree SD=Strongly Disagree 
1. I often have the feeling that I cannot handle things very well.   SA A NS D SD 
2 I find myself giving up more of my life to meet my children's needs  SA A NS D SD 
   than I ever expected. 
3 I feel trapped by my responsibilities as a parent.   SA A NS D SD 
4 Since having this child I have been unable to do new and different things.  SA A NS D SD 
5 Since having a child, I feel that I am almost never able to do things that I  SA A NS D SD 
   like to do. 
6 I am unhappy with the last purchase of clothing I made for myself.   SA A NS D SD 
7 There are quite a few things that bother me about my life.   SA A NS D SD 
8. Having a child has caused more problems than I expected in my   SA A NS D SD 
    relationship with my spouse (male/female friend).  
9. I feel alone and without friends.     SA A NS D SD 
10. When I go to a party, I usually expect not to enjoy myself.  SA A NS D SD 
11 I am not as interested in people as I used to be.   SA A NS D SD 
12. I don't enjoy things as I used to.     SA A NS D SD 
13. My child rarely does things for me that make me feel good.  SA A NS D SD 
14. Most times I feel that my child does not like me and does not want to  SA A NS D SD 
     be close to me. 
15.  My child smiles at me much less that I expected.   SA A NS D SD 
16. When I do things for my child, I get the feeling that my efforts are  SA A NS D SD 
      not appreciated very much. 
17. When playing, my child doesn't often giggle or laugh.   SA A NS D SD 
18. My child doesn't seem to learn as quickly as most children.  SA A NS D SD 
19. My child doesn't seem to smile as much as most children.  SA A NS D SD 
20. My child is not able to do as much as I expected.   SA A NS D SD 
21. It takes a long time & it is very hard for my child to get used to new things. SA A NS D SD 
 
For the next statement, choose your response from the choices “1” to “5" below 
22. I feel that I am: 1. not very good at being a parent   1 2 3 4 5 
   2. a person who has some trouble being a parent 
   3. an average parent 
   4. a better than average parent 
   5. a very good parent 
23. I expected to have closer and warmer feelings for my child than I do  SA A NS D SD 
      and this bothers me. 
24. Sometimes my child does things that bother me just to be mean.  SA A NS D SD 
25. My child seems to cry or fuss more often than most children.  SA A NS D SD 
26. My child generally wakes up in a bad mood.    SA A NS D SD 
27. I feel that my child is very moody and easily upset.   SA A NS D SD 
28. My child does a few things which bother me a great deal.  SA A NS D SD 
29. My child reacts very strongly when something happens that my child  SA A NS D SD 
      doesn't like. 
30. My child gets upset easily over the smallest thing.   SA A NS D SD 
31. My child's sleeping or eating schedule was much harder to establish SA A NS D SD 
      than I expected. 
 
For the next statement, choose your response from the choices "1" to “5" below. 1 2 3 4 5 
32. I have found that getting my child to do something or stop doing something is:  
 1. much harder than I expected 
 2. somewhat harder than I expected 
 3. shout as hard as I expected 
 4. somewhat easier than I expected 
 5. much easier than 1 expected 
 
For the next statement, choose your response from the choices "10+” to "1-3". 
        10+ 8-9  6-7  4-5  1-3 
33.  Think carefully and count the number of things which your child does that bother you.  
 For example: dawdles, refuses to listen, overactive, cries, interrupts, fights, whines, etc. 
34. There are some things my child does that really bother me a lot.  SA A NS D SD 
35. My child turned out to be more of a problem than I had expected.  SA A NS D SD 
36. My child makes more demands on me than most children.   SA A NS D SD 
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HEALTH SERVICE PROVIDER FORM (Data form 4) 
 
 
IDENTIFYING DETAILS: 
Study Identifier No.:   ^^^^ - ^^^ 
 
 
Baby surname: _________________________  Baby first name: ______________________ 
Baby medical record number:   ^^^^^^^^^^ 
 
Baby date of birth:    _________/_________/_________ 
          day          month           year 
 
 
DETAILS OF VISIT TO HEALTH SERVICE PROVIDER: 
 
Date(s) of visit:    _________/_________/_________ 
             day          month           year 
 
Type of provider:   
    GP         Nurse home visit 
    Routine follow up (at hospital clinic)    Early childhood centre 
   Paediatrician (in private rooms)      Other 
   Hospital outpatient visit (e.g. emergency department) 
 
Primary reason for visit:   
    Routine 
    Developmental therapy 
   Specific illness 
 
Details of visit:  _____________________________________________________ 
 
_________________________________________________________________________ 
 
 
Name of provider:  ___________________________________________________________ 
 
Address of provider:  _________________________________________________________ 
 
Contact phone of provider:  (        )_______________________________________________
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RE-HOSPITALISATION FORM (Data form 3) 
 
IDENTIFYING DETAILS: 
Study Identifier No.:  ^^^^ - ^^^ 
 
Baby surname: _________________________  Baby first name: ______________________ 
 
 
Baby date of birth:    _________/_________/_________ 
          day          month           year 
 
 
DETAILS OF RE-HOSPITALISATION: 
 
Hospital of admission (name): __________________________________________________ 
Baby medical record number: ^^^^^^^^^^ 
 
Date of admission:    _________/_________/_________ 
          day          month           year 
 
Date of discharge:    _________/_________/_________ 
          day          month           year 
 
Principal reason for hospitalisation:  
  Surgery       Social problem 
   Respiratory illness      Other 
   Neurological problem 
 
Details:  ___________________________________________________________________ 
 
___________________________________________________________________________ 
DRG: ^^^ _______________________________________________________ 
Maximum treatment required: Admitted ICU:        yes     no 
    Mechanical ventilation:     yes      no 
 
Other treatment (describe): ________________________________________________ 
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SAMPLE SIZE CALCULATIONS 
 
Using a confidence level of 0.95 and power 0.80, with a 1:1 ratio of treatment to controls, we could 
detect the following differences with a sample size of approximately 150 subjects in each arm (300 
total): 
 
Primary outcomes (growth and development) 
 
1. Mean Griffiths scores: 
 Control mean: 101.0 
 Treated mean: 105.0 
 Standard deviation: 12.0 
 
2. Weight <10th centile at 1 year corrected: 
 Percent in Control: 47.0 
 Percent in Treated: 30.0   to reduce from half to less than a third 
 
3. Mean weight (kg) at 1 year corrected: 
 Control mean: 8.8 
 Treated mean: 9.3 
 Standard deviation: 1.4 
 
4. Mean head circumference (cm) at 1 year corrected: 
 Control mean: 46.4 
 Treated mean: 47.0 
 Standard deviation: 1.8 
 
5. Length <10th centile at 1 year corrected: 
 Percent in Control: 40.9 
 Percent in Treated: 23.5   to reduce by half  
 
6. Mean length (cm) at 1 year corrected: 
 Control mean: 72.6 
 Treated mean: 73.9 
 Standard deviation: 3.8 
 
7. Major developmental abnormality (blindness, deafness, CP, Griffiths score < 2 SD mean) at  
    1 year corrected: 
 Percent in Control: 23.9 
 Percent in Treated: 10.0   to reduce by half  
 
8. Major developmental abnormality (blindness, deafness, CP, Griffiths score < 2 SD mean) at 
   1 year corrected (but with normal discharge head ultrasound): 
 Percent in Control: 14.0 
 Percent in Treated:   4.0   to reduce by greater than two thirds 
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Secondary outcomes 
 
1. Postmenstrual age (weeks) to full sucking feeds: 
 Control mean: 35.5 
 Treated mean: 35.0     to reduce time by 0.5 weeks 
 Standard deviation: 1.5     (significantly reduce costs) 
 
2. Postmenstrual age (weeks) at end of oxygen therapy: 
 Control mean: 35.0 
 Treated mean: 35.5     to increase time by 0.5 weeks 
 Standard deviation: 1.5     (significantly increase costs) 
 
3. Lower respiratory illness (rate per year) 
 Control mean: 1.6 
 Treated mean: 1.0     to see 33% reduction 
 Standard deviation: 1.7 
 
3. Emergency department visits (rate per year) 
 Control mean: 1.9 
 Treated mean: 1.0     to see 50% reduction 
 Standard deviation: 2.7 
 
4. Physicians visits (rate per year) 
 Control mean: 10.3 
 Treated mean: 7.3     to see 33% reduction 
 Standard deviation: 8.7 
 
5. Hospitalisations due to lower respiratory illness (rate per year) 
 Control mean: 1.0 
 Treated mean: 0.7     to see 33% reduction 
 Standard deviation: 1.0 
 
6. Postnatal depression: proportion with high postnatal depression scores 
 Percent in Control: 15.0    may see increase in  
 Percent in Treated: 30.0    postnatal depression 
 
7. Parent stress: proportion with high parenting stress scores 
 Percent in Control: 10.0    may see increase in  
 Percent in Treated: 23.0    parental stress 
 
8. Family impact: proportion with high family impact scores 
 Percent in Control: 12.0    may see increase in  
 Percent in Treated: 25.0    impact on families 
 
9. Infant temperament: proportion of “easy” babies 
 Percent in Control: 10.0    may see improvement in  
 Percent in Treated: 23.0    infant temperament 
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DATA REPORT TO SAFETY MONITORING COMMITTEE 
 
 
 
Cut off date for data for this report:  __________ / __________ / ___________ 
 
 
This report relates to data analysed after approximately: 
 
 þ   5 months from commencement 
 ¨   75 subjects enrolled 
 ¨  150 subjects enrolled 
 ¨  225 subjects enrolled 
 ¨  300 subjects enrolled 
 
 
N. B.  Data pertains to the first 75 subjects who were enrolled and have reached 38 weeks 
pma. This covers the time period 16/9/96 to 4/9/97.  
 
Table 1 
 
Total No. subjects  
 Number enrolled   Percent (%) of total 
Group A                   % 
Group B                    % 
Total           100   % 
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Retinopathy of prematurity (ROP) Grades 3 or 4 to 38 weeks postmenstrual age (pma) 
 
Table 2 
 
No. of subjects with Grade 3/4 ROP at 38 weeks pma by gestational age (GA) strata 
 24-27 weeks GA 28-29 weeks GA Total No. Cumulative 
Incidence % 
Group A                      
Group B                      
Total No.                      
 
 
Statistical analyses performed : 
 
Proportion of Grade 3/4 ROP to 38 weeks pma in Group A    compared with   proportion of 
Grade 3/4 ROP to 38 weeks pma in Group B: 
 
p value (2 sided): ________________  Test statistic used: _____________________ 
 
 
Mortality to 38 weeks postmenstrual age (pma) 
 
 
Table 3 
 
No. of deaths to 38 weeks pma by gestational age (GA) strata 
 24-27 weeks GA 28-29 weeks GA Total No. Cumulative 
Incidence % 
Group A                      
Group B                      
Total No.                      
 
 
Statistical analyses performed : 
 
Proportion of deaths to 38 weeks pma in Group A    compared with   proportion of deaths to 
38 weeks pma  in Group B: 
 
p value (2 sided): ________________  Test statistic used: ____________________ 
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Analysis and report provided by: ________________________________________ 
        Print name 
 
     _______________________________________ 
        Signature 
 
      ________ / __________ / _________ 
        Date 
 
 
 
 
Please forward a copy of this analysis to:  
 
    * Prof Craig Mellis 
       Dept. of Respiratory Medicine  
       New Childrens Hospital, Westmead. NSW. 2145. 
 
    * Dr Andrew Berry 
       State Medical Director NETS 
       POB 563, Wentworthville. NSW. 2145. 
 
    * Dr Frank Martin 
       Dept. of Ophthalmology 
       New Childrens Hospital, Westmead. NSW. 2145. 
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REPORT BY THE SAFETY MONITORING COMMITTEE 
 
 
Meeting held:  _________ / __________ / __________ 
     Date 
 
Venue: ______________________________________________________________ 
 
 
Present: _____________________________________________________________ 
  
 
 _______________________________________________________________ 
  
 
 _______________________________________________________________ 
 
 
Cut off date for data for this report:   _______ / ________ / _________ 
       Date 
 
This relates to data analysed after approximately: 
 þ   5 months from commencement 
 ¨   75 subjects enrolled 
 ¨  150 subjects enrolled 
 ¨  225 subjects enrolled 
 ¨  300 subjects enrolled 
 
 
 
Comments by Safety Monitoring Committee Chairperson: 
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Recommendations by Safety Monitoring Committee: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name:  ____________________________________________________ 
 
 
Signature:  _____________________________________________________ 
 
 
Date:   __________ / __________ / ____________ 
 
 
Please forward this report to: Lisa Askie, BOOST Trial Coordinator 
    NSW Centre for Perinatal Health Service Research,  
   Building D02, University of Sydney. NSW. 2006.
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Table 20:     Selected outcomes for all infants, by treatment group, adjusted for  
          known prognostic factors  
Variable SpO2 91-94%  
Control group 
N=178 
SpO2 95-98%  
Treatment group 
N=180 
Median  (MedD) or  
Mean Difference (MD) 
[95% CI]  
Length of stay, after 
randomisation (days) 
50.0 (IQR 39-60) 50.0 (IQR 42-61.5) MedD 2 [-1, 5] P=0.2           
(adjusted P=0.07)± 
pma at discharge (weeks) 39.1 (IQR 37-40) 39.1 (IQR 38-41) MedD 0.3 [-0.1, 0.9] P=0.2 
(adjusted P=0.08)± 
pma at full sucking feeds 
(weeks) 
37.7 (IQR 37-39) 37.7 (IQR 36-39) MedD -0.4 [-0.9, 0] P=0.9  
(adjusted P=0.6)± 
Days assisted ventilation (all 
types), after randomisation - 
only if ventilation ended after 
randomisation 
14.0 (IQR 7-28) 14.0 (IQR 6-35) MedD 0 [-4, 4] P=0.9         
(adjusted P=0.9)± 
Mean weight at 12 months 
corrected age 
9.10kg (SD 1.5) 9.25kg (SD 1.6) MD 0.15kg [-0.18, 0.49] 
P=0.4 (adjusted P=0.3) Å 
Mean Revised Griffiths score 
at12 months corrected age 
88.3 (SD 18.3) 86.8 (SD 21.8) MD -1.5 [-5.9, 2.9]  
P=0.5 (adjusted P=0.3) Å 
±  adjusted for gestational age, sex, maternal ethnicity, plurality (singleton  vs  multiple) 
 using multiple regression 
        Å  adjusted for baseline Edinburgh Postnatal Depression Scale score in addition to ± variables   
 
Table 21:    Selected outcomes for <28 week gestation infants only, by treatment group, 
adjusted for known prognostic factors  
Variable SpO2 91-94%  
Control group 
N=124 
SpO2 95-98%  
Treatment group 
N=132 
Relative Risk or 
 Median Difference  
[95% CI] 
ROP treatment  20 (16.1%) 11 (8.3%) RR 0.52 [0.26, 1.03] 
P=0.06+ 
Length of stay, after 
randomisation (days) 
51.0 (IQR 41-62) 51.0 (IQR 42-62) MedD 1 [-3, 5] P=0.5         
(adjusted P=0.2)± 
pma at discharge (weeks) 39.5 (IQR 38-41) 39.1 (IQR 38-41) MedD 0.3 [-0.3, 0.9] P=0.4 
(adjusted P=0.2)± 
pma at full sucking feeds 
(weeks) 
38.1 (IQR 37-39) 37.9 (IQR 36-39) MedD -0.7 [-1.3, -0.1] P=0.6 
(adjusted P=0.6)± 
Days assisted ventilation (all 
types), after randomisation - 
only if end ventilation after 
randomisation 
14.5 (IQR 8-28) 
N=62 
14.0 (IQR 6-29), 
N=64 
MedD -1 [-6, 4] P=0.7        
(adjusted P=0.4)± 
+ when adjusted for gestational age, sex, maternal ethnicity, and plurality (singleton  vs  multiple) using 
logistic regression  RR 0.42 [95% CI 0.17, 1.05] P=0.06 
± adjusted for gestational age, sex, maternal ethnicity, and plurality (singleton  vs  multiple)                
using multiple regression 
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MAJOR OUTCOMES, STRATIFIED BY CENTRE 
 
 
Experimental group  = SpO2 95-98%  
Control group   = SpO2 91-94%  
 
Analyses:  experimental/control (RR, 95% CI) 
 
1. Canberra Hospital  
 
Variable SpO2 91-94%  
Control gp 
N=15 
SpO2 95-98%  
Treatment gp 
N=15 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 6 (40.0%, N=15) 4 (26.7%, N=15) 0.67 [0.23, 1.89]  
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
2 (13.3%, N=15) 3 (20.0%, N=15) 1.5 [0.296, 7.73]  
Supplemental O2 at 36 wks pma 6 (40.0%) 11 (73.3%) 1.83 [0.92, 3.66] 
Home oxygen 2 (13.3%) 8 (53.3%) 4.00 [1.01, 15.81]  
 
 
2. John Hunter Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=37 
SpO2 95-98%  
Treatment gp 
N=35 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 10 (32.3%, N=31) 11 (35.5%, N=31) 1.10 [0.55, 2.21] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
13 (41.9%, N=31) 8 (25.8%, N=31) 0.62 [0.30, 1.27] 
Supplemental O2 at 36 wks pma 17 (45.9%) 26 (74.3%) 1.62 [1.08, 2.41] 
Home oxygen 5 (13.5%) 10 (28.6%) 2.11 [0.80, 5.57] 
 
 
3. King George V Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=38 
SpO2 95-98%  
Treatment gp 
N=43 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 11 (29.7%, N=37) 14 (34.1%, N=41) 1.15 [0.60, 2.21] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
5 (13.5%, N=37) 5 (12.2%, N=41) 0.90 [0.28, 2.87] 
Supplemental O2 at 36 wks pma 19 (50%) 26 (60.5%) 1.21 [0.81, 1.80] 
Home oxygen 5 (13.2%) 7 (16.3%) 1.24 [0.43, 3.58] 
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4. Liverpool Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=16 
SpO2 95-98%  
Treatment gp 
N=13 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 7 (53.8%, N=13) 4 (30.8%, N=10) 0.74 [0.30, 1.85] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
1 (7.1%, N=14) 2 (20%, N=10) 2.80 [0.29, 26.81] 
Supplemental O2 at 36 wks pma 9 (56.3%) 9 (69.2%) 1.23 [0.70, 2.16] 
Home oxygen 1 (6.3%) 1 (7.7%) 1.23 [0.08, 17.83] 
  
5. Mater Mothers’ Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=23 
SpO2 95-98%  
Treatment gp 
N=20 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 9 (40.9%, N=22) 5 (25.0%, N=20) 0.61 [0.25, 1.52] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
4 (18.2%, N=22) 2 (10.0%, N=20) 0.55 [0.11, 2.69] 
Supplemental O2 at 36 wks pma 8 (34.8%) 12 (60.0%) 1.72 [0.89, 3.35] 
Home oxygen 7 (30.4%) 9 (45.0%) 1.48 [0.67, 3.24] 
 
6. Nepean Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=25 
SpO2 95-98%  
Treatment gp 
N=24 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 5 (21.7%, N=23) 10 (43.5%, N=23) 2.00 [0.81, 4.94] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
8 (34.8%, N=23) 8 (34.8%, N=23) 1.00 [0.45, 2.21] 
Supplemental O2 at 36 wks pma 11 (44.0%) 10 (41.7%) 0.95 [0.50, 1.81] 
Home oxygen 4 (16.0%) 4 (16.7%) 1.04 [0.29, 3.70] 
 
7. Royal Hospital for Women 
 
Variable SpO2 91-94%  
Control gp 
N=3 
SpO2 95-98%  
Treatment gp 
N=6 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 2 (66.7%, N=3) 3 (50.0%, N=6) 0.75 [0.24, 2.33] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
1 (33.3%, N=3) 0 (0%, N=6) 0.19 [0.01, 3.66] 
Supplemental O2 at 36 wks p ma 2 (66.7%) 5 (83.3%) 1.25 [0.52, 3.00] 
Home oxygen 0 (0%) 0 (0%) not estimable 
 
8. Royal North Shore Hospital 
 
Variable SpO2 91-94%  
Control gp 
N=21 
SpO2 95-98%  
Treatment gp 
N=24 
RR  [95% CI]  
Wt <10th centile at 12 mth corr 11 (52.4%, N=21) 4 (18.2%, N=22) 0.35 [0.13, 0.92] 
Major developmental abn at 12 mth corr 
(CP or blind or DQ <2SD below mean) 
6 (28.6%, N=21) 11 (50.0%, N=22) 1.75 [0.79, 3.88] 
Supplemental O2 at 36 wks pma 10 (47.6%) 17 (70.8%) 1.49 [0.89, 2.49] 
Home oxygen 6 (28.6%) 15 (62.5%) 2.19 [1.04, 4.60] 
 
     APPENDIX 22  
 
 
 3 
SUMMARY GRAPHS: major outcomes, stratified by centre 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight <10th centile at 12 months corrected age, by centre  
Major developmental abnormality at 12 months corrected age, by centre  
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Oxygen dependent at 36 weeks pma, by centre  
Home oxygen, by centre  
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SENSITIVITY ANALYSIS WITH RANDOM REMOVAL OF 50% OF 
RELATED MULTIPLES 
 
 
 
Experimental group  = SpO2 95-98%  
Control group   = SpO2 91-94%  
 
Analyses:  experimental/control (RR, 95% CI) 
 
 
 
Sensitivity analysis with random 50% of related multiples+ removed  
 
Variable SpO2 91-94%  
Control gp 
N=167 
SpO2 95-98%  
Treatment gp 
N=166 
RR  [95% CI]  
P value 
Wt <10th centile @ 12 mth 57 (40.1%, N=142) 52 (35.9%, N=145) 0.89 [0.66, 1.20] p=0.46  
Major dev abn @ 12 mth corr 
(CP or blind or DQ <2SD below mean) 
43 (27.7%, N=155) 39 (25.3%, N=154) 0.91 [0.63, 1.32] p=0.63 
Supplemental O2 at 36 wks pma 79 (47.3%) 109 (65.7%) 1.39 [1.14, 1.69] p=0.0007 
Home oxygen 30 (18.0%) 52 (31.3%) 1.74 [1.18, 2.59] p=0.005 
 
 
 
+ Related multiple = pair of infants from the same birth: one infant of the pair was randomised, the 
second infant was allocated to the same treatment group as their sibling. There were 25 pairs of related 
multiples (total n=50) enrolled (see Table 4).  
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